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Abstract	
Autologous	chondrocyte	implantation	(ACI)	is	the	only	UK	approved	cell	therapy	
for	knee	cartilage	defects	which	might	otherwise	progress	to	osteoarthritis.	For	
ACI,	chondrocytes	isolated	from	a	healthy	cartilage	biopsy	are	expanded	in	
number	prior	to	their	re-implantation	into	the	damaged	joint.	ACI	is	cost-
effective	compared	to	alternative	surgical	interventions	but	it	comes	with	a	50%	
failure	rate	at	10	years.	Making	ACI	truly	successful	requires	optimisation.	
Possible	enhancements	include	improvement	of	the	chondrogenic	capacity	of	
chondrocytes	and	better	monitoring	of	the	clinical	outcomes.		
Herein,	we	histologically,	metabolically	and	biochemically	compared	
chondrocytes	sourced	from	the	ankle	and	knee.	We	found	that	chondrocytes	
sourced	from	ankle	cartilage	exhibited	higher	chondrogenic	potential	
metabolically	and	histologically,	irrespective	of	external	stimuli.	
In	separate	experiments,	we	characterised	the	extracellular	matrix	
(ECM)	of	chondrocytes	cultured	in	Stemulate™	to	determine	whether	it	could	be	
used	to	improve	upon	the	existing	ACI	protocol.	While	Stemulate™	was	effective	
at	increasing	chondrocyte	monolayer	proliferation,	it	impacted	upon	the	re-
differentiation	potential.		
To	assess	clinical	outcome	of	ankle	surgery	and	ACI	we	developed	a			
brand	new	patient-reported	outcome	measure	and	performed	validation	
analyses	to	screen	a	cohort	of	206	participants.	It	demonstrated	proven	
reliability,	responsiveness	and	good	correlation	with	existing	scores.	In	clinic,	our	
foot	and	ankle	clinicians	are	using	it	to	monitor	clinical	outcomes.		
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Chapter	1:	General	introduction	
Cartilage	is	a	tough	and	smooth	elastic	tissue	which	has	many	roles	within	the	
body.	Essentially,	it	protects	the	ends	of	long	bones	within	synovial	joints	to	
provide	frictionless,	pain-free	movement	(Anderson,	1962).	It	is	also	a	major	
component	within	several	structures	including	the	knee	joint,	the	ear,	the	nose,	
the	bronchial	tubes	and	the	intervertebral	discs.	There	are	three	different	types	
of	cartilage	in	the	human	body:	elastic	cartilage,	fibrocartilage	and	hyaline	
cartilage	(Wheeless,	2016),	as	shown	in	Figure	1.		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1:	Histology	images	illustrating	the	three	types	of	cartilage	present	in	
human	tissue,	showing	(A)	hyaline	cartilage,	(B)	fibrocartilage	and	(C)	elastic	
cartilage.	Images	taken	from	Junqueira’s	Basic	Histology;	Mescher,	2018.	
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All	three	types	of	cartilage	consist	of	extracellular	matrix	(ECM),	water	and	
specialised	cells	called	chondrocytes.	Chondrocytes	synthesise	and	organise	
collagens,	proteoglycans,	glycosaminoglycans	(GAGs)	and	non-collagenous	
proteins	to	form	the	ECM.	Within	each	cartilage	type,	these	components	differ	in	
their	amount	and	arrangement	whilst	the	chondrocytes	display	different	
morphology,	behaviour	and	metabolic	activities.	Together,	these	variations	
endow	each	type	of	cartilage	with	its	unique	biological	and	mechanical	
properties.	
	
1.1.	The	function,	composition	and	organisation	of	articular	cartilage	
Within	synovial	joints,	there	is	a	specialised	form	of	hyaline	cartilage,	called	
hyaline	articular	cartilage.	It	functions	as	a	shock	absorber	and	reduces	contact	
stress	on	the	underlying	subchondral	bone	by	distributing	load	and	enabling	pain	
free	movement	(Buckwalter	and	Mankin,	1998).	At	its	surface,	healthy	articular	
cartilage	is	smooth	whilst	through	the	depth	of	the	cartilage	it	is	avascular,	
aneural	and	alymphatic	(James	and	Uhl,	2001).	Despite	being	aneural,	sensations	
of	pain	can	still	occur	following	damage	to	the	underlying	cartilage.	However,	
cartilage	damage	can	still	occur	without	pain	sensations.	With	increasing	depth	
from	the	articular	surface,	there	are	at	least	four	architectural	zones	with	striking	
variations	in	their	chondrocyte	arrangement,	mechanical	properties	and	
surrounding	ECM	(Poole	et	al.,	2001;	Wilusz	et	al.,	2014).	
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1.1.1	The	extracellular	matrix	(ECM)	within	articular	cartilage	
Water	and	electrolytes	lubricate	the	cartilage	tissue	and	transport	nutrients	to	
the	chondrocytes.	The	interaction	between	the	water	and	the	macromolecules	
within	the	ECM	provide	the	tissue	with	its	rigidity	and	resilience	(Woo	and	
Buckwalter,	1988).	Despite	the	volume	of	water	remaining	constant	in	cartilage,	
it	differs	throughout	the	tissue	and	decreases	from	the	articular	surface	to	the	
subchondral	bone	based	on	the	interaction	with	the	macromolecules	present	in	
the	ECM	(Mow	et	al.,	1992;	Mankin	et	al.,	2000;	Buckwalter	et	al.,	2005).		
	
1.1.1.1	Collagens	
Collagens	provide	the	cartilage	tissue	with	its	tensile	strength.	There	are	28	
different	types	of	collagen	present	in	all	vertebrates	(Gelse	et	al.,	2003;	Luo	et	
al.,	2017;	Responte	et	al.,	2007).	All	collagen	types	contain	three	polypeptide	
strands	in	a	left-handed	helical	arrangement,	which	bind	together	to	form	a	
triple	helix	structure	stabilised	through	hydrogen	bonds	(Gelse	et	al.,	2003).	
Collagens	typically	contain	a	high	hydroxyproline	content,	of	approximately	100	
residues	per	1,000	amino	acid	residues	(Brown	et	al.,	2001;	Dickson	and	Bagga,	
1985).	Collagens	can	either	be	fibrillar	or	non-fibrillar	depending	on	their	repeat	
amino	acid	structure.	Fibrillar	collagens	have	non-interrupted	repeat	amino	acid	
structures,	whereas	non-fibrillar	collagens	have	interrupted	repeat	amino	acid	
structures.	Fibrillar	collagens	are	present	in	almost	all	animals,	including	humans,	
and	consist	of	types:	I,	II,	III,	V,	XI,	XXIV	and	XXVII,	all	of	which	are	made	up	of	
997-1,020	residues	(Boot-Handford	and	Tuckwell,	2003;	Exposito	et	al.,	2002;	
Kadler	et	al.,	2007).	Whereas,	non-fibrillar	collagens	consist	of	types:	IV,	VI,	VII,	
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VIII,	IX,	X,	XII,	XIII	and	XIV	(Luo	et	al.,	2017;	von	der	Mark	et	al.,	1992;	Responte	et	
al.,	2007;	Van	Der	Rest	and	Mayne,	1988).	
	
	
Figure	2:	The	main	types	of	collagen	in	articular	cartilage,	illustrating	the	
structure,	location	and	function.	Figure	was	created	using	information	derived	
from.	Plumb	et	al.,	2011.	
Articular	cartilage	contains	collagen	types	II,	VI,	IX,	X	and	XI,	as	
demonstrated	in	Figure	2.	Each	collagen	type	plays	a	specific	role	through	the	
depth	of	the	tissue	(Luo	et	al.,	2017;	Mankin	et	al.,	2000;	Responte	et	al.,	2007).		
Collagen	I	is	the	main	component	of	bone	tissue	but	is	found	in	
articular	cartilage.	It	has	a	role	in	structure	and	support,	but	has	been	shown	to	
be	present	in	fibrosis	(Caron	et	al.,	2012).	There	are	two	key	genes	of	collagen	
type	I,	which	are	collagen	type	1	alpha	1	and	collagen	type	1	alpha	2.	Type	one	
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produces	pro-alpha-I	chains,	whereas	type	two	produces	pro-alpha-II	chains.	Two	
pro-alpha-I	chains	combine	with	one	pro-alpha-II	chain	to	create	a	type	I	
procollagen	molecule	which	combine	to	produce	collagen	I	fibrils	(Henriksen	and	
Karsdal,	2016).	Type	one	is	the	more	abundant	gene	in	collagen	I	and	is	used	as	a	
key	gene	marker	for	assessing	chondrocyte	de-differentiation;	the	process	in	
which	chondrocytes	alter	their	phenotype	to	a	more	fibroblastic	state	following	
exposure	to	tissue	culture	plastic	during	monolayer	expansion	and	is	
characterised	by	a	reduced	ECM	quality	with	higher	expression	of	collagen	type	I	
and	a	lower	expression	of	collagen	type	II	(Lin	et	al.,	2008;	Schulze-Tanzil,	2009;	
Watt,	1988).	Hence,	why	collagen	type	1	alpha	1	is	used	as	a	key	gene	marker	to	
assess	chondrocyte	dedifferentiation,	particularly	in	qRT-PCR.	
Collagen	II	is	the	most	abundant	collagen	type	in	articular	cartilage	and	
it	is	distributed	throughout	the	depth.	It	has	only	one	gene,	namely	collagen	type	
II	alpha	1,	which	is	considered	a	key	marker	of	chondrocyte	phenotype.	This	gene	
produces	pro-alpha-II	chains	and	three	of	these	chain	combine	to	create	a	type	II	
procollagen	molecule	(Gudman	and	Karsdal,	2016).	The	main	role	of	collagen	II	is	
to	form	cross-banded	fibrils	to	create	the	fibril	meshwork.	This	meshwork	
provides	the	tissue	with	rigidity	and	high	tensile	strength,	and	entraps	water	
binding-proteoglycans	to	increase	water	retention	in	order	to	hydrate	and	
lubricate	the	tissue	(Rosenburg,	et	al.,	1986;	Van	Der	Rest,	1991).	Collagen	II	
fibrils	are	reported	to	be	thinner	closer	to	the	articular	surface.	They	increase	in	
their	diameter,	from	20	nm	to	50-100	nm,	as	the	cartilage	tissue	matures	from	
foetal	to	adult	cartilage	tissue	(Lane	&	Weiss,	1975).		
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Collagen	VI	is	found	exclusively	in	the	pericellular	matrix	within	
articular	cartilage,	where	it	forms	microfibrils	in	the	pericellular	matrix	that	
surrounds	the	chondrocyte	to	help	it	attach	to	the	ECM.	It	is	unique	in	that	it	
undergoes	supramolecular	assembly	to	form	a	beaded	microfilament	network	in	
the	ECM.	Collagen	VI	consists	of	three	alpha	chains	(a1,	a2	and	a3)	in	a	1:1:1	
ratio	to	form	a	triple	helix	monomer	(Colombatti	et	al.,	1995;	Engel	et	al.,	1985).	
The	associated	genes	are	collagen	type	VI	alpha	1,	collagen	type	VI	alpha	2,	
collagen	type	VI	alpha	3	and	collagen	type	VI	alpha	5.	The	overall	function	of	
collagen	VI	is	to	create	the	three-dimensional	architecture	of	tissues	including:	
skeletal	muscle,	tendons,	bone	and	cartilage;	yet	it	does	also	have	associated	
cytoprotective	roles,	including:	inhibition	of	apoptosis	(Grumati	et	al.,	2010;	
Irwin	et	al.,	2003),	promotion	of	tumour	growth	(Park	and	Scherer,	2012)	and	
maintenance	of	the	cells	ability	to	differentiate		(Urciuolo	et	al.,	2013).	Collagen	
VI	has	also	been	reported	to	have	a	role	in	the	regulation	of	cell	differentiation,	
further	supported	in	studies	performed	by	Smeriglio	in	which	supplemented	
soluble	collagen	VI	was	found	to	increase	cell	proliferation	in	monolayer	culture	
(Smeriglio	et	al.,	2015;	Smeriglio	et	al.,	2017).	However,	the	main	function	
specifically	in	cartilage	is	to	aid	the	attachment	and	integrity	of	chondrocytes	
(Cescon	et	al.,	2015).	Knockout	studies	have	also	demonstrated	that	collagen	VI	
has	associated	roles	with	the	transmission	of	mechanical	and	osmotic	stresses	
from	the	ECM	to	the	pericellular	matrix,	found	through	decreased	pericellular	
matrix	stiffness	(Alexopoulos	et	al.,	2009),	increased	extent	of	chondrocyte	
swelling	and	increased	extent	of	osmosis	induced	signalling	(Zelenski	et	al.,	
2015).		
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Collagen	IX	is	a	fibril-associated	collagen	with	interrupted	triple	helix.	
fibril-associated	collagen	with	interrupted	triple	helix	collagens	do	not	form	
fibrils,	but	rather	they	decorate	the	surface	of	the	fibrillar	collagens	(Luo	et	al.,	
2017).	Collagen	IX	is	usually	found	in	tissues	containing	collagen	II,	including	
growth	plate	cartilage	and	adult	articular	cartilage	(Eyre	and	Wu,	1987).	The	
collagen	IX	associated	genes	are	collagen	type	IX	alpha	1,	collagen	type	IX	alpha	2		
and	collagen	type	IX	alpha	3	(He	and	Karsdal,	2016).	Structurally,	collagen	IX	is	
composed	of	three	helical	domains:	COL1,	COL2	and	COL3.	COL2	has	been	
identified	as	containing	cross-linked	sites	where	collagen	II	covalently	attaches,	
to	create	the	collagen	fibril	meshwork	(Van	Der	Rest	&	Mayne,	1988).	This	
meshwork	is	thought	to	be	organised	by	this	collagen	type	projecting	into	the	
ECM	and	surrounding	the	surface	of	collagen	II	fibrils	(Buckwalter	et	al.,	2005;	
Eyre,	2004;	Van	Der	Rest	and	Mayne,	1988),	and	has	the	role	of	trapping	
proteoglycans	and	resisting	their	swelling	pressure.	Functionally	collagen	IX	is	
speculated	to	play	a	role	in	development	and	maturation,	as	studies	have	shown	
the	collagen	quantity	decreases	from	10%	in	foetal	cartilage	tissue	to	1%	in	adult	
cartilage	tissue	(Eyre,	et	al.,	1991;	Van	Der	Rest,	1991).	It	is	also	speculated	to	
provide	mechanical	stability	and	increase	the	tensile	strength	of	the	tissue	
(Blumbach	et	al.,	2009;	Posey	et	al.,	2008).		
Collagen	XI	is	a	fibril-forming	collagen	found	within	and	on	
macrofibrils.	It	is	usually	retained	at	the	chondrocyte	surface.	It	has	two	
associated	genes:	collagen	type	XI	alpha	1	and	collagen	type	XI	alpha	2	(Luo	and	
Karsdal,	2016).	Structurally,	collagen	type	XI	is	found	primarily	cross-linked	to	
each	other	and	is	widely	distributed	in	articular	cartilage	(Mio	et	al.,	2007).	This	
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collagen	type	accounts	for	10%	of	foetal	cartilage	but	decreases	to	3%	total	
collagen	in	adult	articular	cartilage	(Eyre,	2004).	Functionally,	it	is	thought	to	be	
associated	with	stabilising	the	collagen	fibrils	that	create	the	fibrillar	meshwork.	
The	meshwork	increases	the	tensile	strength	and	therefore	accommodates	the	
general	‘wear	and	tear’	nature	of	the	tissue	(Eyre	et	al.,	1991;	Van	Der	Rest,	
1991).		
Collagen	X	is	a	fibrillar	collagen	usually	only	found	within	the	
pericellular	latticework	in	the	calcified	zone	of	articular	cartilage.	It	is	secreted	by	
hypertrophic	chondrocytes	and	found	exclusively	in	hypertrophic	cartilage	and	
the	calcified	zone	of	articular	cartilage	(Gannon	et	al.,	1991).	Therefore,	collagen	
X	expression	is	increased	during	periods	of	hypertrophy	and	as	it	has	only	one	
associated	gene,	collagen	type	X	alpha	1,	this	is	frequently	used	as	a	hallmark	of	
hypertrophic	expression	in	research	studies	(Eyre	et	al.,	1991;	Gannon	et	al.,	
1991;	Kwan	et	al.,	1991).	Structurally,	it	is	a	homotrimeric	collagen	consisting	of	
three	α1	chains.	It	constitutes	approximately	1%	of	total	collagen	in	adult	
articular	cartilage	(Eyre	et	al.,	1991).	Functionally,	this	structure	is	thought	to	
assist	with	the	role	of	modifying	ECM	for	subsequent	bone	formation	during	
ossification	(Kwan	et	al.,	1991).	In	regards	to	function,	several	studies	have	
associated	this	collagen	type	with	cartilage	mineralisation	and	structural	support	
(Poole,	et	al.,	1992;	Eyre,	2004;	Schmid	&	Linsenmayer,	1985).	Collagen	X	has	
also	been	associated	with	maintaining	tissue	stiffness,	regulating	chondrocyte	
metabolism	(Luckman	et	al.,	2003)	and	facilitating	the	normal	distribution	of	
proteoglycans	within	the	growth	plate	(Shen,	2005).	
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1.1.1.2	Glycosaminoglycans	(GAGs)	
GAGs	are	long	chains	of	repeating	disaccharides	that	are	negatively	charged	and	
variably	sulphated	(Figure	3;	page	10).	They	are	usually	associated	with	a	protein	
core	to	form	a	proteoglycan.	The	variations	in	GAG	chain	length,	composition	
and	sulphation	give	proteoglycans	their	diversity.	An	ECM	without	GAGs	would	
be	drastically	compromised	since	their	biological	functions	include	tissue	
hydration	(Pomin	and	Mulloy,	2018),	resistance	to	compressive	load	
(Hardingham	et	al.,	1991),	intracellular	signalling	(Hardingham	et	al.,	1991)	and	
protein	up-take	(Fraser	et	al.,	1993).	
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Figure	3:	The	molecular	structure	of	the	five	main	glycosaminoglycans	found	in	
human	articular	cartilage:	hyaluronan,	heparan	sulphate,	dermatan	sulphate,	
chondroitin	sulphate	and	keratan	sulphate.	Image	adapted	from	
Papakonstantinou	and	Karakiulakis,	2009.		
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As	shown	in	Figure	3	(page	10),	all	GAGs	are	synthesised	and	covalently	
bound	to	core	proteins	to	form	proteoglycans,	except	for	hyaluronan.	All	three	
types	have	a	similar	structure	but	differ	in	the	sugar	that	they	contain	and	the	
way	the	structure	is	linked	to	the	core	protein	(Gandhi	and	Mancera,	2008).		
In	articular	cartilage,	chondroitin	sulphate	is	the	predominant	GAG	and	
accounts	for	approximately	90%	of	the	total	GAG	content.	It	contains	
galactosamine	as	the	hexosamine	sugar,	has	a	molecular	weight	of	5-50	KDa	and	
is	sulphated	(Hardingham	&	Fosang,	1992;	Mankin,	et	al.,	2000).		
Keratan	sulphate	is	the	most	heterogeneous	GAG	present	in	articular	
cartilage.	Keratan	sulphate	also	contains	galactosamine	as	the	hexane	sugar	and	
is	sulphated.	However,	keratan	sulphate	has	a	smaller	molecular	weight	of	4-19	
KDa.	Keratan	sulphate	chains	contain	the	disaccharide:	-3Galb1-4GlcNAcb1-	and	
is	approximately	8-9	disaccharide	units	in	length	(Caterson	and	Melrose,	2018).	
There	are	two	types	of	keratan	sulphate	found	in	the	human	body:	type	I	found	
in	the	cornea	and	type	II	found	in	cartilage.		
Hyaluronan	is	un-sulphated	and	contains	the	hexane	sugar	glucosamine.	
It	is	found	throughout	the	human	body,	including	in	the	synovial	fluid	and	loose	
connective	tissue.	Hyaluronan	differs	in	size,	ranging	in	molecular	weight	from	
4,000-8,000	KDa	(Hardingham	and	Fosang,	1992),	depending	on	the	isoform	of	
the	associated	hyaluronan	synthases	(HAS)	gene.	There	are	three	hyaluronan	
synthases	genes:	hyaluronan	synthases	1,	hyaluronan	synthases	2	and	
hyaluronan	synthases	3,	each	varies	in	stability	and	the	rate	of	HA	synthesis	
(Itano	et	al.,	1999).	Hyaluronan	synthases1	is	expressed	in	early	development	
and	has	been	reported	to	synthesise	the	hyaluronan	polymers	of	2x105	–	2x106	
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Da.	Whereas	the	hyaluronan	synthases	2	gene	has	associated	expression	with	all	
stages	of	embryogenesis	and	synthesises	the	largest	hyaluronan	polymers	of	
2x106	Da.	Moreover,	the	hyaluronan	synthases	3	gene	is	associated	with	late	
development	and	has	been	shown	to	synthesise	the	shortest	hyaluronan	
polymers	of	1x105	–	1x106	Da	(Cyphert	et	al.,	2015;	Tien	and	Spicer,	2005).		
Dermatan	sulphate	is	sulphated	and	contains	the	hexane	sugar	
galactosamine.	It	has	associated	roles	in	binding	to	proteoglycans,	assisting	the	
function	of	growth	factors,	and	modifies	cofactors	to	influence	proliferation.	It	
has	also	been	observed	that	dermatan	sulphate	is	found	to	circulate	in	the	blood	
until	needed.	It	is	found	mainly	in	the	skin	but	is	also	found	within	bone,	cartilage	
and	blood	vessels	(Pomin	and	Mulloy,	2018).		
	 Heparan	sulphate	is	a	sulphated	GAG	present	on	almost	every	cell	
within	the	human	body.	It	contains	the	hexane	sugar	galactosamine	and	is	
usually	a	molecular	weight	of	0.005-0.07x106	Da.	It	has	associated	roles	in	
regulating	the	activity	of	chemokines,	growth	factors	and	enzymes.	A	further	role	
it	has	is	in	assisting	with	cell	matrix	interactions	involving	connecting	to	ECM	
proteins	such	as	fibronectin,	laminin	and	various	collagens,	including:	collagens	I,	
II,	IV	and	VI	(Gandhi	and	Mancera,	2008;	Papakonstantinou	and	Karakiulakis,	
2009;	Pomin	and	Mulloy,	2018).		
	
1.1.1.3	Proteoglycans	
Proteoglycans	are	defined	as	complex	carbohydrates	and	are	present	in	many	
tissues,	including	the	brain,	(Schwartz	and	Domowicz,	2004)	cartilage	(Roughley,	
2006)	and	skin	(Smith	and	Melrose,	2015).	In	articular	cartilage,	proteoglycans	
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are	synthesised	by	chondrocytes.	They	function	to	retain	water,	facilitated	by	
Donnan	equilibrium,	to	allow	the	tissue	to	withstand	mechanical	stresses	that	
occur	to	the	joint	(Maroudas,	1973;	Maroudas,	1976;	Overbeek,	1956).	
Proteoglycans	have	a	fixed	charge	density	to	promotes	osmosis.	The	osmotic	
pressure	within	the	cell	increases,	relative	to	outside	the	cells,	which	encourages	
water	to	flood	into	the	cell	and	results	in	the	intracellular	matrix	swelling	and	
becoming	pressurised	to	balance	the	Donnan	equilibrium	and	osmotic	pressure.	
The	collagen	meshwork	resists	the	swelling,	which	allows	the	proteoglycan	
complex	in	the	ECM	to	remain	a	highly	concentrated	gel.	
	
Aggrecan	
The	proteoglycan	which	is	specific	to	articular	cartilage	is	aggrecan	(Figure	4;	
page	14).	It	accounts	for	approximately	90%	of	the	total	mass	in	articular	
cartilage.	It	has	a	‘bottle-brush’	like	structure	made	up	of	a	combination	of	
approximately	150	chondroitin	sulphate	and	keratan	sulphate	chains,	usually	in	a	
2:1	ratio.	The	main	function	of	aggrecan	is	to	bind	to	hyaluronan	using	the	small	
glycoprotein,	link	protein,	to	create	large	proteoglycan	aggregates	(Huber,	et	al.,	
2000;	Horkay,	et	al.,	2012).	Aggregation	allows	the	proteoglycan	to	increase	in	
size	and	the	aggregated	GAG	chains	allow	the	proteoglycan	to	exhibit	a	high	
anionic	charge,	both	of	which	are	essential	for	normal	function	of	both	
proteoglycan	aggregates	and	articular	cartilage.		
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Figure	4:	Schematic	of	the	bottlebrush-like	structure	of	aggrecan,	demonstrating	
the	central	protein	core,	chondroitin	sulphate	domain	made	up	of	many	
chondroitin	sulphate	chains	and	the	keratan	sulphate	domain	made	up	of	many	
keratan	sulphate	chains.	
	
The	chain	ratio	and	size	of	aggrecan	has	been	shown	to	vary	with	age,	
disease	and	during	development	(Hardingham	&	Fosang,	1992).	The	content	and	
composition	of	aggrecan	is	largely	related	to	the	state	of	the	articular	cartilage,	
since	synthetic	and	degradative	changes	occur	during	ageing	and	disease.	These	
changes	are	a	consequence	of	the	long	resident	time	of	aggrecan	within	the	
ECM,	but	has	also	been	speculated	to	be	due	to	an	altered	anabolic	response	of	
chondrocytes	(Bayliss	et	al.,	1999;	Maroudas	et	al.,	1998).	Degradation	causes	
cleavage	of	all	components	of	proteoglycan	aggregates,	leading	to	loss	of	
proteoglycan	aggregate	function	and	ultimately	loss	of	cartilage	function.		
	
	
	
Chondroitin sulphate Keratan sulphate 
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Perlecan	
Perlecan	is	a	large	sized	proteoglycan,	consisting	of	chondroitin	sulphate	and	
heparan	sulphate	chains	(Farach-Carson	et	al.,	2014).	It	consists	of	a	core	protein	
of	4,000	amino	acid	residues	and	heparan	sulphate	side	chains	(Farach-Carson	
and	Carson,	2007).	The	chondroitin	sulphate	chains	specific	to	perlecan,	have	
been	reported	to	accelerate	and	catalyse	collagen	fibre	formation	(Kvist	et	al.,	
2006).	It	has	a	major	role	in	development,	as	shown	in	mouse	models	with	a	
deletion	of	perlecan	gene	expression	demonstrating	severe	skeletal	defects	
specifically	with	abnormal	growth	plates	(Farach-Carson	and	Carson,	2007;	
Melrose	et	al.,	2004).	
	
Small	leucine-rich	proteoglycans	
Small	leucine-rich	proteoglycans	account	for	approximately	3%	of	the	total	
proteoglycan	mass	in	articular	cartilage	and	have	the	role	of	further	stabilising	
the	ECM.	The	Small	leucine-rich	proteoglycans	in	cartilage	tissue	are	decorin	and	
biglycan	(Huber	et	al.,	2000).	
	 Decorin	is	a	stromal	small	leucine-rich	proteoglycan	of	90-140	KDa.	
Structurally,	it	consists	of	a	protein	core	with	10	leucine-rich	repeat	sequences	
and	a	GAG	chain	consisting	of	either	chondroitin	sulphate	or	dermatan	sulphate	
(Boskey	and	Robey,	2013).	Decorin	is	considered	a	cellular	or	pericellular	
proteoglycan	where	it’s	roles	include	influencing	fibrillogenesis,	binding	to	
collagen	type	I	fibres	(Bock	et	al.,	2001),	cell	adhesion	and	cell	proliferation	
(Iozzo,	1999;	Neill	et	al.,	2012;	Scott,	1991).	Furthermore,	studies	have	shown	
pivotal	involvement	in	inhibiting	angiogenesis,	to	maintain	the	avascular	nature	
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of	the	tissue	retaining	the	biomechanical	proteins	of	the	cartilage	tissue	(Mohan	
et	al.,	2011;	Neill	et	al.,	2012).			
Biglycan	is	comprised	of	a	protein	core,	leucine-rich	repeat	regions	and	
two	GAG	chains,	consisting	of	either	chondroitin	sulphate	or	dermatan	sulphate	
which	are	attached	at	amino	acids	5	and	10	in	humans	(Bock	et	al.,	2001).	It	is	
expressed	on	either	the	cell	surface,	pericellularly	or	within	the	ECM	of	various	
tissues.	One	associated	role	of	biglycan	is	in	mineralisation	of	bone,	with	
knockout	studies	in	mice	demonstrating	an	osteoporotic-like	phenotype	(Chen	et	
al.,	2002).	Biglycan	also	exhibits	a	strong	affinity	to	collagen	type	II	(Bock	et	al.,	
2001).	More	recent	studies	have	proven	its	role	in	the	regulation	of	inflammation	
(Barreto	et	al.,	2015)	and	as	a	modulator	of	morphogenesis	and	differentiation	
(Hunziker,	1992).	
	
1.1.1.4	Non-collagenous	proteins	
There	are	many	non-collagenous	proteins	found	within	articular	cartilage,	all	of	
which	are	highly	variable	in	structure	and	function	with	some	only	being	present	
in	specific	cartilage	zones,	or	during	periods	of	development	or	ageing.	Despite	
the	high	variability,	many	have	been	shown	to	hold	a	structural	role	in	articular	
cartilage	(Heinegard	and	Oldberg,	1989;	Roughley,	2001).	Several	non-
collagenous	proteins	have	undergone	high	levels	of	research	and	have	been	
described	in	more	detail	regarding	their	function	and	structure	within	articular	
cartilage.	
Link	protein	is	a	non-collagenous	glycoprotein	that	binds	the	
proteoglycan	molecules	to	hyaluronate	chains.	There	are	two	main	link	proteins	
Chapter	1:	General	introduction.							
 
	
-	17	-	
found	in	human	articular	cartilage,	link	1	and	link	2.	In	humans,	these	usually	
consist	in	a	1:1	ratio,	both	in	normal	and	osteoarthritic	human	cartilage.	Link	1	
has	an	approximate	molecular	weight	of	45-54,000	kDA	whereas	link	2	has	an	
approximate	molecular	weight	of	40-48,000	kDA	(Junnoseke	et	al.,	1982).	The	
associated	role	of	link	protein	is	to	increase	the	strength	of	proteoglycan	binding	
and	thus	increase	stability.		
Fibronectin	is	one	of	the	most	abundant	non-collagenous	proteins	within	
the	ECM.	It	is	involved	in	the	ECM	assembly	process,	specifically	in	directing	the	
organisation	of	the	ECM,	with	key	roles	such	as	mediating	cell	attachment,	cell	
aggregation	(To	and	Midwood,	2011),	and	stimulating	cell	migration	during	
embryonic	development	(Hsiao	et	al.,	2017;	Moretti	et	al.,	2007).	
Laminin	has	two	isoforms	associated	with	the	ECM;	laminin-III	is	secreted	
by	chondrocytes	and	found	in	articular	cartilage,	whereas	laminin-332	is	found	in	
embryonic	cartilage	(Kruegel	and	Miosge,	2010).	There	is	increased	expression	of	
laminin-332	in	new-born	cartilage	compared	to	mature	cartilage,	but	it	has	a	
pericellular	distribution	in	mature	cartilage	(Durr	et	al.,	1996;	Foldager	et	al.,	
2016).	Laminin	has	also	been	reported	to	have	a	role	in	promoting	
chondrogenesis	(Schminke	et	al.,	2016).	Studies	have	shown	that	laminin	forms	
part	of	the	pericellular	matrix	in	native	cartilage,	but	is	absent	in	repair	or	
degenerated	tissue	or	in	fibrocartilage	(Foldager	et	al.,	2014;	Foldager	et	al.,	
2016;	Kruegel	and	Miosge,	2010),	which	supports	the	suggestion	of	laminin	
having	a	role	in	promoting	chondrogenesis	(Schminke	et	al.,	2016).	Expression	of	
laminin	is	also	depleted	in	osteoarthritis,	which	suggests	that	it	is	associated	with	
the	homeostasis	of	normal	articular	cartilage.		
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Tenascin-C	is	a	cell-interaction	protein	known	for	its	adhesive	and	anti-
adhesive	interactions.	Tenascin-C	is	not	normally	expressed	in	healthy	adult	
tissue	but	has	upregulated	expression	during	inflammation	and	is	highly	
expressed	during	wound	healing,	where	it	can	promote	cell	migration	(Chiquet-
Ehrismann	and	Chiquet,	2003;	Roughley,	2001;	Yamada,	1991).		
Cartilage	oligomeric	matrix	protein	is	a	member	of	the	thrombospondin	
family	and	is	found	in	all	human	cartilage	tissue	and	is	therefore	speculated	to	
have	a	major	role	in	cartilage	development	and	turnover	(Bornstein	et	al.,	1993).	
Cartilage	oligomeric	matrix	protein	is	reported	to	cause	degradation,	producing	
degraded	fragments	which	circulate	within	the	synovial	fluid.	Higher	levels	of	
these	circulating	fragments	are	associated	with	early	stages	of	primary	
osteoarthritis	(Lohmander	et	al.,	1994).	
	
1.1.2.	Arrangement	of	the	ECM	
1.1.2.1	The	chondrocyte		
Chondrocytes	are	the	only	cells	present	in	cartilage	tissue	and	are	in	sparse	
content,	accounting	for	approximately	3%	of	the	total	tissue	volume	(James	and	
Uhl,	2001).	The	average	chondrocyte	is	spherical	in	shape	and	approximately	13	
μm	in	size	(Kempson,	1979)	as	shown	in	Figure	5	(page	19).	This	low	cellularity	of	
articular	cartilage	contributes	to	the	limited	capability	of	cell-to-cell	
communication	and	self-repair	which	will	be	introduced	later.		
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Figure	5:	Electron	microscopy	image	of	a	chondrocyte	(C)	within	its	lacunae	(L),	
in	articular	cartilage.	Image	taken	from	Patwari	et	al.,	2004.	
	
1.1.2.2	Regional	organisation	of	the	ECM	
There	is	a	further	hierarchical	organisation	within	articular	cartilage	associated	
with	the	ECM	(Figure	6;	page	21),	which	consists	of	three	distinct	matrix	regions:	
the	pericellular	matrix,	the	territorial	matrix	and	the	inter-territorial	matrix.		
A	chondrocyte	surrounded	a	pericellular	matrix	is	termed	a	
‘chondron’,	and	was	first	described	in	1925	(Benninghoff,	1925).	The	chondron	is	
considered	the	structural,	functional	and	metabolic	unit	of	human	articular	
cartilage	(Poole,	et	al.,	1992;	Zhang,	2015).	The	pericellular	matrix	region	is	a	thin	
13	μm	
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layer	of	approximately	1-3	μm	that	immediately	surrounds	the	chondrocyte	
(Zhang	2015;	Wilusz,	et	al.,	2014).	The	pericellular	matrix	is	rich	is	non-sulphated	
GAGs,	proteoglycans	and	collagens	(Wang	et	al.,	2008).	It	contains	fibronectin,	
aggrecan,	collagens	type	II,	IX	and	XI	and	is	the	exclusive	location	of	collagen	VI	
(Wang	et	al.,	2008;	Wotton	et	al.,	1991).	It	provides	a	microenvironment	to	allow	
the	chondrocytes	to	anchor	and	attach	to	the	ECM,	as	well	as	mediating	
communication	between	the	chondrocytes	and	ECM.	Another	function	of	the	
pericellular	matrix	is	to	provide	a	boundary	for	components	to	penetrate	before	
reaching	the	cell	membrane,	offering	extra	protection	to	the	chondrocytes	
(Zhang,	2015;	Wilusz,	et	al.,	2014).	It	is	also	speculated	that	the	pericellular	
matrix	has	a	further	role	of	initiating	signal	transduction	within	cartilage	for	load	
bearing	(Eggli	et	al.,	1985).		
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Figure	6:	Schematic	illustrating	the	three	distinct	regions	in	the	organisation	of	
the	chondrocyte:	the	pericellular	matrix,	the	territorial	matrix	and	the	inter-
territorial	matrix.	
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Beyond	the	pericellular	matrix	there	is	the	territorial	matrix,	which	
surrounds	individual,	and	isogenous	chondrocytes.	This	region	is	thicker	than	the	
pericellular	matrix	region	and	has	the	primary	role	of	protecting	chondrocytes	
from	mechanical	stress	(Poole,	1997).	The	territorial	matrix	is	distinctive	due	to	
its	hallmark	fine	collagen	type	IX	and	XI	fibrils	that	organise	themselves	into	
‘basket-like’	networks.	However,	some	collagen	fibrils	do	protrude	into	the	inter-
territorial	matrix,	connecting	the	two	regions	together	for	further	structural	
support	(Poole,	1997).	
	 The	inter-territorial	matrix	is	situated	furthest	from	the	chondrocyte.	
Collagen	type	IX	and	XI	fibrils	within	the	inter-territorial	matrix	are	organised	into	
random	bundles	orientated	differently	depending	on	their	location	within	this	
region	(Eyre	et	al.,	2006;	Mankin	et	al.,	2000;	Poole	et	al.,	2001).	They	are	
parallel	to	the	surface	of	the	superficial	zone,	oblique	in	the	middle	zone	and	
perpendicular	to	the	articular	joint	surface	in	the	deep	zone	(Buckwalter	et	al.,	
2005;	Poole,	1997).	The	inter-territorial	matrix	region	contributes	highly	to	the	
biomechanical	properties	of	the	cartilage	tissue,	possibly	through	the	abundant	
content	of	proteoglycans	(Mow	and	Guo,	2002).	
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1.1.2.3	Zonal	arrangement	of	the	ECM	
Articular	cartilage	is	composed	of	four	basic	biological	zones,	which	from	the	
articular	surface	to	the	underlying	subchondral	bone	comprise:	the	superficial,	
middle,	deep	and	calcified	zones	(Huber,	et	al.,	2000).	Each	zone	contributes	to	
the	biochemical	properties	of	the	cartilage	tissue,	including	its	high	tensile	
strength	and	durability.	The	chondrocytes	and	their	surrounding	ECM	differ	
within	the	architectural	zones	(Figure	7)	(Huber,	et	al.,	2000).	
Figure	7:	Representative	diagram	demonstrating	(A)	the	organisation	of	
chondrocytes	and	(B)	the	collagen	fibril	arrangement	throughout	the	four	zones	
in	human	articular	cartilage.	Diagram	adapted	from	Fox	et	al.,	2009.	
	
	 Closest	to	the	articular	surface	is	the	superficial	zone,	which	accounts	
for	10-20%	of	the	tissue	thickness.	It	is	the	thinnest	of	the	four	zones.	The	
function	of	the	superficial	zone	is	to	protect	the	deeper	zones	from	sheer	stress	
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and	forces,	and	to	aid	this	there	is	a	high	content	of	collagen	type	II	(Temenoff	&	
Mikos,	2000;	Buckwalter	et	al.,	2005).	Collagens	types	II	and	IX	are	organised	into	
a	tight	acellular	sheet	arranged	parallel	to	the	articular	surface,	and	due	to	this	
arrangement,	the	chondrocytes	are	flattened	in	shape.	There	is	less	aggrecan	
content,	with	the	most	abundant	SLRP	in	this	zone	being	decorin	(Temenoff	&	
Mikos,	2000;	Buckwalter	et	al.,	2005).		
The	middle	zone	occupies	the	most	volume,	accounting	for	approximately	
40-60%	of	the	total	tissue	thickness.	The	function	of	this	zone	is	to	protect	the	
deeper	zones	from	compressive	forces.	To	enable	this,	the	collagen	type	II	fibrils	
are	present	at	a	low	density	but	are	thicker	in	size	when	compared	to	those	
found	in	the	other	zones	and	they	are	obliquely	organised	(Buckwalter,	et	al.,	
2005;	Wheeless,	2016).	This	zone	has	spherical	chondrocytes,	a	low	water	
content	and	high	aggrecan	content	(Wheeless,	C.R.,	2012;	Temenoff	&	Mikos,	
2000;	Buckwalter	et	al.,	2005).		
The	deep	zone	is	the	largest	zone	and	accounts	for	30%	of	the	total	tissue	
volume.	The	primary	function	of	this	zone	is	to	provide	the	greatest	resistance	to	
compressive	forces,	protecting	the	underlying	subchondral	bone	(Buckwalter	et	
al.,	2005;	Temenoff	and	Mikos,	2000).	The	collagen	fibrils	here	have	the	largest	
diameter	and	are	orientated	parallel	to	the	articular	surface.	The	fibres	can	
extend	into	the	tidemark,	which	is	a	basophilic	line	of	unknown	composition	and	
function	that	separates	the	deep	and	calcified	zones	(Temenoff	and	Mikos,	2000;	
Wheeless,	2016).	Here,	the	chondrocytes	have	high	synthetic	activity,	a	rounded	
morphology	and	are	stacked	in	columns	perpendicular	to	the	articular	surface	
and	parallel	to	the	collagen	fibrils.	The	deep	zone	contains	the	lowest	water	
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content,	yet	highest	proteoglycan	content,	which	is	particularly	high	in	aggrecan	
and	perlecan	(Buckwalter	et	al.,	2005;	Temenoff	and	Mikos,	2000).		
The	calcified	zone	is	situated	closest	to	the	subchondral	bone	and	
provides	the	transition	between	cartilage	and	bone	tissue.	The	function	of	the	
calcified	zone	is	to	secure	the	cartilage	to	the	subchondral	bone	with	collagen	
type	X	fibrils	radiating	through	the	tidemark	up	into	the	deep	zone.	The	
chondrocytes	in	the	calcified	zone	are	sparse	in	density,	smaller	in	diameter	and	
are	hypertrophic	in	nature,	meaning	the	cells	become	larger	and	thus	increase	
the	size	of	the	tissue	(Buckwalter	and	Mankin,	1998;	Wheeless,	2016).	
Chondrocytes	are	encased	in	a	calcified	ECM	that	enables	very	little	movement	
or	cellular	metabolic	activity	(Buckwalter	&	Mankin,	1998).		
	
1.2	Osteoarthritis	
Damaged	articular	cartilage	has	a	limited	potential	for	healing	and	untreated	
cartilage	defects	often	progress	to	osteoarthritis	(Bhosale	and	Richardson,	2008).	
Osteoarthritis	is	a	degenerative	joint	disease	characterised	by	the	loss	of	
articular	cartilage	and	changes	within	the	subchondral	bone	(Gardiner	et	al.,	
2015;	Sharma	et	al.,	2013).		
Within	the	UK,	osteoarthritis	is	a	major	healthcare	concern	with	
approximately	8.75	million	people	aged	45	years	or	older	requiring	treatment	
(Arthritis	Research	UK,	2013),	and	it	has	been	reported	that	1	million	adults	
consult	their	GP	with	symptoms	of	osteoarthritis	every	year	(Chen	et	al.,	2012;	
Warner	and	Valdes,	2016).	
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There	are	several	risk	factors	found	to	be	associated	with	
osteoarthritis,	including:	age,	previous	injury,	gender,	body	mass	index	and	
genetics.	Ageing	is	the	most	prominent	risk	factor	and	studies	have	shown	that	
osteoarthritis	prevalence	significantly	increases	with	age,	with	40%	of	adults	over	
the	age	of	65	years	having	some	form	of	osteoarthritis	(Hügle	et	al.,	2012;	Shane,	
Anderson	and	Loeser,	2010).	Injury	to	the	joint	results	in	joint	instability,	altered	
joint	biomechanics	and	altered	joint	loading,	all	of	which	can	progress	to	
osteoarthritis.	Obesity	is	defined	as	a	body	mass	index	of	30	kg/m2	or	greater	
(King	et	al.,	2013).	The	relationship	between	osteoarthritis	and	body	mass	index	
is	mainly	caused	by	the	mechanical	overloading	of	the	joint.	This	risk	factor	can	
be	decreased	through	reducing	weight	by	means	of	a	healthy	diet	and	exercise.	
However,	body	mass	index	can	also	increase	following	exercise	due	to	muscle	
mass,	as	can	joint	loading.	Both	are	considered	risk	factors	for	osteoarthritis	but	
exercise	is	considered	a	preventative	measure.	Females	have	been	proven	to	be	
more	at	risk	of	developing	osteoarthritis	than	males	(Felson,	1990).	This	is	
speculated	to	be	due	to	females	having	a	higher	average	body	fat	content	
compared	to	males.	Furthermore,	there	is	a	reported	genetic	association	with	
osteoarthritis,	in	particular	with	nodular	osteoarthritis	(Fernández-Moreno	et	al.,	
2008).		
	
1.2.1	Cartilage	injury	and	natural	healing	
As	mentioned	previously,	cartilage	has	a	limited	capability	for	self-repair,	in	part	
due	to	its	aneural	and	avascular	nature.	It	has	long	been	accepted	that	‘cartilage	
injury	is	a	troublesome	thing	and	once	injured	is	seldom	repaired’	(Hunter,	
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1742).	Despite	cartilage	being	aneural,	sensations	of	pain	can	still	occur	following	
damage.	These	pain	sensations	mainly	occur	from	the	underlying	bone	
interactions	following	the	‘wear-and-tear’	of	cartilage	through	injury	and	aging.	
There	are	many	types	of	cartilage	injury,	including:	general	wear	and	tear	
and	physical	trauma,	both	of	which	may	lead	to	cartilage	defects.	Cartilage	
defects	can	either	be	of	full	thickness	or	partial	thickness.	Full	thickness	defects	
are	characterised	by	progressing	through	the	cartilage	tissue	and	penetrating	the	
underlying	subchondral	bone,	where	access	to	cells	in	the	bone	marrow	space	
allows	for	an	immediate	repair	response	(Shapiro	et	al.,	1993).	However,	the	
tissue	generated	tends	to	be	fibrocartilaginous	in	nature	which	does	not	possess	
the	same	biomechanical	properties	of	hyaline	articular	cartilage	(Mankin,	1982;	
Redman	et	al.,	2005).	In	contrast,	partial	thickness	defects	are	defined	as	existing	
only	within	the	cartilage	tissue	above	the	calcified	zone	and	not	penetrating	into	
the	subchondral	bone	and	thus	do	not	possess	the	capability	of	healing	
spontaneously	(Mankin,	1982;	Redman	et	al.,	2005).	Any	repair	response	that	
does	occur	is	stimulated	by	injury	to	the	adjacent	tissue	and	has	been	shown	to	
promote	cell	proliferation,	chondrocyte	cluster	formation	and	ECM	synthesis.	
However,	the	repair	response	is	often	short-lived	and	the	defect	fails	to	repair	
(Mankin,	1982).		
Cartilage	repair	or	regeneration	is	notoriously	difficult	but	there	are	
several	surgical	approaches	with	differing	degrees	of	clinical	success	which	are	
discussed	in	the	next	section.	
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1.2.1.1	Cartilage	repair	surgery	
Repair	strategies	use	the	principle	of	smoothing	the	cartilage	surface	to	reduce	
friction	and	pain.	Regeneration	strategies	use	the	principle	that	‘stimulated	
bleeding	leads	to	healing’.	Whereas,	replacement	strategies	either	replaces	the	
whole	joint	when	necessary	or	replaces	cartilage	tissue	where	applicable,	such	as	
when	filling	a	defect.	These	strategies	can	often	be	used	in	combination	to	
generate	a	more	stable	repair	and	more	successful	clinical	outcome.		
	 Cartilage	repair	surgery	was	previously	reserved	for	older	patients	or	
more	severe	cases	of	cartilage	injury,	such	as	with	larger	defect	sizes.	This	was	
due	to	the	belief	that	cartilage	cannot	repair	itself	(Hunter,	1742)	and	that	
attempted	repair	would	not	generate	articular	cartilage	tissue.	Therefore,	
surgical	repair	was	avoided	where	possible.	Since	then,	a	plethora	of	studies	
have	recorded	repair	tissue	in	a	three-dimensional	microenvironment	
maintaining	the	articular	cartilage	phenotype	(Dell’Accio	et	al.,	2001;	Dell’Accio	
et	al.,	2003;	Schulze-Tanzil	et	al.,	2002;	Wu	et	al.,	2009).	More	current	
techniques	aim	to	prevent	further	degeneration	stemming	from	increasing	
knowledge	and	emerging	technology.	These	more	recent	techniques	seem	to	
follow	a	‘regenerate	and	repair	over	replace’	ideology	with	many	progressing	
away	from	techniques	of	marrow	stimulation	or	whole	joint	replacement.	Each	
cartilage	surgical	repair	technique	is	explained	in	more	detail	within	Table	1.	
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Table	1:	Repair	techniques	used	to	repair	cartilage	defects.	
Technique:	 Defect	
size:	
Defect	
thickness:	
Process:	
Microfracture	 <	15	mm		 Partial	
thickness	
Multiple	holes	in	the	surface	of	
the	subchondral	bone	to	
generate	a	blood	supply	and	the	
migration	of	cells,	to	stimulate	a	
healing	response	
Osteotomy	 N/A	 Partial	
thickness	
Reshape	the	bone	to	relieve	
pressure	on	the	affected	joint	
Soft	tissue	grafts	 <	4	mm	 Partial	
thickness	
Implant	grafts	of	perichondrium	
and	periosteum	into	the	defect	
area	
Osteochondral	
transplant	
Autograft	
<	1cm	
Allograft	>	
2cm	
Full	
thickness	
Implant	of	non-weight	bearing	
cartilage	and	subchondral	bone	
into	the	defect	site	
Cell	therapy	 >	2cm		 Full	
thickness	
Transplant	cultured	
chondrocytes	into	the	cartilage	
defect,	to	fill	the	defect	area	
Total	joint	
replacement	
N/A	 Full	
thickness	
Replace	the	defected	joint	by	an	
artificial	joint	
	
Microfracture	uses	the	process	of	creating	multiple	holes,	approximately	
2-3	mm	apart,	in	the	surface	of	the	subchondral	bone	to	create	a	new	blood	
supply	that	subsequently	causes	a	migration	of	cells	and	stimulates	a	healing	
response	(Redman	et	al.,	2005;	American	Academy	of	Orthopaedic	Surgeons,	
2009).	One	key	factor	in	the	success	of	microfracture	is	the	rehabilitation	
programme	associated	with	the	technique,	which	insists	on	early	mobilisation	of	
the	area	and	continuous	passive	motions	with	reduced	weight	bearing	for	an	
extended	period	of	time	(Smith	et	al.,	2005).	The	technique	has	been	particularly	
successful	in	professional	athletes,	with	one	study	showing	that	76%	of	American	
football	players	returned	to	the	sport	the	next	season	following	microfracture	of	
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the	knee,	which	may	not	have	been	possible	with	an	alternative	procedure	
(Steadman	et	al.,	2003).	Furthermore,	a	study	of	105	patients	with	ankle	defects	
treated	by	microfracture	showed	a	high	success	rate	in	lesions	smaller	than	15	
mm	(Chuckpaiwong	et	al.,	2008).	The	technique	is	usually	reserved	for	partial	
thickness	defects	of	less	than	15	mm	in	size.	
Osteotomy	has	the	aim	to	cut	and	reshape	the	bone	to	relieve	pressure	
from	the	damaged	joint,	subsequently	relieving	pain	and	improving	joint	function	
(American	Academy	of	Orthopaedic	Surgeons,	2011).	This	strategy	is	used	to	
transfer	weight	and	loading	from	the	damaged	area	to	a	non-damaged	area,	
correct	poor	alignment	and	extend	the	lifespan	of	the	natural	joint,	thus	
prolonging	the	need	for	total	joint	replacement	surgery.	The	ideal	candidate	for	
an	osteotomy	is	active,	between	40-60	years	of	age	and	experiences	pain	on	only	
one	side	of	their	joint	(American	Academy	of	Orthopaedic	Surgeons,	2011).	
Currently,	osteotomy	surgery	is	less	commonly	used	due	to	the	improvements	
associated	with	total	joint	replacement	surgery	and	the	lifespan	of	artificial	
joints.	Therefore,	osteotomy	surgery	is	more	commonly	reserved	for	early	
asymmetric	osteoarthritis	(Smith	et	al.,	2005).	However,	osteotomy	has	shown	
great	success	in	decreasing	pain,	as	reported	in	a	study	of	35	patients	with	ankle	
osteoarthritis.	This	study	demonstrated	an	overall	average	decrease	in	pain	score	
from	seven	prior	to	surgery	to	three	post-surgery,	with	a	further	ten	patients	
presenting	as	pain	free	at	their	follow	up	appointment	(Pagenstert	et	al.,	2007).	
Furthermore,	a	study	of	95	patients	with	osteoarthritis	in	the	knee	demonstrated	
that	osteotomy	produced	better	coverage	of	the	degenerative	cartilage	by	a	
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thicker	layer	of	repair	tissue,	when	compared	to	debridement	or	bone	drilling	
(Schultz	and	Gobel,	1999).	
Soft	tissue	grafts,	using	the	perichondrium	and	periosteum,	involve	
creating	a	full	thickness	defect	of	4	mm	or	larger,	removing	1-2	mm	of	
subchondral	bone,	and	implanting	the	graft	into	the	defect	and	securing	into	
place	with	fibrin	glue	(Carranza-Bencano	et	al.,	1999).	There	has	been	no	
reported	significant	difference	in	the	clinical	outcome	between	the	two	graft	
sites	(Carranza-Bencano,	A.	et	al.,	1999).	Hyaline	morphology	has	been	reported	
in	histological	studies	of	the	graft	in	the	knee,	but	with	only	six	of	the	22	patients	
having	a	higher	than	50%	presence	of	hyaline	morphology	(Bouwmeester	et	al.,	
1999;	Smith	et	al.,	2005).	Most	published	studies	have	investigated	soft	tissue	
grafts	in	the	knee,	with	very	limited	literature	reporting	grafts	performed	in	the	
ankle.	One	limitation	associated	with	the	periosteal	graft	procedure	is	the	risk	of	
calcification	of	the	graft	long-term	(Redman	et	al.,	2005).	
	 Osteochondral	harvest	and	transplantation	involves	harvesting	non-
weight	bearing	cartilage	as	a	cylindrical	plug	and	subchondral	bone	that	is	
matched	in	size	and	surface	area	to	the	defect	site.	The	plug	is	then	implanted	
into	the	defected	area.	Multiple	plugs	can	be	taken,	which	is	known	as	
mosaicplasty.	Osteochondral	transplantation	is	usually	reserved	for	smaller	
defects	due	to	the	limited	area	of	the	harvest	site.	The	technique	can	be	either	
autograft	or	allograft.	Osteochondral	autograft	transplantation	involves	using	the	
harvest	from	the	individual	and	is	often	performed	arthroscopically	on	defect	
areas	smaller	than	1	cm.	Whereas,	osteochondral	allograft	transplantation	
involves	taking	the	harvest	from	a	cadaver	donor	and	sterilising	it	prior	to	
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transplantation.	It	is	often	reserved	for	defects	larger	than	2	cm	in	size	and	is	
performed	using	open	surgery.	Studies	performed	in	the	ankle	joint	have	been	
successful,	with	one	study	showing	80%	of	patients	with	ankle	osteochondral	
lesions	resulting	in	normal	or	nearly	normal	cartilage	repair	at	18	months	post-
surgery	(Versier	et	al.,	2005).	This	is	further	supported	by	a	comprehensive	
examination	of	243	patients	over	nine	separate	studies,	which	showed	
comparable	results	with	a	87%	success	rate	in	ankle	treatment	(Zengerink	et	al.,	
2010).	
	
1.2.1.2	Cartilage	cell	therapy		
Tissue	engineering	strategies	are	another	relative	new	approach	for	repairing	
cartilage	defects,	having	only	arisen	approximately	four	decades	ago,	therefore	
some	tissue	engineering	strategies	are	still	in	development	or	in	the	optimisation	
stages.	Tissue	engineering	is	defined	as	the	use	of	a	combination	of	cells,	
engineering	materials	and/or	suitable	biochemical	factors,	such	as	growth	
factors,	to	improve	or	replace	biological	functions	in	an	effect	to	improve	clinical	
procedures	(Langer	and	Vacanti,	1993).	It	is	mainly	used	to	repair	or	regenerate	
damaged	tissues	and/or	organs.	
From	a	research	perspective,	successful	tissue	engineering	strategies	
would	provide	medical	and	research	screening	models	on	bioengineered	tissues	
and	organs,	which	consequently	could	speed	up	research	and	drug	discoveries.	
The	successful	generation	of	tissue	engineered	organs	could	lead	to	readily	
available	‘off-the-shelf’	organs	for	transplantation,	eradicating	lengthy	waiting	
lists	for	transplantation.	Furthermore,	the	use	of	successfully	engineered	tissues	
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and	organs,	would	reduce	the	number	of	animal	models	for	research,	for	
example	transplantations	of	heart	valves	are	usually	currently	obtained	from	
porcine	origin.	From	a	healthcare	prospective,	tissue	engineering	and	cell	
therapies	can	facilitate	a	personalised	medicine	approach	to	medical	treatments.	
For	example,	autologous	cell	therapies	are	a	personalised	treatment	approach,	
but	also	have	the	added	advantage	of	no	tissue	rejection	possibility.	There	are	
two	major	issues	associated	with	tissue	engineering	strategies:	cell	death	
following	implantation	and	the	large	scale-up	for	routine	clinical	use,	both	of	
which	limit	the	wide-range	applicability	and	hinders	clinical	implementation.		
A	recent	search	on	clinicatrials.gov	website,	a	registry	for	all	registered	
worldwide	clinical	trials,	using	the	key	words	‘cell	therapy’	and	‘tissue	
engineering’	showed	that	31,480	clinical	trials	are	ongoing	in	cell	therapy,	and	a	
further	79	clinical	trials	are	ongoing	in	tissue	engineering,	as	stated	in	November	
2018	worldwide	(National	Institute	of	Health:	US	national	library	of	medicine,	
2018a;	National	Institute	of	Health:	US	national	library	of	medicine,	2018b).	
Some	examples	of	these	clinical	trials	are	listed	in	Table	2.				
More	specific	an	example	of	tissue	engineering	successfully	being	used	
to	repair	cartilage	is	autologous	chondrocyte	implantation	(ACI),	which	briefly	
involves	transplanting	cells	into	cartilage	defects	to	repair	osteochondral	full	
thickness	defects.	Several	modifications	to	ACI	have	occurred	over	the	last	
twenty	years,	and	they	will	be	outlined	in	the	next	section.	 
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Table	2:	Examples	of	cell	therapy	clinical	trials	conducted	worldwide	in	2018.	
Information	obtained	from	National	Institute	of	Health:	US	national	library	of	
medicine,	2018a.	
Cell	Type:	 Disease/Condition:	 Location:	
T	cell	therapy	 Liver	transplants	 London,	UK	
Dendritic	cells	 Non-Hodgkin	
lymphoma	
Minnesota,	USA	
Autologous	stem	
cells	
Autologous	
chondrocytes	
Non-union	fractures	
Knee	cartilage	
defects	
The	Robert	Jones	&	Agnes	Hunt	
Orthopaedic	Hospital	(RJAH),	
Oswestry,	UK	
Tissue	engineered	
corneal	matrix	
Corneal	ulcers	 Beijing,	China	
Mesenchymal	stem	
cells	(MSCs)	
Spinal	fusion	
treatment	
Cleft	lip	and	cleft	
palate	
Cranial	
reconstruction	
Laryngeal	implants	
Parkinson’s	disease	
Barcelona,	Spain	
Sao	Paolo,	Brazil	
Perth,	Australia	
London,	UK	
Milan,	Italy	
	
Autologous	chondrocyte	implantation	(ACI)	
ACI	was	developed	by	Brittberg	and	his	team	in	1994	by	adapting	a	technique	
originally	used	to	treat	cartilage	defects	in	rabbits		
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Figure	8:	Schematic	illustrating	the	procedure	of	ACI,	using	methodology	from	
Brittberg	et	al.,	1994.	
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(Brittberg,	et	al.,	1994;	Grande,	et	al.,	1989).	In	brief,	autologous	chondrocytes	
are	harvested	from	a	lesser	weight	bearing	area	of	the	affected	joint,	expanded	
in	monolayer	and	re-implanted	into	the	damaged	area	under	a	natural	or	
synthetic	membrane	via	open	joint	surgery,	as	illustrated	by	Figure	8	(page	35).		
Our	centre,	and	others	report	a	high	percentage	of	good	to	excellent	
clinical	results	for	ACI	(Bhosale	et	al.,	2009;	Henderson	et	al.,	2003).	Although	
there	is	limited	long-term	follow-up	data,	positive	clinical	results	are	beginning	to	
emerge	and	as	a	consequence,	ACI	has	recently	been	approved	by	the	National	
Institute	for	Health	and	Care	Excellence	to	be	available	on	the	NHS	as	a	first	line	
treatment	for	knee	cartilage	defects	over	2	cm2	in	size	(National	Institute	of	
Health	and	Care	Excellence,	2017).		
A	limitation	associated	with	ACI	is	the	expensive	treatment	cost	per	
patient.	The	highest	cost	is	associated	with	the	expansion	of	chondrocytes,	which	
can	cost	up	to	£16,000	per	patient.	However	our	centre	currently	cultures	
chondrocytes	for	ACI	at	a	cost	of	£4,125	per	patient	in	the	specialised	Good	
Medical	Practice	OsCell	laboratory	(National	Institute	for	Health	and	Care	
Excellence,	2015).	The	expense	of	the	technique	limits	the	application	of	the	
technique	and	the	availability	for	it	to	be	used	routinely	as	a	first-line	NHS	
treatment	for	other	joint	sites	despite	the	promising	results.	Therefore,	more	
research	into	refining	the	technique,	and	possibly	reducing	culture	costs	
consequently,	would	be	extremely	beneficial.	Optimisations	into	reducing	the	
exposure	to	tissue	culture	plastic	during	the	expansion	process,	which	in	turn	
would	reduce	the	risk	of	cell	de-differentiation,	would	be	highly	beneficial	and	
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would	in	turn	aid	the	potential	for	large	scale	routine	use	on	the	NHS	and	
expansion	of	the	treatment	for	other	joint	sites,	including	the	ankle.		
The	standard	ACI	technique	(known	as	first	generation	ACI)	has	since	
evolved	using	adaptations	with	new	technology	and	research,	streamlining	the	
technique	by	eliminating	any	initial	issues	and	ultimately	improving	clinical	
outcome.		
	
Evolution	of	ACI	
Many	of	the	initial	issues	associated	with	first	generation	ACI	were	with	the	
native	periosteal	tissue	harvest	and	stitching.	These	issues	related	to	time	and	
quality	of	the	harvest.	A	periosteum	harvest	is	relatively	time-consuming	in	
regard	to	the	full	surgical	procedure,	keeping	the	patient	under	anaesthetic	and	
exposing	the	open	wound	for	longer	periods	of	time,	both	of	which	increased	the	
risk	of	possible	complications	and	infection.	A	further	issue	is	that	the	
transplanted	‘flap’	regularly	undergoes	hypertrophy	or	ossification	(Brittberg	et	
al.,	1996;	Kuroda	et	al.,	2011),	which	is	considered	a	major	reason	for	an	
inhomogeneous	outcome	of	first	generation	ACI	(Haddo	et	al.,	2004).	
Second	generation	ACI	aimed	to	eliminate	the	periosteal	tissue	harvest	
issues	by	using	a	synthetic	collagen	membrane	from	porcine	origin	as	an	
alternative.	These	were	found	to	have	superior	clinical	long-term	outcomes	
compared	with	first	generation	ACI	(Gooding	et	al.,	2006;	Zeifang	et	al.,	2010).	
However,	by	using	animal	derived	membranes	this	posed	its	own	risk	of	possible	
cross-species	contamination.	
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	 Third	generation	ACI,	also	known	as	matrix-induced	ACI	(MACI),	
optimised	the	technique	further	to	utilise	hydrogel	scaffold	constructs.	An	
example	of	which	is	Hyalofast	or	CaRes,	both	of	which	are	made	from	type	I	
collagen	gel	(Kuroda	et	al.,	2011)	The	scaffold	is	used	for	culturing	the	cells	in	a	
three-dimensional	environment.	This	optimisation	reduces	the	time	of	cells	in	
monolayer	culture	and	should	therefore	reduce	the	risk	of	de-differentiation,	
ensuring	cells	maintain	their	chondrogenic	phenotype	up	until	re-implantation	
(Schnabel	et	al.,	2002;	Schulze-Tanzil,	2009).	MACI	has	the	added	advantage	of	
requiring	no	patch	to	seal	the	cells	into	the	defect	and	scaffolds	can	be	trimmed	
to	be	an	exact	fit	to	the	size	of	the	defect	site.	When	compared	with	first	and	
second	generation	ACI,	MACI	has	the	advantages	of	being	surgically	simplistic	
and	being	able	to	be	performed	using	an	arthroscopic	approach	(Marcacci	et	al.,	
2005;	Minas	and	Nehrer,	1997;	Ossendorf	et	al.,	2007;	Peterson,	1996).	Despite	
the	three	generations	of	ACI	all	having	undergone	optimisation,	there	are	still	
some	associated	limitations	with	ACI.	
A	recent	health-economic	study	commissioned	by	the	UK	National	
Institute	for	Health	and	Care	Excellence	found	ACI	to	be	cost-effective	compared	
to	alternative	surgical	interventions,	but	it	also	found	that	ACI	comes	with	a	50%	
failure	rate	at	10	years.	We	need	to	consider	the	limitations	of	ACI	to	be	able	to	
optimise	the	technique	and	improve	upon	the	current	failure	rate.	Technical	
steps	at	the	point	of	cell	isolation	and	expansion,	re-implantation,	monitoring	of	
clinical	outcomes	and	the	establishment	and	longevity	of	the	graft	itself,	all	
require	further	attention.	Furthermore,	we	need	to	address	how	we	can	transfer	
ACI	to	other	joint	types.	
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At	the	point	of	cell	isolation	and	expansion,	chondrocytes	begin	to	de-
differentiate	once	exposed	to	tissue	culture	plastic	during	expansion.	De-
differentiation	results	in	the	chondrocytes	exhibiting	an	altered	phenotype,	one	
more	characteristic	of	fibroblast	cells	(Lin	et	al.,	2008;	Schulze-Tanzil,	2009).	This	
altered	phenotype	impacts	upon	tissue	biomechanics	and	function.	Until	
recently,	ACI	has	been	restricted	to	assess	the	efficacy,	cost-effectiveness	and	
efficiency	compared	to	other	treatment	options	that	are	readily	available	on	the	
NHS,	such	as	microfracture.	The	majority	of	this	research	has	been	conducted	on	
the	knee	(Bartlett	et	al.,	2005;	Bentley	et	al.,	2003;	Fu	et	al.,	2005;	McCarthy	et	
al.,	2015;	Steinwachs	and	Kreuz,	2007),	with	little	work	carried	out	on	assessing	
ACI	treatment	into	other	joints,	including	the	ankle	(Giannini	et	al.,	2014;	
McCarthy	et	al.,	2015;	Thermann	et	al.,	2014;	Whittaker	et	al.,	2005;	Zengerink	et	
al.,	2010).	However,	the	use	of	ACI	in	the	ankle	has	increased	over	time	but	still	
requires	further	work	to	be	carried	out	to	allow	for	much	needed	optimisation	to	
adapt	to	treating	a	wide	variety	of	joints,	including	the	ankle	(National	Institute	
of	Health	and	Care	Excellence,	2017;	National	Institute	of	Health	and	Care	
Excellence,	2015).		
	
1.2.1.3	Knee,	foot	and	ankle	cartilage	
Due	to	the	high	prevalence	of	knee	osteoarthritis,	occurring	in	approximately	6%	
of	the	population,	there	are	lots	of	surgical	treatments	currently	available	to	
repair	cartilage	damage	in	this	joint	(page	29;	Felson	et	al.,	1987).	Furthermore,	
high	levels	of	research	are	being	conducted	into	new	or	improved	treatments.		
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Ankle	cartilage	damage	is	usually	treated	by	total	ankle	replacement,	
ankle	fusion	or	osteotomy.	Little	research	has	been	conducted	into	cartilage	
repair	of	the	ankle,	especially	when	compared	to	the	plethora	of	research	
conducted	into	the	other	joints	of	the	lower	extremity	(Bartlett	et	al.,	2005;	Fu	et	
al.,	2005;	McCarthy	et	al.,	2015).	This	is	surprising,	as	the	ankle	has	a	higher	
injury	rate.	However,	this	may	be	explained	by	the	ankle	having	a	lower	
prevalence	of	osteoarthritis	at	just	1%	of	the	population,	compared	to	the	6%	
prevalence	of	osteoarthritis	in	the	knee	(Aurich	et	al.,	2014;	Felson,	1990),	and	
ankle	cartilage	defects	tend	to	be	of	a	lesser	International	Cartilage	Repair	
Society	grade	(Figure	9;	page	41)	and	are	less	likely	to	require	surgical	
intervention.	Combined,	these	findings	possibly	indicate	that	the	ankle	has	a	
protective	mechanism	preventing	cartilage	injuries	either	progressing	to	
osteoarthritis	or	progressing	in	osteoarthritis	severity	(Aurich	et	al.,	2014).	
Osteoarthritis	in	the	ankle	is	less	likely	to	develop	sporadically	but	is	most	likely	
to	be	a	result	of	trauma,	termed	post-traumatic	osteoarthritis.	
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Figure	9:	International	cartilage	repair	society	grading	of	cartilage	lesions,	listing	
key	characteristics	of	severity.	Severity	ranges	from	normal	(grade	0)	to	severely	
abnormal	(grades	3-4).	Image	taken	from	Brittberg	and	Peterson,	1998.		
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There	are	notable	anatomical	differences	between	the	ankle	and	knee	
joints.	The	knee	is	comprised	of	four	main	bones:	the	patella,	the	fibula,	the	tibia	
and	the	femur	(Figure	10),	whereas	the	foot	is	a	small	joint	comprised	of	26	
bones:	five	metatarsal	bones,	14	phalangeal	bones	and	seven	talar	bones	(Figure	
10).	The	ankle	joint	is	a	relatively	unstable	complex	joint	consisting	of	three	
bones:	the	tibia,	fibula	and	talus,	and	three	main	joints:	the	subtalar	joint,	
talocrural	joint	and	talocanconavicular	joint	(Brockett	and	Chapman,	2016).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	10:	Basic	anatomy	of	the	(A)	knee	and	(B)	the	ankle.	Image	adapted	from	
Gray’s	Anatomy;		Drake	et	al.,	2015.	
	
B	
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Ankle	cartilage	is	1-1.7	mm	thick	on	the	talus,	much	thinner	when	
compared	to	knee	cartilage	which	can	range	up	to	6	mm	in	thickness	(Ateshian	et	
al.,	1991;	Schenck	and	Athanasiou,	1993).	Simply,	both	joints	are	considered	
synovial		hinge	joints,	however	the	ankle	is	a	more	complex	joint	comprised	of	
two	joints	and	has	three	planes	of	movement:	the	sagittal	plane,	the	transverse	
plane	and	the	frontal	plane,	whereas	the	knee	is	comprised	of	one	joint	and	has	
only	one	plane	of	movement	(Brockett	and	Chapman,	2016).		
	
1.2.1.4	ACI	for	knee	and	ankle	defects	
A	handful	of	studies	over	the	last	15	years	have	demonstrated	the	recent	success	
of	translating	ACI	to	the	ankle	joint	to	treat	osteochondral	defects	(Giannini	et	
al.,	2014;	Giza	et	al.,	2010;	Nam	et	al.,	2009;	Schneider	and	Karaikudi,	2009;	
Thermann	et	al.,	2014;	Whittaker	et	al.,	2005).		
From	a	clinical	perspective,	MRI	demonstrated	improvements	in	outcome	
and	repair	quality.	This	was	reflected	by	increased	Western	Ontario	and	
McMaster	Universities	Arthritis	Index	scores	post-operatively,	fully	filled	
defects,	a	good	integration	observed	with	no	lamination	of	matrix,	and	a	
decreased	bone	marrow	oedema	observed	in	88.9%	of	patients	(Imhoff	et	al.,	
2011;	Nam	et	al.,	2009;	Thermann	et	al.,	2014).	Histological	findings	further	
support	the	results	seen	radiologically	and	in	outcome	measures.	One	study	
compared	three	successful	ACI	cases	to	three	failed	ACI	cases	and	found	that	the	
quality	of	cartilage	formed	may	be	paramount	to	the	success	of	ACI	within	the	
ankle.	Histologically,	the	three	successful	cases	demonstrated	hyaline-like	
cartilage,	which	contrasted	to	the	three	failed	cases	that	demonstrated	
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fibrocartilage	tissue	with	altered	cell	organisation	and	lower	concentrations	of	
GAGs	(Giannini	et	al.,	2014).	This	correlates	with	a	study	performed	at	our	
centre,	which	evaluated	six	biopsies	of	successful	ACI	within	the	talus	and	found	
mainly	hyaline	cartilage,	indicating	good	quality	cartilage	tissue	formation	
(Whittaker	et	al.,	2005).		
The	high	levels	of	clinical	success	in	ACI	surgery	have	been	partly	credited	
to	the	extensive	rehabilitation	process	associated	with	the	technique.	ACI	
rehabilitation	therapy	is	considered	more	intense	than	standard	rehabilitation	
therapies	assigned	with	other	surgical	therapies.		
Furthermore,	high	levels	of	patient	satisfaction	have	been	recorded	
following	ACI	from	our	centre	and	others.	A	study	performed	at	RJAH	reported	
90%	of	patients	being	pleased	with	the	outcome	of	ACI	performed	in	their	ankle	
(Whittaker	et	al.,	2005),	and	another	study	reporting	100%	of	patients	felt	that	
they	had	improved	following	ankle	MACI	(Giza	et	al.,	2010).	There	was	no	
placebo	effect	assessed,	as	these	studies	compared	one	treatment	to	another	
directly.	
	
1.3 Assessment	of	the	outcomes	for	foot	and	ankle	surgical	treatments		
Patient-reported	outcome	measures	(PROMs)	are	defined	by	the	US	Food	and	
Drug	Administration	as	‘any	report	of	the	status	of	a	patient’s	health	condition	
that	comes	directly	from	the	patient,	without	interpretation	of	patient	response	
by	a	clinician	or	anyone	else’	(U.S.	Department	of	Health	and	Human	Services	
Food	and	Drug	Administration,	2009).	They	are	designed	to	assess	the	impact	of	
the	disease	on	the	patient	and	provide	a	clear	view	of	the	treatment	from	the	
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patient	perspective,	which	can	provide	invaluable	information	that	technology	
and	observers	cannot	provide	(Black,	2013).		
PROMs	are	primarily	used	to	assess	the	success	of	surgical	intervention	
on	patients.	Studies	have	shown	that	patient-reported	healthcare,	including	the	
use	of	PROMs,	results	in	enhanced	treatment	adherence	and	improved	
treatment	outcomes	(Pinsker	et	al.,	2013).	There	are	two	methods	used	in	
PROMs	analysis;	through	direct	answers,	for	example	pain	severity,	or	through	
the	change	from	a	previously	completed	score	(U.S.	Department	of	Health	and	
Human	Services	Food	and	Drug	Administration,	2009).		
As	PROMs	are	solely	patient-reported	with	no	clinician	input,	this	can	
cause	barriers	with	wide	application	and	can	cause	difficulty	with	administration	
and	data	input.	Some	scores	can	be	specific	to	certain	conditions	or	diseases	and	
this	can	limit	their	suitability	and	consequently	their	application.	Despite	this,	
usually	several	PROMs	are	administrated	to	thoroughly	assess	the	outcome	of	
the	condition	or	treatment.	As	there	is	currently	no	gold	standard	PROM,	and	
not	all	PROMs	are	validated,	selecting	an	appropriate	outcome	measure	can	be	
difficult	and	therefore	PROMs	are	usually	selected	based	on	routine	use	or	
preference	of	the	clinician	or	centre	(Nelson	&	Berwick,	1989;	McHorney	&	
Tarlov,	1995;	Martin,	et	al.,	1997;	Binkley,	et	al.,	1999).		
Therefore,	there	is	high	demand	for	a	newly	developed	validated	PROM	
for	assessing	all	the	relevant	areas	for	the	outcome	of	cell	therapy,	including	ACI.		
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1.3.1	Validation	of	patient-reported	outcome	measures	(PROMs)	
Once	developed,	it	is	important	that	any	PROM	is	validated	and	undergoes	
analyses	to	ensure	that	the	score	is	fit	for	purpose,	especially	as	the	purpose	is	to	
measure	clinical	outcome.	Only	once	a	score	is	validated	should	it	then	be	used	
in	clinic.		
Validity	is	defined	as	the	extent	to	which	a	score	actually	measures	what	
it	purports	to.	This	can	be	assessed	using	three	areas,	construct	validity,	content	
validity	and	criterion	validity,	all	of	which	are	further	defined	and	summarised	in	
Table	3.	Other	aspects	to	consider	during	validation	are:	the	type	of	score	and	
whether	it	is	suitable,	the	characteristics	of	the	subjects	and	the	reliability	and	
responsiveness	of	the	outcome	measure	being	assessed.		
All	outcome	measures	must	be	responsive,	specifically	it	must	be	
sensitive	to	changes	in	clinical	outcome.	Therefore,	it	must	be	able	to	accurately	
detect	whether	a	patient	is	improving	or	declining	in	clinical	outcome.	The	
content	must	capture	what	the	score	aims	to	capture	and	must	be	considered	
important	from	the	patient	perspective	as	a	PROM	is	designed	to	be	solely	
patient-reported.	The	score	must	also	be	reliable.	More	specifically,	if	no	change	
has	occurred	then	the	PROM	should	remain	relatively	consistent.	Finally,	the	
score	must	also	be	able	to	correlate	with	existing	validated	outcome	scores.		
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Table	3:	A	summary	of	validation	criteria	for	outcome	measures	and	a	summary	
of	aspects	to	consider	when	designing,	selecting	or	validating	an	outcome	
measure.	
Aspects:	 Details:	
Content	validity	 Defined	as	the	degree	to	which	the	content	of	the	outcome	
measure	is	an	adequate	reflection	of	the	construct	to	be	
measured.	
Construct	
validity	
Defined	as	the	degree	to	which	the	scores	of	the	outcome	
measure	are	consistent	with	the	hypotheses.	
Criterion	
validity	
Defined	as	the	degree	to	which	the	outcome	measure	is	an	
adequate	reflection	of	a	‘gold	standard’.	
Type	of	score	 There	are	eight	types	of	score:	generic,	disease-specific,	
region-specific,	patient-specific,	population-specific,	
dimension-specific,	summary	items	and	utility	measures.	
Subjects	 To	ensure	it	addresses	the	needs	and	characteristics	of	the	
subjects.	
Reliability	 Defined	as	the	degree	to	which	an	outcome	measure	is	free	
form	measurement	error.	For	example,	scores	from	patients	
who	have	not	changed	in	outcome	should	remain	
consistent.	
Responsiveness	 Defined	as	the	ability	of	a	score	to	detect	change	over	time	
in	the	construct,	for	example	following	intervention.	
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Aims	of	PhD	project	
This	PhD	project	has	the	overall	aim	of	advancing	cartilage	repair	of	the	ankle	by	
increasing	the	understanding	of	ankle	defects	and	treatment,	and	improving	upon	
existing	cell	therapies.	This	will	be	addressed	through	the	following	projects:	
(1)	 To	 advance	 cartilage	 cell	 therapy	 by	 improving	 the	 expansion	 and	
chondrogenic	capacity	of	cultured	human	chondrocytes.	
(2)	To	better	understand	why	 the	ankle	 is	 less	prone	 to	osteoarthritis	 than	 the	
knee	by	characterising	the	differences	in	the	metabolism	of	chondrocytes	isolated	
from	knee	and	ankle	cartilage.	
(3)	To	assess	the	outcomes	for	ankle	surgical	treatments,	including	cartilage	cell	
therapy,	by	designing	a	new	PROM	and	then	comparing	it	with	existing	validated	
scores.
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Chapter	2:	Methods	and	materials		
2.1	Laboratory	methods	
2.1.1	Media	and	solution	compositions	
Working	solution	
Dulbecco’s	Modified	Eagles	Medium	(DMEM):F12	containing	0.03	mg/ml	
deoxyribonuclease	I	(Sigma,	Poole,	UK)	and	0.83	mg/ml	type	XI	collagenase	
(Sigma,	Poole,	UK).	Working	solution	was	used	for	digesting	cartilage	samples	to	
obtain	chondrocyte	cells.	
	
Ascorbic	acid	solution	
10	mg	of	ascorbic	acid	(Sigma,	Poole,	UK)	was	dissolved	in	125	ml	of	sterile	water	
for	injection	(Fannin,	Dublin	Ireland).	Ascorbic	acid	solution	was	added	to	all	
media	solutions	used	in	cell	culture,	listed	below.	
	
Serum-free	media		
DMEM:F12	(Gibco	-	Thermo	fisher	Scientific,	Massachusetts,	USA)	supplemented	
with	0.5%	(w/v)	penicillin-streptomycin-amphotericin	(Lonza,	Basel,	Switzerland)	
and	0.5%	(w/v)	ascorbic	acid	solution.	Serum-free	media	was	used	for	re-
suspending	cells	prior	to	cell	counts	during	passaging.	
	
Complete	culture	media		
DMEM:F12	supplemented	with	0.5%	(w/v)	penicillin-streptomycin-amphotericin,	
0.5%	(w/v)	ascorbic	acid	solution	and	10%	(v/v)	foetal	bovine	serum	(FBS;	Gibco	
–	Thermo	Fisher	Scientific,	Massachusetts,	USA).	Complete	culture	media	was	
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used	for	cell	culture	in	all	experiments,	unless	otherwise	stated,	for	the	culture	of	
all	cells	used	in	Chapter	4,	and	the	FBS	culture	of	samples	in	Chapter	3.	
	
Stemulateä	culture	media	
DMEM:F12	supplemented	with	0.5%	(w/v)	penicillin-streptomycin-amphotericin,	
0.5%	(w/v)	ascorbic	acid	solution	and	10%	(v/v)	Stemulateä	(Cook	Regentec,	
Indianapolis,	USA).	Stemulateä	culture	media	was	used	for	‘Stemulateä’	
defined	samples	in	Chapter	3.	
	
Chondrogenic	media	
DMEM:F12	supplemented	with:	1%	(v/v)	FBS,	1%	(v/v)	non-essential	amino	acids	
(Gibco	-	Thermo	fisher	Scientific,	Massachusetts,	USA),	1%	(v/v)	L-glutamine	
(Lonza,	Basel,	Switzerland),	0.5%	(v/v)	penicillin-streptomycin-amphotericin,	
0.5%	(w/v)	ascorbate,	1%	(v/v)	insulin-transferrin-selenium	(Gibco	-	Thermo	
fisher	Scientific,	Massachusetts,	USA),	200	ng/ml	transforming	growth	factor-b1	
(TGF-b1;	Peprotech,	New	Jersey,	USA),	10	nM	dexamethasone	(Sigma,	Poole,	UK)	
and	3.2	µg/ml	L-proline	(Sigma,	Poole,	UK).	Chondrogenic	media	was	used	
throughout	Chapter	3	and	Chapter	4	for	all	chondrogenic	pellet	culture.	
	
Blocking	agent	for	flow	cytometry	
1	ml	of	blocking	agent	was	prepared	by	diluting	10%	(v/v)	human	IgG	in	2%	(w/v)	
bovine	serum	albumin	(w/v).	Blocking	agent	was	used	to	incubate	cell	
suspensions	prior	to	flow	cytometry	in	Chapter	4.	
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Proteinase	K	solution		
Proteinase	K	(Life	Technologies,	California,	USA)	was	diluted	in	100	mM	of	
ammonium	acetate	(Sigma,	Poole,	UK)	in	a	final	concentration	of	1	mg/ml.	
Proteinase	K	solution	was	used	to	digest	three-dimensional	chondrogenic	pellets	
for	biochemical	analysis	in	Chapter	3	and	Chapter	4.	
	
1,9-dimethylmethylene	blue	(DMMB)	dye	solution	
The	dye	was	prepared	by	diluting	4	mg	DMMB	(Sigma,	Poole,	UK)	in	225	ml	of	
distilled	water	containing	0.76	g	glycine	(Sigma,	Poole,	UK)	and	0.595	g	sodium	
chloride.	The	final	solution	was	adjusted	to	pH	3.0	using	2	M	hydrochloric	acid	
and	the	final	volume	was	adjusted	to	250	ml	using	distilled	water.	The	solution	
was	protected	from	light,	kept	at	room	temperature	and	filtered	prior	to	use	
using	Whatman	filter	paper.	DMMB	dye	solution	was	used	in	Chapter	3	and	
Chapter	4	for	GAG	analysis	experiments	of	chondrogenic	pellets.	
	
Citrate/acetate	buffer		
It	was	prepared	by	dissolving	34	g	sodium	hydroxide	(Sigma,	Poole,	UK),	34	g	
citric	acid	monohydrate	(Sigma,	Poole,	UK)	and	120	g	sodium	acetate	trihydrate	
(Sigma,	Poole,	UK)	in	250	ml	of	distilled	water.	The	final	solution	was	adjusted	to	
pH	6.0	and	to	a	final	volume	of	1	L	using	distilled	water.	Citrate/acetate	buffer	
was	used	to	further	prepare	oxidation	buffer,	outlined	below,	for	hydroxyproline	
assays	to	determine	total	collagen	content	of	chondrogenic	pellets	in	Chapter	3	
and	Chapter	4.	
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Oxidisation	buffer		
Oxidisation	buffer	was	prepared	by	mixing	600	ml	isopropanol,	330	ml	distilled	
water	and	390	ml	citrate/acetate	buffer.	Oxidation	buffer	was	used	as	a	standard	
control,	and	to	further	prepare	oxidation	solution,	outlined	below,	for	
hydroxyproline	assays	to	determine	total	collagen	content	of	chondrogenic	
pellets	in	Chapter	3	and	Chapter	4.	
	
Oxidisation	solution	
Oxidation	solution	was	prepared	in	a	dark	reservoir	by	dissolving	300	mg	of	
chloramine	T	(Sigma,	Poole,	UK)	in	50	ml	oxidation	buffer.	Oxidation	solution	was	
used	for	hydroxyproline	assays	to	determine	total	collagen	content	of	
chondrogenic	pellets	in	Chapter	3	and	Chapter	4.	
	
Ehrlich’s	reagent	
Ehrlich’s	reagent	was	prepared	by	dissolving	6	g	of	p-
dimethylaminobenzaldehyde	(Sigma,	Poole,	UK)	in	a	mixture	of	52	ml	of	
isopropanol	and	16	ml	of	50%	perchloric	acid	(Sigma,	Poole,	UK).	Ehrlich’s	
reagent	was	used	for	hydroxyproline	assays	to	determine	total	collagen	content	
of	chondrogenic	pellets	in	Chapter	3	and	Chapter	4.	
	
Reaction	mix	for	complementary	DNA	(cDNA)	conversion	
It	was	prepared	by	mixing	5	µl	of	reverse	transcriptase	(RT)	buffer,	5	µl	of	
random	primers,	2.5	µl	of	multiscribe	RT	enzyme,	2	µl	of	deoxynucleotide	mix	
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and	10.5	µl	of	RNAse-free	water.	Final	volume	of	solution	was	25	µl.	Reaction	
mix	was	used	to	convert	mRNA	to	cDNA	for	further	qRT-PCR	analysis	for	gene	
expression	profiling.	
	
Reaction	mix	for	qRT-PCR	
The	reaction	mix	consisted	of	10	µl	of	SYBR	green	reaction	mix,	2	µl	of	primers	
for	targeted	genes	and	6.4	µl	of	RNAse	free	water.	The	reaction	mix	(18.4	µl)	was	
added	to	the	wells	containing	cDNA	to	give	a	20	µl	reaction.	Reaction	mix	of	each	
gene	of	interest	was	used	during	qRT-PCR	for	gene	expression	profiling.	
	
2.1.2	Obtaining	patient	consent	
Fully	informed	consent	was	taken	from	individuals	undergoing	total	joint	
replacement	surgery	at	our	centre,	RJAH,	for	either	the	ankle	or	knee	with	
ethical	approval	(11/NW/0875;	Appendix	I,	page	225).	All	patient	consents	were	
obtained	by	research	assistants	Dr	Sharon	Owen	and	Mrs	Annie	Kerr.	
Demographics	for	each	experiment	are	shown	in	the	relevant	experimental	plans	
outlined	in	each	chapter.	
	
2.1.3	Chondrocyte	isolation		
Each	tissue	sample	was	photographed	and	full	depth	cartilage	was	removed	from	
macroscopically	healthy	areas	of	the	femoral	condyle	of	knee	samples	and	the	
talus	of	ankle	samples	using	a	sterile	scalpel.	Cartilage	extraction	was	performed	
within	24	hours	of	receiving	the	tissue.	Chondrocytes	were	isolated	following	
established	protocols	(Harrison	et	al.,	2000;	Nguyen	et	al.,	2010;	Sykes	et	al.,	
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2018;	Wang	et	al.,	2008).	Briefly,	cartilage	tissue	(100-300	mg)	was	placed	into	
10	ml	working	solution	in	an	upright	T25	tissue	culture	flask	at	37	°C	with	5%	CO2	
for	16	hours.	After	16	hours,	the	digest	was	filtered	through	a	0.2	µm	cell	
strainer	and	chondrocytes	were	pelleted	at	750	g	for	10	minutes.	Trypan	blue	
(Sigma,	Poole,	UK)	was	used	to	determine	cell	viability.			
	
2.1.4	Chondrocyte	culture	
Chondrocytes	were	seeded	into	appropriately	sized	tissue	culture	flasks	at	a	
density	of	5x104	cells/cm2	in	serum-free	media	and	supplemented	specifically	for	
each	experiment,	as	listed	in	the	experimental	design	of	each	chapter.	
Chondrocytes	were	incubated	at	37	°C	with	5%	CO2	for	4	days	to	allow	for	
adherence,	after	which	media	were	replenished	three	times	weekly.	This	was	
considered	passage	zero.	Once	80%	confluency	had	been	reached,	chondrocytes	
were	passaged.		
	
2.1.5	Chondrocyte	passaging	to	increase	cell	number	
Once	approximately	80%	confluent,	chondrocytes	were	washed	with	phosphate	
buffered	saline	(PBS;	Gibco	-	Thermo	fisher	Scientific,	Massachusetts,	USA)	to	
weaken	cell	attachments	and	5	ml	or	10	ml	trypsin/EDTA	(Gibco	-	Thermo	fisher	
Scientific,	Massachusetts,	USA)	was	added	to	T75	or	T175	culture	flasks	
respectively	and	incubated	at	37	°C	with	5%	CO2	for	5	minutes.	Chondrocytes	
were	detached	by	gentle	agitation.	An	equal	volume	of	culture	media	was	mixed	
with	the	trypsin	and	pelleted	at	750	×g	for	10	minutes.	Supernatant	was	
discarded	and	the	cell	pellet	was	re-suspended	in	1	ml	of	serum-free	media.	A	
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cell	count	was	performed	and	cell	viability	was	determined	using	trypan	blue	
(Sigma,	Poole,	UK).	Chondrocytes	were	then	seeded	into	relevantly	sized	tissue	
culture	flasks	at	a	density	of	5x104	in	the	relevant	culture	media.	Cells	were	
cultured	in	monolayer	until	passage	two.		
	
2.1.6	Growth	kinetics	during	monolayer	expansion	
Throughout	each	passage,	cell	counts	were	performed	and	used	to	determine	
growth	kinetics	of	each	sample.	Still-images	using	brightfield	microscopy	were	
taken	throughout	monolayer	culture	using	a	Nikon	Eclipse	TS100	microscope	
(Nikon,	Tokyo,	Japan),	the	Hamamatsu	C4742-95	camera	(Phototonics,	Japan)	
and	IP	Lab	imaging	software	(BD	Biosciences,	California,	USA,	version	3.6).	
Growth	kinetics	were	assessed	throughout	monolayer	expansion,	by	absolute	
population	doublings	(PDs)	and	population	doubling	times	(PDTs).	PDs	and	PDTs	
were	recorded	at	each	passage	and	calculated	from	cell	counts	using	the	
following	formula	(McAteer	and	Davis,	2002):	
	
PD	=		 			time	in	culture	(days)	÷	PDT	
	
	
PDT	=	1	÷	multiplication	rate	
	
	
Multiplication	rate	=	3.32	*	[log	(final	cell	number)	–	log	(initial	cell	number)]	
time	difference	
	
2.1.7	Detection	of	chondrocyte	cell	surface	markers	by	flow	cytometry	analysis	
Flow	cytometry	uses	light	scatter	produced	by	light	refraction	to	determine	the	
count	and	profiles	of	the	cells	within	a	heterogeneous	mixture.	Forward	scatter	
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is	produced	from	light	being	refracted	by	the	cells	into	the	same	path	and	is	
usually	used	to	identify	cell	size,	whereas	side	scatter	is	produced	from	light	
being	refracted	by	the	cells	into	another	path	and	is	used	to	identify	the	
complexity	of	the	cells.	A	dot	plot	of	forward	scatter	and	side	scatter	(Figure	11)	
can	be	used	to	identify	‘probable’	cell	types.	However,	to	determine	definitive	
cell	types	using	flow	cytometry	labelling	with	cell	type-specific	markers	is	
required.	
	
	
	
	
	
	
	
	
	
Figure	11:	Examples	of	flow	cytometry	analysis	profiles	used	to	determine	the	
profile	of	cells	based	on	forward	scatter	and	side	scatter.	This	example	was	used	
to	determine	blood	cells	in	a	homogenous	population.	Image	taken	from	BD	
Biosciences,	2008.		
Neutrophil	
	
	
	
	
	
	
Monocytes	
	
	
	
	
	
	
Lymphocytes	
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A	profile	of	cell	surface	markers	was	selected	to	determine	
chondrogenic	potency	of	chondrocytes	and	based	upon	published	work	from	our	
centre	(Garcia	et	al.,	2016a).	These	consisted	of:	CD39,	CD44,	CD49c	and	CD166.	
Details	of	clones	and	isotype	controls	are	listed	in	Table	4.	
Briefly,	cells	were	harvested	from	monolayer	culture	at	passage	three.	
4x104	cells	were	harvested	and	re-suspended	in	1	ml	blocking	agent	and	
incubated	protected	from	the	light	for	1	hour	at	4	°C.	The	samples	were	
centrifuged	at	350	g	for	8	minutes	and	re-suspended	in	200	µl	of	2%	(w/v)	bovine	
serum	albumin	and	aliquoted	equally	into	two	flow	cytometry	tubes.	
Fluorochrome	conjugated	antibodies	against	CD39,	CD44,	CD49c	and	CD166	
were	added	in	the	volumes	specified	in	Table	4	and	incubated	for	30	minutes	at	
4	°C	protected	from	the	light.	The	samples	were	then	washed	in	1	ml	of	2%	(w/v)	
bovine	serum	albumin	and	centrifuged	at	350	×g	for	8	minutes.	Supernatant	was	
discarded	and	the	pellets	were	re-suspended	in	300	µl	2%	(w/v)	bovine	serum	
albumin,	before	being	analysed	in	the	FACS	CantoII	cytometer	using	the	
FACSCanto	II	flow	cytometry	machine	(BD	biosciences)	and	FACSDiva	software	
(BD	biosciences,	version	7.0).	
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Table	4:	Cell-specific	markers	used	to	determine	chondrogenic	potency	of	the	
cultured	chondrocytes,	listed	with	the	volumes,	clone,	isotype	control	and	
fluorochrome	used	to	analyse	the	flow	profile.	
	
2.1.8	Three-dimensional	pellet	culture	to	re-differentiate	chondrocytes	
Re-differentiation	of	chondrocytes	is	the	process	in	which	chondrocytes	regain	
their	original	chondrogenic	phenotype	following	de-differentiation	caused	by	
prolonged	exposure	to	plastic	during	monolayer	culture	(Caron	et	al.,	2012;	Wu	
et	al.,	2009).	Re-differentiation	results	in	chondrocytes	re-expressing	the	
cartilage	marker	molecules,	regaining	expression	of	GAGs,	ACAN	(gene	for	
aggrecan)	and	COL2A1,	and	having	a	reduced	expression	of	COL1A1	(Elima	and	
Vuorio,	1989;	Tallheden	et	al.,	2004).	Re-differentiation	is	usually	achieved	using	
three-dimensional	cell	culture	conditions	(Lin	et	al.,	2006;	Lin	et	al.,	2008).	
Once	80%	confluent	at	passage	2,	chondrocytes	were	passaged	and	
seeded	at	2.5x105	cells	into	1.5	ml	Eppendorf	tubes,	cultured	in	500	µl	
chondrogenic	media	and	centrifuged	at	750	×g	for	7	minutes	to	create	spherical	
chondrogenic	pellets.	After	24	hours,	the	Eppendorf	tubes	were	inverted	to	
Marker:	 Volume:	 Clone:	 Isotype	
control:	
Fluorochrome:	
CD39	 5	µl	 TU66	 IgG2b	 Allophycocyanin		
CD44	 5	µl	 G44-
26	
IgG2b	 Peridinin-Chlorophyll-Protein-
Cyanine	5.5	
CD49c	 80	µl	 C3	IL1	 IgG1	 Phycoerythrin		
CD166	 1	µl	 3A6	 IgG1	 Brilliant	Violet	421		
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ensure	the	pellets	did	not	adhere	to	the	tubes	but	remained	suspended	in	the	
chondrogenic	media.	Chondrogenic	media	was	replenished	twice	weekly	
(Johnstone	et	al.,	1998).	
	
2.1.9	Chondrogenic	pellet	processing	for	biochemical	analyses	
Chondrogenic	pellets	were	digested	in	250	µl	of	proteinase	K	solution	for	2	hours	
at	60	oC	to	release	GAG	and	DNA	content.	The	proteinase	K	was	inactivated	for	
5	minutes	at	100	°C.	These	samples	were	stored	at	-20	°C.	Standard	stock	
solutions	for	the	biochemical	assays	are	described	in	Table	5	(page	61).	
	
2.1.10	Total	cell	number		
Cell	number	within	the	chondrogenic	pellets	was	determined	using	the	
PicoGreenÒ	fluorescent	DNA	quantification	assay,	following	the	manufacturer’s	
instructions	for	the	PicoGreenÒ	fluorescent	DNA	quantification	kit	(Thermo	fisher	
Scientific,	Massachusetts,	USA).	All	reagents	were	included	in	the	kit.	This	assay	
uses	the	PicoGreenÒ	double	stranded	DNA	quantification	reagent,	which	binds	to	
the	double-stranded	DNA	present	in	the	samples	and	creates	an	increase	in	the	
fluorescence	proportional	to	the	amount	of	DNA	present	(Dragan,	et	al.,	2010).		
Stock	standard	solution	and	standard	concentrations	were	prepared	as	
listed	in	Table	5	(page	61).	Tris-Edta	buffer	(10	mM	Tris-HCl,	1	mM	EDTA)	was	
used	as	a	control.	PicoGreenÒ	dye	was	diluted	(1:200)	in	Tris-Edta	buffer	and	
protected	from	light.	Experimental	samples	were	diluted	(1:20)	in	Tris-Edta	
buffer.		
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Standards	were	diluted	with	an	equal	volume	(500	µl)	of	the	diluted	
PicoGreenÒ	dye	solution.	Experimental	standards	(25	µl)	were	mixed	with	200	µl	
Tris-Edta	buffer	and	225	µl	of	the	diluted	PicoGreenÒ	dye.	The	standards	and	
experimental	samples	(200	µl)	were	transferred	in	duplicate	to	a	96-well	flat-
bottomed	plate.	Fluorescence	was	read	at	excitation	480	nm	and	emission	
520	nm	on	a	FluorStar	Omega	microplate	reader	(BMG	Labtech,	Ortenberg,	
Germany).	The	fluorescence	value	for	the	control	was	subtracted	from	each	
sample	and	the	DNA	concentration	was	determined	from	the	standard	curve.	
Cell	number	was	calculated	using	the	widely	reported	value	of	7.7	pg	of	DNA	per	
chondrocyte	(Kim	et	al.,	1988).		
The	cell	number	obtained	from	the	PicoGreenÒ	assay	was	used	to	
normalise	the	sGAG	production,	total	collagen	production	and	gene	expression	
profiles	to	determine	results	per	cell	number	and	to	eradicate	any	slight	
variations	in	pellet	size.		
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Table	5:	Details	of	stock	solutions	and	standard	concentrations	for	biochemical	
analyses.	
Assay:	 Standard	stock	
solution:	
Standard	concentrations:	
Total	cell	number	
determined	by	
PicoGreenÒ	assay	
Lambda	DNA	(1:50	
dilution)	diluted	1:40	in	
10	mM	Tris-Edta	buffer.		
Final	stock	
concentration	of	2	
µg/ml	
100	ng/ml,	200	ng/ml,	
400	ng/ml,	600	ng/ml,	
800	ng/ml,	1	µg/ml.	
Diluted	in	Tris-Edta	buffer	
Total	sGAG	content	
assessed	by	DMMB	
assay	
Chondroitin	sulphate	A	
from	bovine	trachea,	
diluted	in	PBS.	
Final	stock	
concentration	of	1	
mg/ml	
2	µg/ml,	10	µg/ml,	50	
µg/ml,	100	µg/ml,	200	
µg/ml.	
Diluted	in	distilled	water	
Total	collagen	content	
assessed	by	
hydroxyproline	assay	
Hydroxyproline	diluted	
in	10	mM	hydrochloric	
acid.		
Final	stock	
concentration	of	1	
mg/ml	
0.1	µg/ml,	0.2	µg/ml,	0.4	
µg/ml,	0.6	µg/ml,	0.8	
µg/ml,	1.0	µg/ml.	
Diluted	in	10	mM	
hydrochloric	acid	
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2.1.11	Total	sulphated	glycosaminoglycan	(sGAG)	content		
The	total	sGAG	content	was	quantified	using	a	1,9-DMMB	assay	(Farndale	et	al.,	
1986).	This	assay	uses	DMMB	dye	(page	50),	which	presents	a	change	in	
absorbance	due	to	the	induction	of	metachromasia	when	the	dye	is	bound	to	
sGAGs	within	cartilage	tissue.		
Stock	DMMB	solution	and	standard	concentrations	were	prepared	as	
listed	(page	61;	Table	5).	Duplicate	samples	and	standards	(50	µl)	were	
transferred	to	a	96-well	flat-bottomed	plate	and	mixed	with	200	µl	of	the	DMMB	
dye.	Absorbance	was	read	immediately	at	530	nm	on	a	FluorStar	Omega	
microplate	reader	(BMG	Labtech,	Ortenberg,	Germany).	The	absorbance	value	
for	the	control	was	subtracted	from	each	sample	and	the	sGAG	concentration	
was	determined	from	the	standard	curve.	The	sGAG	content	was	normalised	to	
cell	number	using	the	cell	number	data	obtained	from	the	PicoGreenÒ	assay.	
	
2.1.12	Total	collagen	content		
The	total	collagen	content	was	determined	using	a	hydroxyproline	assay	(Brown	
et	al.,	2001).	This	assay	measures	hydroxyproline	which	relies	on	the	oxidation	of	
hydroxyproline	to	a	pyrrole	derivative	that	reacts	with	p-
dimethylaminobenzaldehyde	to	produce	a	coloured	product.	This	can	be	used	to	
estimate	collagen	fibril	content	based	on	100	hydroxyproline	residues	are	
present	per	1,000	amino	acid	residues	in	collagen	(Altman	and	Gerber,	1983).	
Stock	solution	and	standard	concentrations	were	prepared	as	listed	(Table	5;	
page	61).		
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Experimental	samples	(100	µl)	were	transferred	to	screw	cap	
polypropylene	tubes	and	hydrolysed	in	100	µl	of	hydrochloric	acid	(specific	
gravity	1.16,	approximately	10	M;	Sigma,	Poole,	UK)	for	16	hours	at	108	°C	in	a	
dry-heat	block.	On	cooling,	samples	were	partially	neutralised	with	800	µl	of	1	M	
sodium	hydroxide	(Sigma,	Poole,	UK).	Duplicate	samples	and	standards	(50	µl)	
were	transferred	to	a	96-well	flat-bottomed	plate.	Oxidation	buffer	(100	µl)	was	
used	as	a	negative	control.	Oxidation	solution	(100	µl)	was	added	to	all	samples	
and	standards.	The	plate	was	gently	shaken	and	then	incubated	at	room	
temperature	for	5	minutes.	Ehrlich’s	reagent	(100	µl)	was	added	to	all	wells	and	
mixed	well.	The	plate	was	sealed	with	adhesive	plate	seal	and	incubated	in	a	
60	°C	water	bath	for	45	minutes.	The	absorbance	was	read	at	570	nm	on	a	
microplate	reader	and	the	total	collagen	content	was	calculated	using	the	widely	
reported	multiplication	factor	of	7.2	(Sims	et	al.,	2000).		
	
2.1.13	Gene	expression	analyses	
2.1.13.1	Sample	preparation	for	gene	expression	analysis		
Chondrogenic	pellets	(2.5x105)	were	prepared	for	RNA	extraction	by	
homogenisation,	using	a	21g	needle	and	syringe,	in	350	µl	RLT	lysis	buffer	
(Qiagen,	Hildner,	Germany)	containing	1%	(v/v)	β-mercaptoethanol	(Sigma,	
Poole,	UK)	and	then	stored	at	-80	°C	in	1.5	ml	Eppendorf	tubes.	All	products	for	
messenger	RNA	(mRNA)	extraction,	cDNA	conversion	and	qRT-PCR	analysis,	
including	primers,	were	procured	from	Qiagen	(Hildner,	Germany)	unless	
otherwise	stated.	
	
Chapter	2:	Methods	and	materials.	
 
	
-	64	-	
2.1.13.2	Optimisation	of	reference	genes	
Gene	expression	was	determined	relative	to	two	reference	genes	according	to	
published	MIQE	guidelines	(Bustin	et	al.,	2009).	Five	commonly	used	reference	
genes	were	used	to	determine	co-efficiency	of	variance	across	chondrocyte	
culture	conditions	and	were	as	follows:	peptidylprolyl,	β-Actin,	glyceraldehyde	3-
phosphate	dehydrogenase,	hypoxanthine-guanine	phosphoribosyltransfrase-1	
and	TATA	box-binding	protein.	The	two	human	reference	genes	hypoxanthine-
guanine	phosphoribosyltransfrase-1		(Foldager	et	al.,	2009;	Rushton	et	al.,	2014)	
and	TATA	box-binding	protein	(Foldager	et	al.,	2009;	Pombo-Suarez	et	al.,	2008)	
were	selected	for	all	experiments	based	on	the	lowest	co-efficiency	of	variance	
values	(Figure	12).	Lowest	co-efficiency	of	variance	indicates	the	most	stable	
reference	genes	across	chondrocytes	cultured	in	both	FBS	and	StemulateTM	sera	
supplements.	A	co-efficiency	of	variance	of	7	or	less	is	considered	good.	
Figure	12:	Preliminary	experiment	to	determine	the	most	suitable	two	reference	
genes	from	a	selection	of	five	commonly	used	reference	genes	for	qRT-PCR	
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analysis	of	chondrogenic	pellets,	selected	based	on	the	lowest	co-efficiency	of	
variance.		
	
2.1.13.3	Qualitative	Real	Time-Polymerase	Chain	Reaction	(qRT-PCR)		
Amplification	of	targeted	DNA	molecules	was	assessed	using	qRT-PCR,	allowing	
for	assessment	of	fold	changes	in	gene	expression	to	quantify	gene	expression	
profiles	within	samples.	qRT-PCR	assesses	the	amplification	of	targeted	DNA	
molecules	and	occurs	in	real	time	and	therefore	allows	for	the	recording	and	
analysis	of	fold	changes	in	gene	expression	to	be	reported	as	they	occur,	as	
opposed	to	just	the	end-product	analysis.	mRNA	was	first	extracted	and	then	
converted	to	cDNA	to	be	able	to	perform	qRT-PCR.	
mRNA	was	extracted	from	the	chondrogenic	pellets	using	the	Qiagen	
RNeasy	mini	kit	as	per	manufacturers’	instructions.	All	required	reagents	were	
included	in	the	kit.	In	brief,	cells	were	thawed	and	re-suspended	in	350	µl	of	70%	
molecular	grade	ethanol	(Sigma,	Poole,	UK).	The	full	volume	was	then	
transferred	to	a	spin	column	placed	inside	a	2	ml	collection	tube	and	centrifuged	
at	8,000	×g	for	1.5	minutes.	RPE	buffer	(500	µl)	was	used	to	perform	two	washes	
of	the	mRNA	and	centrifuged	at	8,000	×g	for	1.5	minutes.	RNAse-free	water	(50	
µl)	was	added	and	centrifuged	at	8,000	×g	for	1.5	minutes	to	elute	the	mRNA.	
The	final	volume	was	collected	in	sterile	0.5	ml	Eppendorf	tubes	and	stored	at	-
80	°C.	
mRNA	was	then	converted	to	cDNA	using	a	high-capacity	cDNA	
reverse	transcription	kit	(Applied	Biosystems,	California,	USA)	in	a	Progene	
thermocycler	(Techne,	Minnesota,	USA)	following	the	manufacturers’	
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instructions.	All	reagents,	apart	from	RNAse	free	water,	were	provided	in	the	kit	
and	all	steps	were	performed	on	ice.	mRNA	(25	µl)	was	transferred	to	sterile	
tubes	containing	reaction	mix,	as	previously	described.	The	tubes	were	
transferred	to	the	thermocycler,	which	was	pre-programmed	to	25	°C	for	10	
minutes,	37	°C	for	2	hours	and	a	final	holding	step	of	4	°C.	Samples	were	stored	
at	-20	°C.	
	 For	each	patient,	qRT-PCR	was	performed	using	SYBR	green	(Applied	
Biosystems,	California,	USA)	on	three	pellet	replicates	from	days	0,	21	and	28.	
Genes	(Table	6;	page	67)	were	chosen	to	determine	the	chondrogenic	phenotype	
after	re-differentiation.	All	genes	were	human	derived.	Gene	expression	was	
expressed	relative	to	the	two	reference	genes	and	normalised	to	cell	number	
obtained	from	the	PicoGreenÒ	assay.	
All	steps	were	performed	on	ice.	Briefly,	1.6	µl	of	cDNA	from	three	
pellet	replicates	from	each	patient	was	added	to	the	96-well	flat-bottomed	plate.	
A	reaction	mix	for	each	gene	of	interest	was	prepared	as	explained	previously.	
The	plate	was	then	sealed	using	optical	adhesive	film	(Applied	Biosystems,	
California,	USA)	and	transferred	to	the	Quant	Studio3	Real-Time	PCR	machine	
(Applied	Biosystems,	California,	USA)	programmed	to	run	the	protocol	listed	in	
Table	7	(page	68).	
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Table	6:	Genes	selected	for	qRT-PCR	analysis	to	determine	the	chondrogenic	
phenotype	of	the	cells	and	to	determine	if	the	chondrocytes	had	de-
differentiated	to	a	hypertrophic	state.		
	
	 	
Gene:	 Official	name:	 Amplicon	length:	 Entrez	
ID:	
Reference	genes	
HPRT1	 Hypoxanthine	phosphoribosyl	
transferase	1	
-	130	(NM_000194)	 3251	
TBBP	 TATA	box-binding	protein	 -	132	(NM_001172085)	
-	132	(NM_003194)	
6908	
Chondrogenic	markers		
ACAN	 Aggrecan	 -	62	(NM_001135)		
-	62	(NM_013227)	
-	62	(XM_001131727)	
-	62	(XM_001131734)	
-	62	(XM_00670419)	
176	
COL2A1	 Collagen	type	2	alpha	1	 -	95	(NM_001844)		
-	95	(XM_006719242)	
1280	
SOX9	 SRY	(sex	determining	region	
Y)-box	9	
-	112	(NM_000346)	 6662	
De-differentiation	markers	
COL1A1	 Collagen	type	1	alpha	1	 -	118	(NM_000088)		
-	118	(NM_003257058)	
-	118	(XM_005257059)	
-	118	(XM_006721703)	
1277	
Hypertrophic	markers	
ALK1	 Activin	A	receptor	type	II-like	1	 -	74	(NM_000020)	 94	
COL10A1	 Collagen	type	10	alpha	1	 -	91	(NM_000493)	 1300	
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Table	7:	Programme	used	during	qRT-PCR.	
Process:	 Stage:	 Temperature	
(°C):	
Time	
(mins):	
Cycles:	
Activation	of	SYBR	Green	 Activation	 95	 10:00	 	1	
Separation	of	DNA	
strands	and	building	of	
cDNA		
Denaturation	 94	 00:10	 	
	40	Annealing	 55	 00:30	
Extending	 72	 00:34	
SYBR	green	analysis	of	
target	genes		
	
Dissociation	
94	 00:10	 	
	1	55	 00:30	
94	 00:10	
	
The	Quant	Studio	Design	and	Analysisä	Software	(Applied	Biosystems,	
California,	USA)	was	used	to	determine	cycle	threshold	(CT)	Values	and	the	
baseline	of	which	cycles	had	no	or	little	signal.	The	comparative	CT	method	(2-ΔCT)	
was	used	to	determine	the	relative	expression	profiles	of	each	gene	of	interest	
(Schmittgen	and	Livak,	2008).	Data	was	expressed	relative	to	the	two	reference	
genes	as	per	the	following	equation:		
2-ΔCT		 	 ΔCT	=	CT	GENE	OF	INTEREST	–	CT	COMBINED	REFERENCE	GENES		
	
2.1.14	Histological	analysis	of	chondrogenic	pellets	
2.1.14.1	Sample	preparation	for	histological	analyses		
Pellets	were	placed	onto	1	cm2	pieces	of	Whatman	filter	paper	(Whatman,	
Maidstone,	UK)	and	snap	frozen	in	liquid	nitrogen	cooled	n-hexane	and	stored	at	
-80	°C.	All	solutions	and	products	used	for	sectioning	were	obtained	from	Cell	
Path	Ltd,	Newtown,	USA.	
Frozen	pellets	were	mounted	onto	pre-cooled	chucks	with	optimal	
cutting	temperature	compound	and	secured	with	cryospray.	Sections	of	7	µm	
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thickness	were	cut	using	the	cryostat	(Bright,	Luton,	UK;	Model:	OTF)	and	
collected	onto	poly-L-lysine	pre-coated	slides.	Three	sections	were	collected	per	
slide.	Sections	were	stained	with	Haematoxylin	and	Eosin	(H&E)	or	Toluidine	Blue	
according	to	our	established	methods	(Roberts	and	Menage,	2004).	All	
histological	stains	were	procured	from	VWR	International,	Pennsylvania,	USA.	
	
2.1.14.2	Haematoxylin	and	Eosin	(H&E)	staining		
H&E	stain	is	used	to	evaluate	the	general	morphology	of	tissue	or	pellet	samples.	
As	haematoxylin	is	positively	charged	it	reacts	with	negatively	charged	
components	and	stains	these	blue-black,	such	as	nucleic	acids	in	the	nucleus.	
Eosin	is	negatively	charged	and	therefore	reacts	with	positively	charged	
components	and	stains	these	pink,	such	as	the	cytoplasm	and	ECM	(Roberts	and	
Menage,	2004).		
To	perform	the	H&E	stains,	slides	of	sectioned	pellets	were	flooded	in	
Mayer’s	Haematoxylin	Gurr	for	1-2	minutes.	Excess	dye	was	removed	and	slides	
were	washed	in	a	running	flow	of	tap	water.	Slides	were	transferred	into	a	coplin	
jar	of	tap	water	for	5	minutes	to	allow	tissue	sections	to	‘blue’.	Slides	were	
flooded	in	1%	Eosin	for	1	minute	and	then	washed	in	tap	water.	Slides	were	
dehydrated	through	increasing	concentrations	of	isopropanol	from:	70%,	90%,	
100%	in	which	the	slides	were	left	for	2	minutes,	after	which	the	slides	were	
placed	into	a	fresh	jar	of	100%	isopropanol	for	a	further	2	minutes	then	cleared	
in	xylene	for	5	minutes	and	then	transferred	into	a	fresh	jar	of	xylene	for	a	
further	5	minutes.	Slides	were	mounted	with	a	coverslip	using	pertex	(Histolab	
Products,	Othenburg,	Sweden)	and	left	to	air-dry	for	at	least	1	hour.	
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2.1.14.3	Toluidine	blue	staining		
Toluidine	blue	is	a	thiazine	metachromatic	dye	used	to	visualise	proteoglycans	in	
cartilage	tissue.	The	dye	changes	from	a	blue	to	a	purple	colour	when	attached	
to	GAGs	within	the	tissue	ECM	(Horobin,	2010).		
To	perform	the	toluidine	blue	stains,	slides	of	sectioned	pellets	were	
flooded	in	1%	aqueous	toluidine	blue	for	30	seconds.	Excess	dye	was	removed	
and	slides	were	washed	in	a	running	flow	of	tap	water.	Excess	water	was	
removed	and	slides	were	left	to	air-dry	for	at	least	30	minutes.	Slides	were	
mounted	with	a	coverslip	using	pertex	and	left	to	air-dry	for	at	least	1	hour	
(Roberts	and	Menage,	2004).	
Once	dry,	the	mounted	tissue	sections	were	viewed	using	the	Leitz	
Diaplan	307-148-001	light	microscopy	(Leitz,	Stuttgart,	Germany)	to	assess	the	
cell	and	tissue	morphology	of	the	stained	structures.	Images	were	taken	using	
´6.3,	´25,	´40	and	´63	objective	lenses.	Images	were	captured	using	the	Nikon	
DS-Fi1	camera	(Nikon,	Tokyo,	Japan)	and	analysed	with	NIS-Elements	BR	imaging	
software	(Nikon,	Tokyo,	Japan;	version	3.2).	Images	were	white	balanced	using	
Photoshop	Elements	(Adobe,	California,	USA;	version	15).		
	
2.1.14.4	Semi-quantification	of	toluidine	blue	staining	intensity		
To	semi-quantify	the	toluidine	blue	staining	intensity,	four	central	images	of	each	
pellet	were	randomly	selected	and	the	integrated	intensity	was	determined	
using	ImageJ	Software	(National	Institute	of	Health,	Washington,	USA;	version:	
24)	according	to	published	methodology	(Jensen,	2013;	Owida	et	al.,	2017;	
Prasad	and	Prabhu,	2012).	Using	ImageJ	software	an	area	of	stained	ECM	was	
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selected	and	measured	for	integrated	density.	An	area	of	slide	background	
containing	neither	cells	nor	ECM	was	selected	and	measured	for	integrated	
density.	The	total	staining	intensity	was	then	calculated	accounting	for	the	
background	using	the	following	formula:	
Total	staining	intensity	=	Integrated	density	ECM	–	integrated	density	BACKGROUND	
	
2.1.14.5	Histological	grading	
The	BERN	score	was	used	to	grade	the	histological	quality	of	the	chondrogenic	
pellets	(Table	8;	page	72).	This	score	accounts	for	uniformity	and	intensity	of	
ECM	staining,	cell	density/extent	of	the	ECM	produced	and	cellular	
morphologies.	There	are	three	set	criteria,	each	given	equal	weight	in	the	BERN	
scoring	system.	The	minimum	score	is	0	indicating	the	poorest	histological	
quality	and	the	maximum	score	is	9	indicating	the	highest	histological	quality.	
There	is	a	reported	relationship	between	the	BERN	score	and	the	GAG/cell	
content	within	pellets,	which	generally	indicates	the	lower	the	BERN	score,	the	
lower	the	GAG/cell	score	(Grogan,	et	al;	2006).		
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Table	8:	The	BERN	score	used	to	grade	histological	quality	of	the	chondrogenic	
pellets.		
Scoring	category:	 Assessment:	 Score:	
A	–	uniformity	and	
darkness	of	stain	
Observed	using	a	´10	
objective	lens	
No	stain	 0	
Weak	staining	of	poorly	formed	ECM	 1	
Moderately	even	staining	 2	
Even	dark	staining	 3	
B	–	distance	between	
cells/amount	of	ECM	
accumulated	
Observed	using	a	´20	
objective	lens	
High	cell	densities	with	no	ECM	in	
between		
0	
High	cell	densities	with	little	ECM	in	
between		
1	
Moderate	cell	density	with	ECM		 2	
Low	cell	density	with	moderate	distance	
between	cells	and	an	extensive	ECM	
3	
C	–	cell	morphologies	
represented	
Observed	using	a	´40	
objective	lens	
Condensed/necrotic/pycnotic	bodies	 0	
Spindle/fibrous	 1	
Mixed	spindle/fibrous	with	rounded	
chondrogenic	morphology	
2	
Majority	rounded/chondrogenic	 3	
Total:	 	/9	
	
2.1.15	Statistical	methods	for	biochemical	and	gene	expression	tests	
All	independent	outcomes	(PDTs,	cell	number,	sGAG,	total	collagen,	q-RTPCR	and	
staining	intensity),	patient	variability	and	differences	between	conditions	over	
the	experimental	time	courses	were	analysed	using	multilevel	modelling	in	
Statistical	Package	for	the	Social	Sciences	(SPSS)	statistical	software	package	
(IBM,	New	York,	USA;	version	24).	In	this	model,	condition	(either	supplement	
type	or	cartilage	source)	and	time	points	were	considered	fixed	variables.	Patient	
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was	considered	a	random	intercept	variable	to	accommodate	for	natural	patient	
variability.	All	qRT-PCR	data	was	log-transformed	before	any	statistical	analysis	
to	make	the	data	fit	a	normal	distribution.	Log-transformed	data	was	used	for	
reporting	the	qRT-PCR	data.	
Cell	number,	sGAG	and	total	collagen	data	were	expressed	as	mean	±	
standard	error	of	the	mean	(SEM).	Gene	expression	data	was	shown	as	a	box	
plot	with	the	box	representing	the	second	and	third	quartiles,	the	horizontal	line	
inside	the	box	representing	the	median	and	the	whiskers	either	side	of	the	box	
representing	the	lower	and	upper	quartiles.	All	statistical	analyses	were	
performed	with	SPSS	statistical	software	and	for	all	analyses	p£0.05	was	deemed	
to	denote	significance.	
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Chapter	3:	Investigating	the	impact	of	Stemulateä,	a	type	
of	human	platelet	lysate,	on	the	expansion	and	
chondrogenic	capacity	of	cultured	human	chondrocytes	for	
cartilage	cell	therapy.	
3.1	Introduction	
To	obtain	sufficient	cell	numbers	from	small	cartilage	biopsies	for	use	in	cell	
therapy,	chondrocytes	need	to	undergo	in	vitro	expansion,	which	usually	means	
the	chondrocytes	undergo	2-3	passages.	De-differentiation	is	a	key	limitation	in	
ACI,	as	chondrocytes	lose	their	chondrogenic	phenotype	(Benya	and	Shaffer,	
1982;	Schnabel	et	al.,	2002).	Consequently,	de-differentiation	decreases	the	
capacity	of	re-implanted	chondrocytes	to	regenerate	functional	cartilage	
(Schulze-Tanzil,	2009).	To	reduce	the	risk	of	de-differentiation,	RJAH	culture	the	
majority	of	freshly	isolated	chondrocytes	up	to	passage	2	to	achieve	sufficient	
cell	numbers	for	clinical	cell	therapy,	with	a	small	percentage	of	approximately	
15%	of	patients	having	their	cells	cultured	up	to	passage	3	(Harrison	et	al.,	2000).	
Complete	de-differentiation	is	known	to	occur	in	as	few	as	three	passages	(Kang	
et	al.,	2007).	Nevertheless,	further	minimising	of	conditions	which	promote	
chondrocyte	de-differentiation	may	improve	ACI	and	this	includes	reducing	the	
number	of	passages	the	chondrocytes	undergo.		
Current	standardised	protocols	for	chondrocyte	expansion	involve	culture	
in	serum-free	media,	or	growth	medium	supplemented	with	FBS	or	human	
autologous	serum.	Sera	is	commonly	used	as	it	is	known	to	support	cell	growth	
and	proliferation,	in	addition	to	stabilising	detoxifying	factors,	including	pH	and	
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aiding	transport	of	protein	carrying	hormones.	FBS	is	traditionally	used	in	
research	for	in	vitro	expansion	of	many	different	cell	types	including	
chondrocytes.		
However,	there	is	a	high	demand	to	find	alternatives	to	the	use	of	animal	
sera,	such	as	FBS,	in	cell	research.	FBS	is	an	ill-defined	cocktail	of	growth	factors,	
cytokines	and	adhesion	molecules	used	to	support	the	basic	cell	functions,	
including	proliferation,	growth	and	cell	adhesion.	However,	there	have	been	
several	issues	raised	regarding	the	use	of	FBS	in	cell	culture.	One	issue	is	there	is	
a	reported	high	batch-to-batch	variation,	meaning	that	batch	testing	is	required	
prior	to	conducting	research	and	only	the	appropriate	batch	can	be	used	
throughout	that	research	project	in	an	attempt	to	reduce	variability	(Jayme	et	
al.,	1988;	Jochems	et	al.,	2002).	An	increase	in	demand,	from	typically	500,000	L	
per	year,	and	limited	stocks	are	consistently	increasing	the	current	cost	price.	
Another	issue	is	the	possibility	of	cross-species	contamination	and	the	Good	
Manufacturing	Practice	guidelines	for	treatments	stating	any	animal	product	
must	be	replaced	with	a	human	alternative	whenever	possible	(European	
Medicines	Agency,	2013).	These	Good	Manufacturing	Practice	guidelines	
compliment	the	guidelines	set	by	the	National	Centre	of	the	Replacement,	
Refinement	and	Reduction	of	Animals	in	Research	(National	Centre	of	the	Three	
Rs,	2011).	A	final	issue	raised	is	concerning	the	ethics	regarding	the	animal	
welfare	during	the	production	and	collection	of	animal	sera.	FBS	is	produced	
from	a	cardiac	puncture	of	bovine	foetuses	collected	from	pregnant	cows	at	the	
slaughter	house.	The	cardiac	puncture	is	performed	without	anaesthetic	to	
minimise	risk	of	serum	contamination,	but	it	is	thought	that	the	foetuses	begin	
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to	feel	once	exposed	to	oxygen.	A	bovine	foetus	produces	approximately	150-
550	ml	of	raw	FBS,	which	increases	as	the	foetus	ages	(Jochems	et	al.,	2002).	
Therefore,	a	human	alternative	is	in	high	demand.	A	natural	choice	for	an	
alternative	would	be	human	autologous	serum,	however	this	is	not	always	
feasible	due	to	the	volumes	of	sera	required	for	long-term	cell	expansion.	
Human	platelet	lysate	(HPL)	is	one	alternative	currently	available	for	long-
term	cell	expansion	and	has	been	used	since	the	1980’s	(Choi	et	al.,	1980).	Much	
of	the	work	conducted	into	the	use	of	HPL	as	an	alternative	to	FBS	in	cell	
expansion	has	been	studied	using	Mesenchymal	Stem	Cells	(MSCs)	and	studies	
have	shown	that	HPL	increases	the	proliferative	rates	without	comprising	the	
MSC	phenotype	(Bieback	et	al.,	2009;	Juhl	et	al.,	2016).	Very	little	work	has	been	
conducted	into	the	effect	of	HPL	on	human	chondrocytes	(Doucet	et	al.,	2005;	
Hildner	et	al.,	2015;	Juhl	et	al.,	2016;	Kim	et	al.,	2015).		
StemulateÔ	is	a	commercially	available	source	of	HPL	provided	by	Cook	
Regentec	(Indianapolis,	USA).	It	contains	a	cocktail	of	all	essential	ingredients	to	
support	the	requirements	of	the	cell,	including:	growth,	proliferation	and	cell	
adhesion.	It	is	prepared	in	accordance	with	Good	Manufacturing	Practice	
guidelines	using	large	donor	pools	from	accredited	blood	centres	that	screen	for	
routine	human	viruses,	including	HIV.	StemulateÔ	has	been	used	to	expand	a	
range	of	different	cell	types,	including	adipose	tissue-derived	MSCs	and	bone	
marrow-derived	MSCs	(Badowski	et	al.,	2017;	Juhl	et	al.,	2016;	Mangum	et	al.,	
2017;	Riis	et	al.,	2016;	Søndergaard	et	al.,	2017).	Despite	little	research	
conducted	into	the	effect	of	StemulateÔ	on	chondrocytes,	it	could	be	used	as	an	
alternative	supplement	to	increase	chondrocyte	proliferation	for	cartilage	cell	
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therapy.	If	StemulateÔ	did	indeed	increase	the	proliferation	of	articular	human	
chondrocytes,	it	could	reduce	time	in	monolayer	culture	and	reduce	exposure	to	
tissue	culture	plastic,	which	in	turn	could	decrease	the	possibility	of	de-
differentiation,	and	by	extension	reduce	associated	cell	culture	cost.	
	
3.2	Experimental	design	
Figure	13	(page	78)	illustrates	the	experimental	design	for	this	project.	
Chondrocytes	were	isolated	following	enzymatic	digestion	and	split	
equally	into	two	sera	supplement	types:	FBS	and	Stemulate™	and	expanded	in	
monolayer	up	to	passage	2.	Once	approximately	80%	confluent	at	passage	2,	
chondrocytes	were	pelleted	(2.5	x105	cells/pellet)	in	CM	and	retained	in	culture	
for	up	to	28	days.	The	chondrogenic	capacity	was	investigated	at	7-day	intervals	
over	a	28-day	period	(day	0,	7,	14,	21,	28)	assessed	by	histological	analysis,	
biochemical	analysis	(determining	cell	number,	sGAG	synthesis	and	total	collagen	
synthesis)	and	through	gene	expression	profiles	specifically	for	markers	of	
chondrogenesis,	de-differentiation	and	hypertrophy.	
Five	knee	samples	were	received	from	patients	undergoing	total	knee	
replacement	surgery	at	RJAH.	Demographics	were	recorded	for	each	patient,	
including:	the	age	and	gender	of	the	patient	and	surgery	performed	(Table	9;	
page	79).	All	cartilage	was	taken	from	macroscopically	healthy	areas	of	the	
femoral	condyle	region	of	the	knee	joint.		
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Figure	13:	Schematic	illustrating	the	experimental	design	of	the	project	comparing	the	
chondrogenic	capacity	of	chondrocytes	cultured	in	FBS	and	StemulateTM	sera	
supplements.	
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Table	9:	Demographics	of	the	human	knee	tissue	sample	donors	from	which	the	
chondrocytes	were	obtained.	
	
Isolated	chondrocytes	(section	2.1.3,	page	53)	extracted	from	macroscopically	
healthy	cartilage	tissue	on	the	femoral	condyle	of	the	knee	joint	and	was	split	
equally	into	two	culture	conditions:	FBS	and	Stemulateä.	Samples	were	then	
cultured	in	monolayer	until	passage	2	(section	2.1.4	page	54).	Representative	
images	were	taken	of	the	knee	samples	received	and	are	displayed	in	Figure	14	
(page	80).	
	
	
	
	
	
	
	
Gender:	 Age:	 Procedure:	
Male	 55	years	 Total	knee	replacement	
Female	 62	years	 Total	knee	replacement	
Female	 74	years	 Total	knee	replacement	
Male	 70	years	 Total	knee	replacement	
Male	 76	years	 Total	knee	replacement	
Total:	2	females	
	……….3	males	
Mean	age:	67.4	years	
Age	range:	55-76	years	
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(A)	All	tissue	received	that	was	not	macroscopically	healthy	cartilage,	such	as	
meniscus	(m),	bone	(b)	and	fat	(f)	was	discarded.	Macroscopically	healthy	
cartilage	tissue	(c)	was	extracted	using	a	sterile	scalpel	and	digested	to	obtain	
chondrocytes,	avoiding	any	obvious	cartilage	lesions	or	artefact	damage.	
	
Once	confluent	at	passage	2,	chondrocytes	were	passaged	and	seeded	
into	three-dimensional	pellets	(2.5x105)	in	chondrogenic	media,	using	methods	
outlined	in	section	2.1.8	(page	58).	Pellets	were	maintained	in	culture	for	up	to	
28	days	for	three	patients	and	21	days	for	two	patients,	with	assessments	being	
carried	out	at	days	0,	7,	14,	21	and	28	as	outlined	in	Figure	13	(page	78).			
Chondrogenic	pellets	(n>3)	were	snap	frozen	at	days	7,	21	and	28.	Frozen	
pellets	were	sectioned	and	stained	with	toluidine	blue	(section	2.1.14.3,	page	70)	
and	H&E	(section	2.1.14.2,	page	69).		
	
Figure	14:	Representative	images	of	the	knee	tissue	obtained	following	total	knee	
replacement	surgery.	
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3.3	Results	
3.3.1	Stemulate™	positively	influences	proliferation	of	chondrocytes	in	
monolayer	culture	
For	all	five	patients,	the	chondrocytes	expanded	in	Stemulate™	(13.10	days	±	
2.57	SEM	mean	PDT)	proliferated	at	a	significantly	quicker	rate	than	the	
chondrocytes	expanded	in	FBS	(25.07	days	±	6.98	SEM	mean	PDT,	p=0.050).	
Patient	variability	was	considered	not	significant	(p=0.48)	in	affecting	the	PDT.	
Cell	number	obtained	during	monolayer	expansion	(Figure	15)	indicated	cell	
number	increased	over	time	for	both	sera	supplement	types,	as	expected	
(p<0.001)	but	was	consistently	higher	in	Stemulate™-expanded	chondrocytes	
(p=0.014)	across	all	passages	supported	by	the	increased	PDTs.		
Figure	15:	Cell	number	during	monolayer	expansion	of	chondrocytes	expanded	
in	FBS	and	Stemulate™	sera	supplements.	Cell	number	was	calculated	from	cell	
counts	during	chondrocyte	isolation,	were	seeded	at	an	equal	cell	density,	and	
across	three	passages.	Data	is	presented	as	mean	±	SEM	and	was	obtained	from	
five	patients	in	total.	
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Despite	proliferation	rates	being	higher	in	Stemulate™-expanded	
chondrocytes,	Figure	16	shows	both	sets	of	chondrocytes	underwent	less	than	
1.5	PDs	with	no	significant	difference	seen	between	sera	supplement	type.		
Figure	17	(page	83)	shows	the	morphology	of	the	human	chondrocytes,	
obtained	using	still	images	taken	by	light	microscopy	at	day 4	of	each	passage	
(passage	0,	passage	1	and	passage	2)	in	the	presence	of	either	Stemulate™	or	
FBS.	For	Stemulate™-expanded	chondrocytes,	there	were	markedly	more	
chondrocytes	that	appeared	to	be	more	clustered	together	at	all	passages.	There	
appeared	to	be	little	difference	in	cell	shape	between	the	two	supplement	types,	
as	the	chondrocytes	appeared	elongated	and	flattened	in	both	sera	supplement	
conditions.	
	
Figure	16:	Average	absolute	population	doublings	of	chondrocytes	expanded	in	
FBS	and	Stemulate™	at	each	of	the	three	passages.	Data	is	presented	as	mean	±	
SEM	and	was	obtained	from	five	patients	in	total.		
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Figure	17:	Representative	images	of	chondrocytes	expanded	in	culture	media	
supplemented	with	10%	(A)	FBS	and	(B)	Stemulate™	at	each	passage.	Images	were	
taken	at	day	4	of	each	passage	to	allow	the	chondrocytes	to	adhere.	All	images	were	
taken	using	a	Nikon	TS100	light	microscope,	Hamamatsu	C4742-95	camera	and	´20	
magnification	lens.	Images	were	acquired	using	IPLab	3.2.6	software.	All	scale	bars	
represent	10	µm.	
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3.3.2	Stemulate™	negatively	influences	the	re-differentiation	potential	of	
chondrocytes	in	three-dimensional	pellet	culture,	compared	to	standard	FBS.	
To	investigate	the	impact	of	the	sera	supplements	on	the	re-differentiation	
potential	of	the	chondrocytes	at	the	end	of	monolayer	expansion,	both	sera	
supplements	were	removed	and	chondrocytes	were	cultured	into	three-
dimensional	chondrogenic	pellets	in	chondrogenic	media.	The	pellets	were	
assessed	for	cell	number	(Figure	18),	total	sGAG	(Figure	19;	page	86),	total	
collagen	(Figure	20;	page	87),	and	gene	expression	by	qRT-PCR	(Figure	21;	page	
88).	
	 	
Cell	number	was	assessed	by	the	PicoGreenÒ	assay	throughout	the	time	
course	(Figure	18).	This	was	to	determine	if	the	chondrocytes	could	recover	their	
Figure	18:	Cell	number	in	chondrogenic	pellets	created	from	chondrocytes	
expanded	in	FBS	and	Stemulate™	sera	supplement	over	a	28-day	time	course.	Data	
is	presented	as	the	mean	±	SEM	and	was	obtained	from	five	patients	in	total	for	
day	0	–	day	21	and	three	patients	up	to	day	28.		
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morphology	and	prevent	further	proliferation	once	in	chondrogenic	pellet	
structures.	For	both	supplement	types,	cell	number	remained	consistent	
throughout	the	time	course,	at	approximately	the	number	of	cells	that	were	
originally	pelleted	(2.5	x106;	p=0.84).	Cell	number	was	used	to	normalise	the	
total	sGAG	and	total	collagen	production.	
Chondrocytes	expanded	in	both	supplement	types	demonstrated	a	
steady	and	significant	increase	in	sGAG	production	within	the	three-dimensional	
pellet	(Figure	19;	page	86)	across	all	time	points	(p<0.001).	sGAG	concentration	
was	higher	in	FBS	compared	to	Stemulate™	across	all	time	points	(p=0.009),	as	
determined	by	multi-level	modelling.	There	was	a	steady	increase	between	days	
0	and	7,	a	significant	sharp	increase	in	sGAG	concentration	between	days	7	and	
14	(p<0.001)	and	then	appeared	to	slightly	level	off	at	day	28	for	FBS-expanded	
chondrocytes.	Whereas,	there	was	a	steady	increase	between	days	0	and	21,	and	
then	a	sharp	increase	in	sGAG	concentration	between	days	21	and	28	in	
Stemulate™-expanded	chondrocytes.	The	trend	for	Stemulate™-expanded	
chondrocytes	appeared	to	lag	behind	that	of	FBS-expanded	chondrocytes.	There	
was	no	evidence	of	variability	between	individual	patients	at	any	time	point	
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(p=0.60).	
	
Total	collagen	production	(Figure	20;	page	87)	demonstrated	a	similar	
trend	in	both	sera	supplement	types.	The	production	levels	remained	consistent	
until	an	increase	between	day	21	and	day	28.	Total	collagen	production	
demonstrated	a	significant	interaction	between	treatment	and	time	(p=0.001).	
Total	collagen	levels	were	significantly	higher	in	FBS	compared	to	Stemulate™	
(p=0.001)	with	FBS-expanded	chondrocytes	having	a	sharper	increase	between	
day	21	and	day	28	than	Stemulateä-expanded	chondrocytes.	There	was	no	
evidence	of	variability	between	individual	patients	at	any	time	point	(p=0.26).		
	
	
Figure	19:	sGAG	production	per	cell	in	chondrogenic	pellets	from	chondrocytes	
expanded	in	FBS	and	Stemulate™	sera	supplement	over	28-days.	Data	is	
presented	as	the	mean	±	SEM	and	was	obtained	from	five	patients	in	total	for	
days	0–21	and	three	patients	up	to	day	28.	a,	b,	c	denotes	statistical	significance	of	
time,	supplement	type	and	at	the	specific	time	point	of	day	14	respectively.	
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Gene	expression	profiles	were	investigated	using	qRT-PCR	to	determine	
the	chondrogenic	capacity	of	the	pellets	and	establish	whether	the	pellets	were	
in	a	hypertrophic	or	de-differentiated	state	(Figure	21;	page	88).	
	
Figure	20:	Total	collagen	production	per	cell	in	chondrogenic	pellets	created	
from	chondrocytes	expanded	in	FBS	and	Stemulate™	sera	supplement	over	a	28-
day	time	course.	Data	is	presented	as	the	mean	±	SEM	and	was	obtained	from	
five	patients	in	total	for	days	0-21	and	three	patients	up	to	day	28.	a	and	b	denote	
statistical	significance	of	time	and	at	the	specific	time	point	of	day	28	
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Figure	21:	Box	and	whisker	plots	of	the	gene	expression	profiles	of	the	chondrogenic	pellets	created	
from	chondrocytes	expanded	in	FBS	and	Stemulate™.	Data	is	expressed	relative	to	two	reference	genes,	
normalised	to	cell	number	and	was	obtained	from	five	patients	using	three	experimental	pellet	
replicates	per	patient.	a-g	denotes	significance	of	time,	significance	of	ACAN	expression	at	day	0,	
significance	of	ACAN	expression	between	supplement	types	at	day	21,	significance	of	COL2A1	expression	
between	supplement	type	at	day	0,	significance	of	COL2A1	expression	between	supplement	types	at	day	
21,	significance	of	SOX9	expression	between	supplement	types	at	day	21	and	significance	of	SOX9	
expression	between	supplement	type	at	day	28	respectively.	
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Gene	expression	profiles	was	determined	by	the	comparative	CT	method	
(Schmittgen	and	Livak,	2008)	at	days	0,	21	and	28.	Data	was	expressed	relative	to	
two	reference	genes	and	normalised	to	cell	number.	No	gene	expression	of	
COL1A1,	COL10A1	or	ALK1	were	observed	in	either	supplement	type.	There	were	
striking	differences	between	gene	expression	profiles	for	each	serum	
supplement	types,	for	the	key	chondrogenic	markers:	ACAN,	COL2A1	and	SOX9.	
ACAN	expression	increased	over	the	time	course	in	both	supplements	
(p<0.001	for	time)	but	was	significantly	higher	in	FBS-expanded	pellets	than	
Stemulate™-expanded	pellets	at	day	0	(p<0.001)	and	day	21	(p=0.013),	with	day	
28	being	equal.	There	was	no	evidence	for	a	general	increase	in	COL2A1	
expression	over	time	(p=0.20	for	time).	However,	COL2A1	expression	was	
significantly	higher	in	FBS	cultured	cells	than	that	seen	in	Stemulate™-expanded	
pellets	at	day	0	(p=0.033)	and	day	21	(p=0.034),	with	day	28	again	being	equal.	
Similar	to	COL2A1,	there	was	no	evidence	for	a	general	change	over	time	in	SOX9	
expression	(p=0.15	for	time).	SOX9	expression	was	similar	at	day	0	in	both	sera	
supplements,	then	FBS-expanded	pellets	demonstrated	a	significantly	higher	
expression	of	SOX9	at	day	21	(p=0.012)	and	day	28	(p=0.002)	when	compared	
with	Stemulate™-expanded	pellets.	As	the	samples	obtained	were	from	humans,	
significance	of	patient	variability	was	determined	using	mixed	model	analysis.	
There	was	no	evidence	of	variability	between	individual	patients	for	any	of	three	
key	chondrogenic	markers:	ACAN	expression	(p=0.48),	COL2A1	expression	
(p=0.33),	or	SOX9	expression	(p=0.203)	
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3.3.3	FBS	improves	the	quality	of	the	ECM	produced	in	three-dimensional	pellet	
culture	
Frozen	chondrogenic	pellets	at	day	7,	day	21	and	day	28	were	sectioned	at	a	
thickness	of	7	µm	using	a	Bright	cryostat	(Bright,	Luton,	UK;	Model:	OTF).	Central	
sections	were	stained	with	H&E	to	show	general	morphology	or	toluidine	blue	to	
show	proteoglycan	distribution	(Figure	22;	page	92).	At	day	7,	chondrocytes	
expanded	in	Stemulate™	appeared	to	form	less	stable	and	more	fragile	pellets	
compared	with	chondrocytes	expanded	in	FBS.	Morphological	differences	were	
apparent	in	the	chondrocytes	occupying	the	periphery	of	the	pellets.	These	cells	
appeared	to	more	fibroblastic	in	nature	in	pellets	created	from	the	Stemulate™-
expanded	chondrocytes	compared	to	those	created	from	FBS-expanded	
chondrocytes.	
Histological	grading	of	the	toluidine	blue	stained	chondrogenic	pellets	
were	assessed	at	day	7,	day	21	and	day	28	using	the	BERN	scoring	system.	FBS-
expanded	chondrocytes	formed	chondrogenic	pellets	of	a	higher	mean	
histological	grading	across	all	three	time	points	(Table	10;	page	91).	The	range	of	
scores	obtained	from	several	pellet	replicates	demonstrated	that	the	
chondrogenic	pellets	formed	by	the	Stemulate-expanded	chondrocytes	had	
consistently	lower	scores	than	the	chondrogenic	pellets	formed	by	the	FBS-
expanded	chondrocytes,	indicating	lesser	histological	quality.		
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Table	10:	Histological	grading	of	the	FBS-expanded	and	Stemulate™-expanded	
chondrogenic	pellets	at	day	7,	day	21	and	day	28.	
	
		
	 	
Time	point:	 FBS	grading:	 Stemulate™	grading:	
Day	7	
Day	21	
7	
9	
6	
7	
Day	7	
Day	21	
7	
9	
0	
7	
Day	7	
Day	21	
Day	28	
8	
7	
9	
6	
6	
6	
Day	7	
Day	21	
Day	28	
8	
8	
8	
7	
6	
6	
Day	7	
Day	21	
Day	28	
7	
9	
8	
6	
6	
5	
Mean	grades	
Day	7	
Day	21	
Day	28	
	
7.4	
8.4	
8.3	
	
5	
6.4	
5.6	
Range	of	grades:	
Day	7	
Day	21	
Day	28	
7-8	
7-9	
8-9	
0-6	
6-7	
5-6	
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Figure	22:	Representative	histological	images	from	the	centre	of	FBS-expanded	chondrogenic	pellets	
and	Stemulate™-expanded	chondrogenic	pellets	across	the	28-day	time	course,	stained	with	H&E	to	
demonstrate	morphology	and	toluidine	blue	to	demonstrate	proteoglycan	content.	A-F:	Pellets	
stained	with	H&E	to	assess	overall	morphology.	G-L:	Pellets	stained	with	toluidine	blue	to	assess	
proteoglycan	content.	Insert	images	are	higher-powered	images	of	the	regions	marked	with	a	solid	
line	to	demonstrate	the	centre	and	edges	of	the	chondrogenic	pellets.	A,	B,	G,	H	are	pellets	at	day	7.	
C,	D,	I,	J	are	pellets	from	day	21.	E,	F,	J,	K	are	pellets	from	day	28.	All	scale	bars	represent	100	µm.		
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The	toluidine	blue	staining	intensity	was	semi-quantified	in	both	sera	
supplement	types	using	ImageJ	analysis	as	previously	described	(Figure	23).	A	
similar	trend	was	observed	in	both	sera	supplement	types,	in	which	the	staining	
intensity	of	the	chondrogenic	pellets	increased	over	time.	Pellets	created	from	
FBS-expanded	chondrocytes	demonstrated	an	increase	in	metachromasia	
indicated	by	a	decreased	staining	intensity	in	Figure	23.		
	
Figure	23:	Semi-quantitation	of	toluidine	blue-stained	chondrogenic	pellets	
demonstrating	an	increase	in	metachromasia,	determined	by	integrated	density	
analysis	using	ImageJ	imaging	software	(National	Institute	of	Health,	
Washington,	USA;	version:	24).	a	denotes	significance	of	staining	intensity	at	day	
21.	Data	is	presented	as	the	mean	±	SEM	and	was	obtained	from	five	patients	for	
days	0-21	and	three	patients	up	to	day	28.	
	
This	increase	was	semi-quantitated	using	ImageJ	software	and	
confirmed	that	FBS-expanded	chondrocytes	had	a	significantly	more	intense	
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staining	at	day	21	compared	to	Stemulate™-expanded	chondrocytes	at	the	same	
time	point	(p=0.045).	The	staining	intensity	was	at	comparable	levels	for	both	
sera	supplement	types	at	day	28	(p=0.911).	Despite	there	being	obviously	a	
higher	staining	intensity	in	FBS-expanded	chondrocytes	compared	to	
Stemulate™-expanded	chondrocytes	at	day	0,	this	was	shown	to	be	non-
significant	statistically	due	to	high	variation	in	pellet	staining	(p=0.269),	which	
could	be	possibly	due	to	an	anomalous	patient	at	day	0	and	day	21,	which	was	
then	removed	at	day	28	resulting	in	tighter	error	bars	and	no	statistical	
significance.	As	with	all	the	other	analysis,	there	was	no	evidence	of	variability	
between	patients	for	staining	intensity	(p=0.48).		
	
3.4	Discussion	
This	study	focussed	on	two	sera	supplement	types:	FBS	and	Stemulate™	and	
investigated	their	effects	on	human	chondrocyte	proliferation	and	the	
subsequent	recovery	of	their	chondrogenic	capacity	using	standard	
chondrogenic	pellet	differentiation	protocols.	Our	findings	provide	a	detailed	
analysis	of	ECM	production	from	five	individual	patients	and	to	our	knowledge	
there	is	no	other	study	available	providing	such	insights.		
Five	key	points	were	demonstrated	during	this	study.	First,	when	in	
monolayer	culture	Stemulate™	increased	chondrocyte	proliferation	compared	to	
FBS	as	highlighted	significantly	quicker	PDT.	Stemulate™	had	a	PDT	of	13.10	days	
±	2.57	compared	to	FBS	which	had	a	PDT	of	25.07	days	±	6.98	(p=0.050).	This	is	
not	surprising,	as	it	was	expected	that	Stemulate™	would	cause	similar	results	to	
HPL,	that	has	been	reported	by	several	studies	to	increase	cell	proliferation	in	
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many	cell	types.	However,	this	is	the	first	study	to	show	Stemulate™	causes	an	
increased	cell	proliferation	in	human	chondrocytes.	The	second	key	finding	was	
that	monolayer	expansion	of	human	chondrocytes	in	Stemulate™	negatively	
influenced	the	stability	of	the	three-dimensional	pellets	compared	to	human	
chondrocytes	expanded	in	FBS.	Chondrogenic	pellets	formed	from	Stemulate™-
expanded	chondrocytes	were	more	fragile	and	seemed	to	take	longer	to	become	
stable.	This	was	particularly	evident	in	the	cells	occupying	the	periphery	of	the	
pellets	in	the	which	appeared	to	be	more	fibroblastic	in	nature	within	the	
Stemulate™-pellets	compared	to	the	FBS	pellets.	The	third	key	finding	of	this	
study	was	that	total	sGAG	and	total	collagen	synthesis	by	Stemulate™-expanded	
chondrocytes	in	chondrogenic	pellet	culture	lagged	behind	FBS-expanded	human	
chondrocytes	in	chondrogenic	pellet	culture.	Despite	both	sera	supplement	
types	following	a	similar	trend	of	increasing	sGAG	synthesis	throughout	the	time	
course	(p<0.001),	Stemulate™-expanded	chondrocytes	consistently	displayed	
lower	sGAG	production	compared	to	FBS-expanded	chondrocytes.	FBS-expanded	
chondrocytes	had	a	significantly	sharp	increase	in	sGAG	production	between	day	
7	and	day	14	(p<0.001)	whereas	Stemulate™-expanded	chondrocytes	only	the	
sharpest	increase	between	day	21	and	day	28.	This	was	further	supported	by	
total	collagen	synthesis	also	increasing	over	time	(p=0.001).	Total	collagen	
synthesis	was	comparable	levels	for	both	sera	supplement	types	until	day	28,	
where	total	collagen	synthesis	displayed	an	increase	in	both	sera	supplement	
types.	Similar	to	sGAG	synthesis,	there	was	a	significantly	sharper	increase	in	
total	collagen	synthesis	at	day	28	in	the	FBS-expanded	chondrocytes	compared	
to	the	Stemulate™-expanded	chondrocytes.	(p=0.001)		
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The	fourth	key	finding	of	this	study	was	that	expanding	chondrocytes	in	
Stemulate™	negatively	influenced	chondrogenic	gene	expression	in	three-
dimensional	pellets	compared	to	expansion	in	FBS.	Markers	of	hypertrophy	and	
de-differentiation	were	not	seen	in	either	sera	supplement.	There	were	striking	
difference	in	gene	expression	of	key	chondrogenic	markers	between	the	two	
sera	supplement	types.	Although	ACAN	expression	increased	over	time	in	both	
supplement	types	(p<0.001),	it	was	significantly	higher	in	FBS-expanded	pellets	
compared	to	Stemulate™-expanded	pellets	at	day	0	(p>0.001)	and	day	21	
(p=0.013).	Whereas,	COL2A1	expression	remained	consistent	across	time	in	both	
sera	supplement	type	but	was	significantly	higher	in	FBS-expanded	pellets	
compared	to	Stemulate™-expanded	pellets	at	day	0	(p=0.033)	and	day	21	
(p=0.034).	In	contrast,	SOX9	expression	remained	fairly	consistent	across	time	in	
both	sera	supplement	types	but	was	consistently	higher	in	FBS-expanded	pellets	
compared	to	Stemulate™-expanded	pellets	at	day	21	(p=0.012)	and	day	28	
(p=0.002).		
The	final	key	finding	of	this	study	was	that	FBS-expanded	chondrocytes	
produce	higher	quality	chondrogenic	pellets	compared	to	Stemulate™-expanded	
pellets,	when	assessed	histologically.	This	supports	the	findings	of	higher	total	
sGAG	and	total	collagen	synthesis	in	FBS-expanded	pellets	and	is	evident	in	the	
BERN	scores	and	the	semi-quantitative	analysis	of	the	toluidine	blue	stained	
pellets.	
Studies	investigating	the	effects	of	HPL	have	been	performed	using	MSCs.	
These	studies	have	provided	clear	evidence	to	confirm	that	5-10%	(v/v)	HPL	is	
more	effective	at	supporting	monolayer	expansion	of	human	MSCs	than	both	
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FBS	and	autologous	serum	at	the	same	concentration	range	(Bieback	et	al.,	2009;	
Juhl	et	al.,	2016;	Trojahn	Kølle	et	al.,	2013).	Further,	both	Bieback	et	al.	(2009)	
and	Juhl	et	al.	(2016)	reported	that	HPL	supported	long	term	monolayer	
expansion	whilst	still	maintaining	the	MSCs	phenotype	and	differentiation	
potential.	Currently,	no	published	studies	have	used	Stemulate™	for	chondrocyte	
expansion	but	increased	proliferation	has	been	shown	using	derivatives	of	HPL	
(Bieback	et	al.,	2009;	Juhl	et	al.,	2016).	Given	these	positive	data	in	MSCs	and	
lack	of	published	data	in	chondrocytes,	we	chose	to	investigate	Stemulate™	in	
human	articular	chondrocytes.	Herein	we	established	that	Stemulate™	was	
better	than	FBS	when	it	came	to	increasing	chondrocyte	proliferation	in	
monolayer	culture.		
Studies	using	HPL	derivatives	have	provided	a	range	of	contrasting	
results.	Spreafico	et	al.	(2009)	compared	the	effects	of	platelet	rich	plasma,	
platelet	poor	plasma	and	FBS	on	human	chondrocytes	over	a	20-day	cell	
proliferation	time	course	(Spreafico	et	al.,	2009).	Platelet	rich	plasma	was	found	
to	be	the	most	stimulatory	in	terms	of	chondrocyte	proliferation.	More	recently,	
Hildner	et	al.	(2015)	reported	that	5-10%	HPL	significantly	increased	human	
chondrocyte	proliferation	compared	to	FBS	(Hildner	et	al.,	2015).	From	these	
studies	and	our	own,	it	is	evident	that	HPL	increases	the	proliferation	of	human	
chondrocytes	in	monolayer	culture.	
In	our	study,	we	found	no	morphological	differences	in	human	
chondrocytes	that	were	monolayer	expanded	in	Stemulate™	or	FBS.	No	other	
published	study	has	investigated	morphological	differences	between	human	
chondrocytes	expanded	in	HPL	or	FBS.	However,	Trojahn-Kolle	et	al.	(2013)	
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reported	morphological	differences	with	monolayer	expanded	MSCs	appearing	
smaller	and	less	spindle-like	when	cultured	in	HPL	compared	with	FBS	(Trojahn	
Kølle	et	al.,	2013).	It	was	noted	from	our	study,	that	three-dimensional	pellets	
created	from	human	chondrocytes	monolayer	expanded	in	Stemulate™	did	
create	more	fragile,	less	compact	pellets	compared	to	those	expanded	in	FBS.		
Very	few	studies	have	used	HPL	with	human	chondrocytes	and	even	
fewer	have	investigated	the	quality	of	the	ECM	produced	in	three-dimensional	
pellet	cultures.	Following	a	published	three-dimensional	pellet	chondrogenic	
differentiation	protocol	(Johnstone	et	al.,	1998;	Pittenger,	1999)	this	study	
demonstrated	that	FBS-expanded	human	chondrocytes	generated	significantly	
more	sGAG	than	Stemulate™-expanded	human	chondrocytes	across	a	28-day	
time	course.	These	results	oppose	the	findings	of	Hildner	et	al.	(2015)	who	
reported	that	HPL-expanded	chondrocytes	produced	more	sGAG	than	FBS-
expanded	chondrocytes	in	micromass	pellets	over	a	5-week	period,	created	
using	the	same	chondrogenic	differentiation	protocol	that	was	used	in	our	study	
(Hildner	et	al.,	2015).	These	contrasting	differences	could	be	accounted	for	by	
the	difference	in	supplement	types	since	we	used	Stemulate™	whereas	Hildner	
et	al.	used	HPL	generated	in	their	own	laboratory	from	platelet	rich	plasma	
obtained	from	36	expired	thrombocyte	concentrates	produced	at	a	transfusion	
blood	centre.	Five	batches	of	HPL	were	characterised	by	Quantikine	ELISA	for	
these	experiments	but	no	further	details	on	the	characterisation	was	given	
(Hildner	et	al.,	2015).	Another	difference	is	that	in	our	study,	the	three-
dimensional	pellets	were	cultured	in	chondrogenic	medium	without	HPL	
whereas	Hildner	et	al.	continued	to	add	HPL	into	three-dimensional	pellet	
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cultures.		
In	contrast	to	sGAG	synthesis	levels,	this	study	found	total	collagen	
production	levels	to	be	quite	low	throughout	the	three-dimensional	pellet	
culture	28-day	time	course.	Despite	this,	it	was	observed	that	total	collagen	
production	by	Stemulate™-expanded	human	chondrocytes	appeared	to	lag	
behind	FBS-expanded	human	chondrocytes.	Gaissmaier	et	al.	(2005)	also	found	
HPL-expanded	chondrocytes	seeded	into	three-dimensional	alginate	beads	
produced	low	levels	of	collagen	over	a	shorter	time	course	of	14 days	
(Gaissmaier	et	al.,	2005).		
In	the	three-dimensional	pellet	cultures,	we	also	investigated	a	range	of	
genes	which	determine	chondrocyte	differentiation	state.	We	investigated	de-
differentiation	through	the	expression	of	COL1A1	(Benya	et	al.,	1978;	Brew	et	al.,	
2010)	and	hypertrophy	through	the	expression	of	COL10A1	(Caron	et	al.,	2012;	
Dell’Accio	et	al.,	2001)	and	ALK1	(Blaney	Davidson	et	al.,	2009;	Dell’Accio	et	al.,	
2001).	ALK1	is	up-regulated	during	monolayer	expansion	due	to	a	loss	of	in	vivo	
cartilage	formation	potential	and	is	associated	with	irreversible	chondrocyte	de-
differentiation	(Blaney	Davidson	et	al.,	2007;	Blaney	Davidson	et	al.,	2009;	
Dell’Accio	et	al.,	2001).	None	of	these	genes	were	detected	in	three-dimensional	
pellets	derived	from	either	Stemulate™	or	FBS	suggesting	that	our	human	
chondrocytes	had	not	undergone	de-differentiation	or	hypertrophy.	In	addition,	
we	assessed	chondrogenic	capacity	through	the	expression	of	COL2A1,	ACAN	
and	SOX9.	COL2A1	and	ACAN	are	necessary	for	ECM	formation	and	the	
transcription	factor	SOX9	regulates	chondrocyte	proliferation,	chondrogenesis	
and	transition	to	a	non-hypertrophic	state.	Expression	of	COL2A1	and	ACAN	
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genes	are	known	to	decline	following	prolonged	monolayer	culture,	particularly	
after	passage	4	(Schulze-Tanzil	et	al.,	2002).	For	both	these	ECM	markers,	we	
found	an	increase	across	our	4-week	time	course.	However,	we	expected	a	much	
larger	increase	in	gene	expression,	especially	by	d 28	as	found	in	similar	
published	studies	(Hildner	et	al.,	2015).	One	reason	for	this	could	be	that	we	
were	approaching	nutrient	saturation	before	d 28.	Overall,	SOX9	gene	
expression	was	more	striking	in	FBS	three-dimensional	pellets	compared	to	those	
pellets	maintained	in	Stemulate™,	indicating	that	the	FBS-expanded	human	
chondrocytes	recovered	chondrogenic	potential	more	quickly.	Taken	together,	
our	findings	suggest	that	Stemulate™	causes	a	delay	in	the	recovery	of	
chondrogenic	phenotype	following	monolayer	expansion.	It	would	be	interesting	
for	future	studies	to	explore	gene	expression	levels	in	non-cultured	chondrocytes	
so	comparisons	could	be	made	between	freshly	isolated	chondrocytes	and	
cultured	chondrocytes	to	determine	culture	effects	on	these	gene	expression	
levels.	
The	multilevel	modelling	analyses	performed	in	our	study	have	allowed	
us	to	compare	between	the	sera	supplement	types	over	the	time	course	and	
explore	the	impact	of	patient	variability	(Hox,	2010;	Vaughn,	2008).	One	
limitation	of	this	study	was	that	the	cartilage	obtained	was	from	joints	that	were	
potentially	osteoarthritic	and	undergoing	joint	replacement	surgery.	
Osteoarthritis	is	classified	as	a	whole	joint	disease	and	so	although	the	cartilage	
was	taken	from	macroscopically	healthy	areas,	chondrocytes	could	still	have	a	
slightly	altered	phenotype	and	this	should	be	taken	into	consideration	when	
analysing	the	results	(Poole,	2012).	To	explore	this	possibility	further,	ALK1	gene	
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expression	was	investigated	as	previous	studies	have	shown	that	chondrocytes	
that	are	osteoarthritic	or	undergoing	hypertrophy	express	higher	levels	of	ALK1.	
In	this	study,	ALK1	expression	was	not	detected	at	day	0,	day	21	or	day	28	in	
monolayer-expanded	chondrocytes	expanded	in	either	sera	supplement	(Blaney	
Davidson	et	al.,	2009;	Finnson	et	al.,	2008).		
Some	patient	variability	was	expected	within	our	results	as	the	samples	
being	used	were	human	derived,	but	in	these	experiments,	we	found	no	
statistical	evidence	for	a	patient-specific	influence	on	any	of	the	outcomes	
measured.	However,	patient	variability	within	this	study	was	assessed	across	a	
small	sample	size	of	just	five	patients.	The	sample	size	of	five	patients	is	one	of	
the	limitations	of	this	study.	If	the	sample	size	was	increased	to	a	larger	donor	
pool	the	patient	variability	assessed	would	be	more	reliable	and	may	alter	the	
significance	of	patient	variability.	However,	we	found	no	statistical	evidence	for	a	
patient-specific	influence	on	any	of	the	outcomes	measured	within	this	study.	An	
example	of	further	investigation	that	could	elucidate	some	findings	further,	
would	be	to	utilise	patient	demographics	further,	for	example	BMI,	smoking	
status	and	activity	levels.	These	were	not	determined	for	this	study,	but	could	be	
obtained	from	patient	electronic	medical	records	and	used	in	future	
investigations.	
There	were	other	limitations	to	this	project.	One	limitation	is	that	we	
were	not	able	to	compare	autologous	serum	for	each	individual	because	our	
existing	ethically	approved	protocol	did	not	allow	us	to	take	a	sufficient	volume	
of	blood	to	provide	sera	that	would	support	monolayer	in	vitro	expansion	to	the	
end	of	passage	2	to	ensure	efficient	cell	numbers	for	our	experiments.	Another	
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limitation	is	that	we	have	only	evaluated	chondrocytes	obtained	from	total	knee	
replacement	surgery.	This	means	that	we	should	be	cautious	in	how	we	interpret	
these	data	compared	with	chondrocytes	sourced	from	patients	undergoing	ACI,	
as	the	patient	populations	for	these	treatments	differ.	For	example,	patients	
undergoing	ACI	tend	to	be	younger	than	those	undergoing	joint	replacement	
surgery.	Despite	these	limitations,	we	were	able	to	demonstrate	the	five	key	
points	mentioned	above.		
The	findings	of	this	thesis	chapter	demonstrate,	for	the	first	time,	that	
Stemulate™	does	increase	the	proliferation	rates	of	human	articular	
chondrocytes	in	monolayer.	Stemulate™	has	also	been	proven	to	negatively	
impact	upon	the	re-differentiation	potential	when	the	expanded	chondrocytes	
were	seeded	into	three-dimensional	pellet	cultures,	evidenced	by	an	altered	
phenotype	mimicking	a	more	fibroblastic	nature.	The	altered	phenotype	
resulting	from	expansion	in	Stemulate™	supplement	sera	was	characterised	by	
negatively	influenced	ECM	production	compared	to	FBS-expanded	chondrocytes,	
determined	via	reduced	and	delayed	synthesis	of	sGAG,	delayed	synthesis	of	
total	collagen	production	and	reduced	proteoglycan	content	apparent	in	the	
reduced	toluidine	blue	staining.	The	altered	phenotype	of	the	Stemulate™-
expanded	chondrocytes	resulted	in	poorer	pellet	quality	evident	in	the	BERN	
scores	and	a	more	fibroblastic	gene	expression	profile	determined	by	reduced	
ACAN	expression,	reduced	COL2A1	expression	and	reduced	SOX9	expression.	
Therefore,	these	findings	provide	evidence	that	Stemulate™	should	be	used	with	
caution	when	expanding	chondrocytes	for	clinical	use,	for	example	for	use	in	cell	
therapies	including	ACI.		
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There	is	more	work	to	be	done	to	expand	on	the	findings	presented	thus	
far.	It	would	be	interesting	to	perform	flow	cytometry	on	the	expanded	
chondrocytes	to	determine	if	the	cell	marker	profiles	differ	and	to	explore	cell	
cycle	changes	between	the	two	sera	supplement	types.	Also,	expanding	qRT-PCR	
analysis	to	incorporate	the	other	time	points	of	day	7	and	day	14,	and	show	the	
fold	change	of	expression	relative	to	baseline	(day	0)	would	be	interesting,	to	
pinpoint	more	accurately	where	the	gene	is	expressed.	It	is	noteworthy	that	
there	were	apparent	vesicles	present	in	the	light	microscopy	images	of	the	
monolayer	expanded	chondrocytes	which	are	of	unknown	composition	and/or	
origin.	Exploring	this	further	could	be	interesting,	especially	as	the	full	
composition	of	Stemulate™	is	still	not	disclosed	or	published.	Therefore,	one	
theory	could	be	that	these	vesicles	could	be	present	in	the	Stemulate™	itself	and	
causing	proliferative	effects	in	the	chondrocytes,	or	another	theory	is	that	the	
vesicles	are	produced	by	the	chondrocytes	in	response	to	Stemulate™.	Finally,	
immunohistochemistry	for	collagen	types	I	and	II	would	provide	further	
information	to	support	the	current	collagen	findings	within	this	thesis	chapter,	as	
the	collagen	findings	are	for	the	total	collagen	production	and	not	the	individual	
collagen	types.	By	characterising	between	the	collagen	types,	it	would	provide	
further	information	into	whether	the	chondrocytes	are	undergoing	de-
differentiation	and	the	quality	of	the	ECM	produced,	as	it	is	known	that	collagen	
type	I	expression	is	indicative	of	de-differentiation	and	collagen	type	II	is	a	
hallmark	of	hyaline	cartilage.		
Future	work	into	the	impact	of	Stemulate™	on	the	chondrogenic	capacity	
of	human	articular	chondrocytes	should	cater	towards	whether	other	versions	of	
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HPL	have	a	similar	or	contrasting	impact	on	the	chondrogenic	phenotype,	or	
whether	Stemulate™	does	negatively	impact	the	chondrogenic	capacity	on	a	
short	time-scale	and	needs	longer	to	recover	chondrogenic	phenotype	in	vitro.		
In	conclusion,	we	have	demonstrated	that	although	Stemulate™	leads	to	
rapid	proliferation	of	human	articular	chondrocytes	in	monolayer,	it	impacts	
upon	the	re-differentiation	potential	when	seeded	into	three-dimensional	pellet	
cultures	(Sykes	et	al.,	2018).	These	presented	findings,	the	first	of	their	kind,	
demonstrate	that	Stemulate™	induces	an	altered	phenotype	or	enhances	
monolayer	induced	chondrocyte	de-differentiation	and	reduces	chondrogenic	
capacity.	These	findings	are	clinically	important,	particularly	in	cell	therapies,	as	
it	provides	new	evidence	that	Stemulate™	should	be	used	with	caution	when	
expanding	chondrocytes	for	clinical	use	as	the	altered	phenotype	results	in	a	
lesser	quality	ECM.	This	in	turn	would	cause	speculation	that	a	lesser	quality	ECM	
would	result	in	lesser	quality	cartilage	formation	and	so	would	be	not	be	ideal	for	
cartilage	repair	techniques,	including	cell	therapies	such	as	ACI.		
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Chapter	4:	Characterising	the	chondrogenic	capacity	of	
chondrocytes	isolated	from	human	ankle	and	knee	joints.	
4.1	Introduction	
Over	the	past	17	years,	ACI	has	been	expanded	to	treat	cartilage	defects	of	the	
foot	and	ankle	joint	(Brittberg	et	al.,	2003;	Giannini	et	al.,	2001;	Thermann	et	al.,	
2014;	Whittaker	et	al.,	2005).	For	foot	and	ankle	ACI,	chondrocytes	are	sourced	
from	either	knee	(McCarthy,	Helen	and	Roberts,	2013;	Whittaker	et	al.,	2005)	or	
ankle	cartilage	(Giannini	et	al.,	2005).		
Only	a	few	research	groups	have	compared	the	clinical	outcome	of	ACI	
using	different	cartilage	sources.	There	have	been	reports	that	have	assessed	the	
joint	morbidity	of	cartilage	taken	from	the	knee	to	treat	other	joints,	including	
the	ankle	(Ahmad	et	al.,	2002;	Paul	et	al.,	2009;	Reddy	et	al.,	2007;	Valderrabano	
et	al.,	2009;	Whittaker	et	al.,	2005),	the	hip	(McCarthy	et	al.,	2015)	and	the	
elbow	(Iwasaki	et	al.,	2007).	No	correlation	between	the	number	of	harvests	or	
the	size	of	harvest	on	joint	morbidity	or	treatment	outcome	were	reported	in	the	
knee	(Paul	et	al.,	2009;	Reddy	et	al.,	2007).	There	are	indications	of	joint	
morbidity,	degenerative	changes	and	poor	repair	histologically	at	the	harvest	site	
in	the	knee	and	ankle	(Reddy	et	al.,	2007;	Valderrabano	et	al.,	2009).		
Several	groups	have	demonstrated	recent	success	in	ACI	being	applied	to	
defects	of	the	ankle	joint	using	healthy	biopsies	sourced	from	either	knee	or	
ankle	cartilage	(Aurich	et	al.,	2011;	Giannini	et	al.,	2014;	Giza	et	al.,	2010;	Nam	et	
al.,	2009;	Schneider	and	Karaikudi,	2009;	Thermann	et	al.,	2014;	Whittaker	et	al.,	
2005).		
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Despite	all	this	research,	there	is	a	paucity	of	information	to	determine	
whether	there	are	any	differences	in	the	growth	kinetics	or	the	cartilage-forming	
capacity	of	chondrocytes	isolated	from	the	ankle	and	the	knee.	Making	ACI	truly	
successful	in	both	knee	and	ankle	joints	requires	a	better	understanding	of	the	
source	of	chondrocytes	to	determine	whether	joint	specificity	offers	any	
advantages.	Herein,	we	have	made	steps	to	characterise	these	chondrocytes	
isolated	from	ankle	and	knee	cartilage	tissue	with	a	long-term	goal	to	improve	
the	efficacy	of	ACI.		
There	are	differences	in	the	disease	susceptibility	of	the	knee	and	ankle	
joints	(Arthritis	Research	UK,	2013).	In	terms	of	osteoarthritis,	knee	osteoarthritis	
tends	to	be	primary	in	nature	and	the	knee	is	the	most	commonly	affected	joint	
in	the	UK,	with	an	estimated	4.71	million	individuals	over	the	age	of	45	years	
having	osteoarthritis	of	the	knee	(Arthritis	Research	UK,	2013;	Jordan	et	al.,	
2007;	Jordan	et	al.,	2010).	By	comparison	from	the	same	reports,	osteoarthritis	
of	the	ankle	joint	is	of	a	lower	prevalence	with	an	estimated	1.77	million	
individuals	over	the	age	of	45	years	having	ankle	osteoarthritis.	Another	UK	
study	coincides	with	these	findings,	demonstrating	that	41.2%	of	the	500	
patients	observed	had	symptomatic	knee	osteoarthritis,	whereas	only	4.4%	had	
symptomatic	ankle	osteoarthritis	(Cushnaghan	and	Dieppe,	1991).	Compared	to	
knee	osteoarthritis,	ankle	osteoarthritis	tends	to	require	less	surgical	
intervention	as	it	is	usually	of	a	less	severe	degeneration	(as	per	international	
cartilage	repair	society	grading)	and	is	usually	post-traumatic	osteoarthritis	in	
nature	(Muehleman	et	al.,	2010;	Takakura	et	al.,	998;	Thomas	and	Daniels,	
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2003).	Muehleman	et	al.	(2010)	studied	1,060	adult	knee	and	ankle	pairs	from	
545	cadaveric	donors	and	the	findings	of	this	study	revealed	that	severe	defects,	
as	per	the	international	cartilage	repair	society	grading,	were	extremely	rare	in	
the	ankle	with	only	three	reported	cases	in	contrast	to	50%	of	knee	joints	studied	
being	of	severe	grading	(Brittberg	et	al.,	2002;	Muehleman	et	al.,	2010).	This	
might	suggest	that	the	ankle	has	a	protective	mechanism	against	cartilage	
damage	progression	to	osteoarthritis	that	is	either	not	present,	or	not	as	well	
established,	in	the	knee.	However,	to	date,	these	differences	have	been	
attributed	to	a	combination	of	joint	anatomy	and	biomechanics	(Eger	et	al.,	
2002;	Huch	et	al.,	1997).	
	 Anatomically,	the	ankle	is	made	up	of	26	bones:	five	metatarsal	bones,	
14	phalange	bones	and	seven	talar	bones	(Drake	et	al.,	2015),	and	is	covered	in	a	
thin	layer	of	articular	cartilage	less	than	1	mm	thick.	Most	cartilage	injuries	occur	
within	the	talar	region	of	the	ankle.	Whereas,	the	knee	joint	comprises	four	
bones:	the	femur,	fibula,	tibia	and	patella	(Drake	et	al.,	2015a),	and	the	articular	
cartilage	is	thicker	than	that	of	the	ankle,	ranging	from	2-6	mm	thick	(Al-Ali	et	al.,	
2002;	Ateshian	et	al.,	1991;	Shepherd	and	Seedhom,	1999).	Most	cartilage	
injuries	occur	on	the	condyle	region	of	the	knee,	where	the	cartilage	is	up	to	6	
mm	thick.	So	together,	the	cartilage	thickness	as	well	as	the	bone	topography	
might	have	some	influence	on	the	type	of	injury	and	progression	to	
osteoarthritis.		
There	are	some	key	biomechanical	differences	between	the	two	joints.	
For	example,	the	ankle	is	a	highly	congruent	joint,	and	thus	it	can	withstand	high	
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levels	of	loading	and	stress	despite	the	small	contact	area	(11-13	cm2)	across	the	
joint.	This	results	in	the	ankle	experiencing	lower	stress	than	other	joints	within	
the	leg,	for	example	the	knee	or	hip	(Nordin	and	Frankel,	2001;	Sammarco	and	
Hockenbury,	2001).	The	knee	and	ankle	joints	must	be	able	to	withstand	high	
levels	of	load	during	everyday	activities,	such	as	walking.	It	has	been	reported	
that	the	ankle	can	withstand	5x	body	weight	during	walking,	with	most	of	this	
load	transmitted	through	the	tibiotalar	joint	and	applied	to	the	talar	dome	
(Brockett	and	Chapman,	2016).	Whereas,	the	knee	has	been	shown	to	regularly	
withstand	lower	levels	of	loading,	of	3-4x	body	weight	when	walking	(Andriacchi	
et	al.,	1980;	Morrison,	1969;	Naaijkens	et	al.,	2012).		
Although	anatomical	and	biomechanical	differences	have	been	
documented,	there	has	been	a	single	comprehensive	study	comparing	the	
biochemical	and	cellular	differences	in	the	two	joints	(Quinn	et	al.,	2013)	Using	
cadaveric	donor-matched	adult	human	knee	and	ankle,	Quinn	et	al.	(2013)	found	
elevated	cell	densities	within	the	superficial	zone	of	the	knee	but	not	the	ankle.	
Matrix	volume	per	cell	in	the	superficial	zone	of	the	knee	was	significantly	less	
compared	to	the	ankle.	Chondrocyte	density	per	unit	of	articular	cartilage	were	
found	to	be	significantly	higher	in	knee	cartilage,	compared	to	ankle	cartilage.	
Whilst	this	study	was	thorough	in	nature,	its	limitation	was	that	it	did	not	explore	
aspects	relevant	to	ACI;	cell	growth	kinetics	and	ECM	production	in	three-
dimensional	culture.	The	study	focused	heavily	on	qualitative	histological	
findings,	which	have	been	suggested	to	not	correlate	well	with	clinical	outcome	
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and	so	may	not	be	the	best	indicator	to	characterise	differences	in	ankle	and	
knee	cartilage	tissue	(McCarthy	and	Roberts,	2013).		
Since	ACI	requires	a	harvest	of	healthy	cartilage,	it	is	necessary	to	
determine	whether	there	are	any	differences	in	the	chondrogenic	properties	of	
chondrocytes	from	different	joints.	If	so,	it	would	be	necessary	to	assess	whether	
chondrocytes	from	a	joint	alternative	to	the	one	being	treated	could	be	of	more	
benefit.	
Our	study	is	the	first	of	its	kind	to	compare	the	growth	kinetics	of	
chondrocytes	isolated	from	ankle	and	knee	cartilage	with	ACI	protocol	in	mind.	
Herein,	we	aim	to	characterise	and	compare	chondrocytes	isolated	from	freshly	
obtained	human	ankle	and	knee	cartilage	tissue	donated	following	total	joint	
replacement	surgery,	by	assessing	chondrocyte	expansion	through	growth	
characteristics	and	cell	morphology.	Initial	cartilage	structure	will	be	assessed	
using	histological	analysis	of	core	biopsies.	Furthermore,	three-dimensional	
pellet	culture	will	be	utilised	to	assess	the	ECM	through	biochemical,	histological	
and	gene	expression	analyses.	
	
4.2	Experimental	design	
Five	ankle	samples	and	five	knee	samples	were	received	from	patients	
undergoing	total	joint	replacement	surgery.	Demographics	were	recorded	for	
each	patient	and	are	displayed	in	Table	11	(page	110).	Demographics	recorded	
include:	the	age	and	gender	of	the	patient	and	the	source	of	the	cartilage	
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obtained	(ie:	ankle	or	knee).	All	cartilage	was	taken	from	the	femoral	condyle	
region	of	the	knee	joint	or	from	the	talus	region	of	the	ankle	joint.		
	
Table	11:	Demographics	of	the	human	ankle	and	knee	tissue	sample	donors	from	
which	chondrocytes	were	obtained.	All	tissue	was	obtained	following	joint	
replacement	surgery	at	our	centre.	
Age	of	donor:	 Gender	of	donor:	
Ankles	-		
44	 Male	
55	 Male	
62	 Male	
59	 Female	
47	 Female	
Age	range:	44-62	years;	mean	age:	53.4	
years	
3	males;	2	females	
Knees	-		
72	 Male	
61	 Male	
64	 Male	
55	 Female	
47	 Female	
Age	range:	47-72	years;	mean	age:	59.8	
years	
3	males;	2	females	
	
Figure	24	(page	111)	illustrates	the	experimental	design	for	this	project.	
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Figure	24:	Schematic	illustrating	the	experimental	design	of	the	project	
comparing	the	chondrogenic	capacity	of	chondrocytes	isolated	from	ankle	and	
knee	cartilage.		
	
Chondrocytes	were	isolated	from	macroscopically	healthy	cartilage	tissue	
on	the	femoral	condyle	of	the	knee	joint	and	the	talus	of	the	ankle	joint,	
following	enzymatic	digestion	(section	2.1.3,	page	53).	Representative	full	depth	
core	biopsies	were	taken	from	macroscopically	healthy	areas,	assessed	by	eye,	of	
the	condyle	of	one	knee	cartilage	tissue	sample	and	the	talus	of	one	ankle	
cartilage	tissue	sample.	Core	biopsies	were	snap-frozen	in	liquid	nitrogen	and	
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stored	at	-80o	until	histologically	stained	with	H&E	and	toluidine	blue	to	illustrate	
morphological	differences	and	proteoglycan	content	of	ankle	and	knee	full	depth	
cartilage	tissues.	
Chondrocytes	were	expanded	in	monolayer	up	to	passage	2.	During	
monolayer	culture,	growth	kinetics	were	recorded	and	phase	contrast	images	
were	taken	to	observe	morphology	using	a	TS100	Eclipse	Nikon	microscope	and	
acquired	using	IP	Lab	3.2.6	software.	(section	2.1.6,	page	54).	Once	confluent	at	
passage	2,	chondrocytes	(4x104)	from	one	ankle	and	one	knee	patient,	were	
prepared	for	flow	cytometry	analyses	(section	2.1.7,	page	55).		
Remaining	cells	were	passaged	and	seeded	into	three-dimensional	pellets	
(2.5x105)	in	chondrogenic	media,	using	methods	outlined	in	section	2.1.4	(page	
49).	Pellets	were	maintained	in	culture	for	up	to	21	days	for	all	patients,	with	
assessments	being	carried	out	at	days	0,	7,	14	and	21	as	outlined	in	Figure	24	
(page	111).	Chondrogenic	pellets	(n>4)	were	digested	in	proteinase	K	at	days	0,	
7,	14	and	21	and	processed	for	biochemical	analyses	(determining	cell	number,	
sGAG	synthesis	and	total	collagen	synthesis).	Chondrogenic	pellets	(n>3)	were	
snap	frozen	at	days	7	and	21	for	histological	analysis,	and	were	sectioned	and	
stained	with	toluidine	blue	(section	2.1.14.3,	page	70)	and	H&E	(section	2.1.14.2,	
page	69).	Chondrogenic	pellets	(n>3)	at	days	0	and	21	were	homogenised	in	RLT	
buffer	containing	1%	(v/v)	β-mercaptoethanol	and	stored	at	-80oC	until	
processed	for	RNA	extraction	and	subsequent	qRT-PCR	analysis	(section	2.1.13.3,	
page	65),	specifically	for	markers	of	chondrogenesis,	de-differentiation	and	
hypertrophy.	
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4.3	Results	
4.3.1	Chondrocyte	yield	appears	more	variable	across	the	age	range	of	ankle	
cartilage	
Across	the	age-range,	the	average	chondrocyte	yield	was	1658.39	±	266.47	cells	
per	mg	for	knee	and	2514.34	±	487.43	cells	per	mg	for	ankle	(Table	12).		
	
Table	12:	Details	of	cell	yields	and	wet	weight	of	tissue	obtained	from	the	
cartilage	extraction	of	joint	tissue	received.	
	
These	summary	data	are	graphically	represented	in	Figure	25	(page	
114).	In	the	five	knee	samples,	chondrocyte	yield	per	mg	of	cartilage	tissue	
appeared	to	be	consistent	across	the	age	range,	whereas	in	the	five	ankle	
samples	chondrocyte	yield	per	mg	of	cartilage	tissue	appeared	variable	with	
Age	of	donor	
(years):	
Cell	yield:	 Wet	weight	of	
tissue	(mg):	
Cell	yield	per	wet	
weight	of	tissue	
(cells/mg):	
Ankles	-	
44	 820,000	 392	 2091.84	
47	 422,222	 96	 4398.15	
55	 750,000	 456	 1644.74	
59	 640,000	 212	 3018.87	
62	 580,000	 409	 1418.09	
Knees	-	
47	 3,720,000	 1950	 1907.69	
55	 1,890,000	 1200	 1575	
61	 2,330,000	 2728	 854.11	
64	 625,000	 472	 1323.59	
72	 1,000,000	 380	 2631.58	
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increasing	age	(Figure	25).	The	mean	cell	yield	per	wet	weight	of	tissue	was	
significantly	higher	in	ankle	cartilage	compared	to	knee	cartilage	(p=0.009).	
	 Flow	cytometry	analysis	was	performed	to	determine	the	absence	or	
presence	of	chondrogenic	markers	(Figure	26;	page	115).	Immunoprofiling	of	one	
representative	ankle	and	one	representative	knee	sample	showed	varying	
degrees	of	expression	for	CD44,	CD49c,	CD39	and	CD166.		
Figure	25:	Cell	yield	per	wet	weight	of	cartilage	tissue	displayed	at	each	age	of	
the	donors,	for	ankle	cartilage	and	knee	cartilage.	
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Figure	26:	Representative	potency	profiles	of	key	cell	surface	markers	to	
determine	chondrogenic	potency	of	the	chondrocytes	extracted	from	cartilage	
obtained	from	one	ankle	and	one	knee	joint.	
	
Immunoprofiling	revealed	that	both	ankle	and	knee	chondrocytes	were	
>98%	positive	for	CD44.	Ankle	chondrocytes	exhibited	a	more	potent	expression	
of	CD49c	compared	to	knee	chondrocytes	which	did	not	demonstrate	any	
detectable	expression	of	CD49c.	Ankle	chondrocytes	had	higher	cell	surface	
expression	of	CD39	at	36.8%	compared	to	0.4%	in	knee	chondrocytes.	CD39,	also	
known	as	ENTPD1,	is	a	cell	surface-located	enzyme	member	of	the	enzyme	
family	expressed	on	a	variety	of	cell	types,	which	is	highly	associated	with	
suppression	of	inflammation	and	regulation	of	the	immune	system	(Kaczmarek	
et	al.,	1996;	Kukulski	et	al.,	2005).	CD166	was	expressed	by	ankle	chondrocytes	
(33.6%)	but	very	little	expression	(0.2%)	was	observed	in	knee	chondrocytes.		
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4.3.2	Cartilage	source	does	influence	the	growth	kinetics	of	chondrocytes	during	
monolayer	expansion	
Figure	27	illustrated	no	morphological	differences	between	the	chondrocytes	
isolated	from	ankle	and	knee	cartilage.	There	appeared	to	be	no	differences	in	
cell	shape	or	size,	as	both	sets	of	chondrocytes	had	an	elongated	flattened	shape	
characteristic	of	adhered	chondrocytes.	However,	chondrocytes	isolated	from	
ankle	cartilage	appeared	to	be	more	clustered,	compared	to	chondrocytes	
isolated	from	knee	cartilage	where	the	chondrocytes	appeared	to	be	more	
homogeneously	dispersed.		
	
Figure	27:	Representative	images	of	chondrocytes	at	passage	1,	3	days	after	
seeding,	isolated	from	(A)	knee	cartilage	and	(B)	ankle	cartilage	tissue.	Images	
were	taken	using	the	Nikon	TS100	light	microscope,	Hamamatsu	C4742-95	
camera	and	a	´10	magnification	lens.	Images	were	acquired	using	IPLab	3.2.6	
software.	Scale	bars	represent	100	μm.		
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Average	absolute	PDs	demonstrated	that	ankle	chondrocytes	grew	at	a	
significantly	slower	rate	(p=0.001)	compared	to	knee	chondrocytes,	across	all	
three	passages	(passage	p=0.132),	as	shown	in	Figure	28.	Ankle	chondrocytes	
underwent	less	than	1	PD	at	all	three	passages,	whereas	knee	chondrocytes	
demonstrated	more	variable	growth	kinetics,	and	underwent	more	PDs	than	
ankle	chondrocytes,	at	less	than	1.5	absolute	PDs	at	any	of	three	passages.		
	
Figure	28:	Absolute	population	doublings	(PDs)	of	chondrocytes	expanded	from	
ankle	and	knee	cartilage	tissue,	at	each	of	the	three	passages.	Data	is	presented	
as	mean	±	SEM	and	was	obtained	from	five	ankle	patients	and	five	knee	patients	
in	total.		
	
Cell	number	obtained	during	monolayer	expansion	showed	that	cell	
number	increased	over	time	for	both	cartilage	sources,	as	expected	(p<0.001)	
but	was	significantly	higher	in	knee	chondrocytes	across	all	passages	except	
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passage	3	(p=0.007),	as	supported	by	the	increased	PDTs.	Patient	variability	was	
deemed	to	be	not	significant	(p=0.149)	in	affecting	cell	number	during	
monolayer	expansion.		
	
4.3.3	Cartilage	source	does	not	influence	the	re-differentiation	potential	in	
three-dimensional	pellet	culture	
To	determine	whether	ankle-derived	chondrocytes	produced	higher	or	lower	
quantities	of	ECM	than	knee-derived	chondrocytes,	three-dimensional	
chondrogenic	pellets	were	prepared	and	maintained	over	a	21-day	time	course.	
Pellets	were	characterised	by	assessing	total	cell	number	(Figure	29A;	page	120),	
total	sGAG	production	(Figure	29B;	page	120),	total	collagen	production	(Figure	
29C;	page	120),	histological	appearance	and	gene	expression	profiles	as	
determined	by	qRT-PCR.	
Pellet	cell	number	(Figure	29A;	page	120)	remained	constant	for	both	
cartilage	sources	(p=0.963)	and	across	all	four	experimental	time	points	(p=1.0).	
Patient	variability	was	deemed	to	be	not	significant	in	affecting	pellet	cell	
number	over	time	(p=0.728).	Total	sGAG	production	(Figure	29B;	page	112)	was	
normalised	to	pellet	cell	number.	Chondrocytes	sourced	from	both	the	ankle	and	
knee	joints	demonstrated	a	steady	increase	in	sGAG	production	across	all	time	
points.	sGAG	concentration	was	higher	in	knee	pellets	compared	to	ankle	pellets	
at	days	0	and	7,	but	levelled	off	at	days	14	and	21.	There	was	no	significant	
difference	in	sGAG	production	observed	between	chondrocyte	source	(p=0834),	
but	both	sets	of	chondrocytes	exhibited	a	significant	trend	of	increasing	over	
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time	(p=0.003).		
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Figure	29:	(A)	Cell	number,	(B)	sGAG	production	per	cell	and	(C)	collagen	
production	per	cell,	in	pellets	created	from	chondrocytes	isolated	from	ankle	and	
knee	cartilage	tissue	over	a	21-day	time	course.	Date	is	presented	as	the	mean	of	
each	patient	±	SEM	for	each	time	point,	plotted	against	donor	age.	Data	was	
obtained	from	five	ankles	and	five	knee	patients	in	total.	
	 	
A	 	 	 				B	 	 	 										C	
Chapter	4:	Characterising	the	chondrogenic	capacity	of	chondrocytes	isolated	from	human	
ankle	and	knee	joints.	
 
	
-	121	-	
In	this	instance,	there	was	some	evidence	of	variability	between	
individual	patients	(p=0.023).	Interestingly,	there	was	one	ankle	(donor	age	55	
years)	and	one	knee	(donor	age	72)	that	consistently	did	not	produce	higher	
quantities	of	sGAGs	at	any	of	the	time	points	tested.		
Total	collagen	production	(Figure	29C;	page	120)	was	normalised	to	pellet	
cell	number.	Total	collagen	production	demonstrated	no	significance	in	
chondrocyte	source	(p=0.779),	and	showed	no	significance	in	the	trend	of	
increasing	over	time	(p=0.108).	However,	total	collagen	production	remained	
higher	in	ankle	chondrogenic	pellets	compared	to	knee	chondrogenic	pellets	at	
day	0	and	day	7,	before	levelling	off	at	day	14	and	becoming	lower	than	knee	
chondrogenic	pellets	at	day	21.	Again,	there	was	no	evidence	of	variability	
between	individual	patients	at	any	time	point	(p=0.267).	Interestingly,	one	ankle	
(donor	age	47	years)	and	one	knee	(donor	age	72	years)	demonstrated	strikingly	
low	collagen	production	across	the	full	time	course	(8.29-69.95	pg/cell	for	ankle	
chondrocytes	and	3.83-15.63	pg/cell	for	knee	chondrocytes).	
	
4.3.4	Ankle	chondrocytes	produce	a	higher	quality	ECM	in	three-dimensional	
pellet	culture	
Representative	core	biopsies	were	taken	of	both	sets	of	tissue	from	fresh	surgical	
samples,	and	were	stained	with	H&E	to	assess	morphology	and	toluidine	blue	to	
assess	proteoglycan	content	(Figure	30;	page	122).		
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Figure	30:	Representative	histological	images	of	core	biopsies	of	ankle	cartilage	
taken	following	fusion	(A-D)	and	knee	cartilage	taken	following	total	knee	
replacement	(E-H).	Both	were	stained	with	H&E	(A-C,E-F,H)	and	toluidine	blue	
(D,G).	Cartilage	and	bone	were	shown	to	have	good	integration	(A,E).	Higher	
powered	images	(B,H)	of	the	dashed	line	region	in	(A,E)	demonstrates	cells	at	the	
surface.	Polarised	light	(C,F)	revealed	hyaline	cartilage	in	both	tissues.	Differences	
were	observed	in	the	arrangement	of	the	collagen	fibres,	which	appeared	in	a	
diagonal	linear	alignment	in	ankle	cartilage	and	arranged	randomly	within	knee	
cartilage.	
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Visualising	the	core	biopsies	using	polarised	light	demonstrated	that	both	
tissues	were	hyaline	cartilage.	Differences	were	observed	in	the	arrangement	of	
the	collagen	fibres,	which	appeared	in	a	diagonal	linear	alignment	in	ankle	
cartilage	tissue	and	arranged	randomly	within	knee	cartilage	tissue.	Both	tissues	
demonstrated	good	integration	between	bone	and	cartilage.	
Histological	quality	of	the	pellets	at	day	7	and	day	21	were	assessed	using	
toluidine	blue	stained	pellets	and	determined	using	the	BERN	score,	and	
demonstrated	no	significant	difference	in	histological	quality	between	the	two	
cartilage	sources	(Table	13).		
	
Table	13:	Grading	of	the	pellets	isolated	from	ankle	and	knee	cartilage	tissue	at	
day	7	and	day	21.		
	
Time	(days):	 BERN	score	
Ankles	-	
7	
21	
8	
9	
7	
21	
/	
6	
7	
21	
9	
/	
7	
21	
8	
7	
7	
21	
7	
8	
Knees	-	
7	
21	
8	
8	
7	
21	
6	
7	
7	
21	
/	
8	
7	
21	
9	
7	
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Histological	grading	of	quality	remained	consistent	at	both	time	points	
in	both	sets	of	pellets	(p=0.721	for	day	7,	p=0.945	for	day	21).	The	average	
histological	grade	for	the	ankle	pellets	at	day	7	was	8	(range:	7-9)	and	at	day	21	
was	7.5	(range:	6-9),	whereas	the	average	histological	grade	for	knee	pellets	at	
day	7	was	7.6	(range:	6-9)	and	7.5	at	day	21	(range:	7-8).		
Figure	31	(page	125)	illustrates	representative	histology	data	for	both	
knee	and	ankle	chondrogenic	pellets	at	both	day	7	and	day	21	time	points.		
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Figure	31:	Representative	histological	images	from	the	centre	of	(A,B,E,F)	ankle	
pellets	and	(C,D,G,H)	knee	pellets	at	(A,C,E,G)	day	7	and	(B,D,F,H)	day	21.	Pellets	
stained	with	(A-D)	H&E	and(E-H)	toluidine	blue.	Insert	images	are	higher-
powered	images	of	the	regions	marked	with	a	solid	line	to	demonstrate	the	
pellet	centre	and	edge.	All	scale	bars	represent	100	µm.	
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	 Chondrocytes	isolated	from	ankle	cartilage	appeared	to	form	more	
robust	pellets	than	those	created	from	knee	chondrocytes.	In	both	sets	of	
pellets,	it	appeared	there	was	no	difference	in	matrix	being	produced	over	time.	
Pellets	created	from	ankle	chondrocytes	displayed	a	higher	level	of	
metachromasia,	indicating	that	ankle	chondrocytes	had	more	ECM	produced	at	
both	time	points	assessed.		
	 Staining	intensity	of	the	toluidine	blue	stained	chondrogenic	pellets	
(section	2.1.14.4,	page	69)	demonstrated	no	significant	differences	between	
cartilage	sources	(Figure	32,	page	127;	p=0.837)	but	showed	significance	of	
intensity	changing	over	time	(p=0.004).	A	higher	staining	intensity	in	the	ankle	
pellets	was	observed	at	day	7	(p=0.001).	This	is	a	reversely	proportional	
relationship	due	to	metachromasia.		
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Figure	32:	Semi-quantitation	of	toluidine	blue-stained	chondrogenic	pellets	
demonstrating	an	increase	in	metachromasia,	determined	by	integrated	density	
analysis	using	ImageJ	imaging	software	(National	Institute	of	Health,	
Washington,	USA;	version:	24).	a,b,c	denotes	significance	of	cartilage	source	on	
staining	intensity,	time	and	specifically	at	day	7	respectively.	Data	is	presented	as	
the	mean	±	SEM	and	was	obtained	from	five	ankles	and	five	knee	patients.	
	
Time	significantly	affected	the	staining	intensity	of	the	pellets	(p=0.004),	
with	ankle	pellet	staining	intensity	decreasing	over	time,	but	the	reverse	
occurring	in	knee	pellets	where	staining	intensity	increased	over	time.	Again,	
there	was	no	evidence	of	variability	between	individual	patients	at	any	time	
point	(p=0.194).	This	data	is	reflected	in	sGAG	synthesis	(Figure	29B;	page	120),	
toluidine	blue	stain	intensity	(Figure	32)	and	BERN	scores	(Table	13;	page	123).	
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4.3.5	Chondrocyte	source	influences	gene	expression	profiles	in	chondrogenic	
three-dimensional	pellets		
qRT-PCR	was	performed	at	day	0	and	day	21,	relative	to	the	two	reference	
genes:	hypoxanthine-guanine	phosphoribosyltransfrase-1	and	TATA	box-binding	
protein,	determined	by	the	comparative	CT	method	(Schmittgen	and	Livak,	2008)	
and	normalised	to	pellet	cell	number.	Expression	of	COL1A1,	COL10A1	or	ALK1	
were	not	detected	in	either	cartilage	source,	indicating	no	evidence	of	
hypertrophy	or	de-differentiation.	For	the	key	chondrogenic	markers:	ACAN,	
COL2A1	and	SOX9,	there	were	striking	differences	between	gene	expression	
profiles	in	ankle	and	knee	chondrogenic	pellets	(Figure	33;	page	129).	
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Figure	33:	Box	and	whisker	plots	of	the	gene	expression	profiles	of	the	
chondrogenic	pellets	created	from	chondrocytes	isolated	from	ankle	and	knee	
cartilage.	Data	is	expressed	relative	to	two	reference	genes,	hypoxanthine-
guanine	phosphoribosyltransfrase-1	and	TATA	box-binding	proteins,	obtained	
from	five	ankles	and	five	knee	patients	using	three	experimental	replicated	and	
normalised	to	cell	number.	a,	b	denotes	statistical	significance	of	ACAN	expression	
between	cartilage	sources	and	significance	of	ACAN	expression	over	time	
respectively.	c,	d	denote	statistical	significance	of	COL2A1	expression	between	
cartilage	source	and	significance	of	COL2A1	expression	over	time	respectively.	e,	f	
denote	significance	of	SOX9	expression	between	cartilage	source	and	
significance	of	SOX9	expression	over	time	respectively.		
C	
d	
e	
f	
Chapter	4:	Characterising	the	chondrogenic	capacity	of	chondrocytes	isolated	from	human	
ankle	and	knee	joints.	
 
	
-	130	-	
	
ACAN	expression	increased	over	the	time	course	(p=0.017)	and	showed	
significant	differences	between	the	two	chondrocyte	sources	(p=0.002).	There	
was	no	evidence	of	variability	between	individual	patients	for	ACAN	expression	
(p=0.921).	There	was	a	significant	change	in	COL2A1	expression	over	time	
(p=0.025),	and	COL2A1	expression	was	significantly	higher	in	ankle	pellets	
compared	to	that	seen	in	knee	pellets	at	both	time	points	(p=0.004	for	source),	
and	a	trend	was	seen	for	change	of	expression	over	time	between	sources	of	
cartilage	(p=0.017).	There	was	no	evidence	of	variability	between	individual	
patients	for	COL2A1	expression	(p=0.084).	In	contrast,	there	was	no	evidence	for	
a	general	change	over	time	in	SOX9	expression	(p=0.695).	However,	ankle	pellets	
demonstrated	significantly	higher	expression	of	SOX9	than	knee	pellets	
(p<0.001).	As	with	all	three	chondrogenic	markers	assessed,	there	was	no	
evidence	of	variability	between	individual	patients	for	SOX9	expression	
(p=0.079).		
	
4.4	Discussion	
This	study	has	characterised	primary-isolated	articular	chondrocytes	from	the	
ankle	and	knee	joints	of	human	donors,	to	determine	whether	cartilage	tissue	
location	has	any	effect	on	human	chondrocyte	growth	kinetics	and	chondrogenic	
capacity	using	standard	chondrogenic	pellet	differentiation	protocols.	Our	
findings	provide	a	detailed	analysis	of	ECM	production	from	five	individual	ankle	
patients	and	five	individual	knee	patients	from	a	similar	mean	age	(53.4	years	for	
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ankle,	59.8	years	for	knee).		
	 Several	key	points	were	demonstrated	during	this	study.	First,	
cartilage	source	did	influence	growth	characteristics	of	the	chondrocytes,	as	
ankle-derived	chondrocytes	grew	at	a	slower	rate	than	knee	chondrocytes.	Ankle	
chondrocytes	underwent	significantly	less	PDs,	despite	having	a	similar	PDTs	to	
knee	chondrocytes,	and	knee	chondrocytes	achieved	significantly	higher	cell	
numbers	during	monolayer	culture	compared	to	ankle	chondrocytes.	The	second	
key	finding	was	that	no	significant	differences	in	sGAG	or	total	collagen	
production	were	observed	between	the	ankle	and	knee	chondrocytes,	but	both	
exhibited	the	same	trends	over	time.	Histologically,	representative	images	
showed	more	ECM	was	observed	in	the	chondrogenic	pellets	created	from	ankle	
cartilage	tissue	as	seen	by	the	increased	induction	of	metachromasia	between	
day	7	and	day	21,	yet	there	was	no	significant	difference	in	the	histological	
quality	of	the	pellets	or	in	the	overall	staining	intensity	across	the	full-time	
course.	However,	at	day	7	knee	chondrocytes	had	a	significantly	lower	staining	
intensity	than	ankle	chondrocytes,	suggesting	earlier	time	points	are	more	
indicative	of	ECM	production	in	ankle	cartilage.	Finally,	the	last	key	finding	was	
that	chondrocyte	source	was	deemed	to	be	significant	metabolically,	as	assessed	
in	the	gene	expression	profiles	of	the	three	key	chondrogenic	markers:	ACAN,	
COL2A1	and	SOX9.	Collectively,	these	findings	were	interesting	as	many	studies	
have	reported	differences	between	these	two	joints,	both	biomechanically	and	
anatomically,	but	limited	investigations	have	occurred	biochemically,	
metabolically	or	at	a	cellular	level.	It	could	be	hypothesised	that	there	would	be	
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significant	biochemical	differences	in	the	production	of	key	ECM	components,	
but	this	was	not	found	in	our	studies.	
Investigations	into	ankle	and	knee	chondrocytes	have	been	performed	
across	several	studies	but	none,	to	our	knowledge,	have	used	freshly	isolated	
human	cartilage	tissue.	One	study	by	Candrian	evaluated	ten	donor	matched	
chondrocytes	isolated	from	the	talus	and	femoral	head	of	cadavers,	performing	a	
similar	range	of	tests	to	our	study	(Candrian	et	al.,	2009).	This	study	reported	
similar	findings	to	ours	in	growth	kinetics,	showing	similar	proliferation	rates	
exhibited	between	ankle	and	knee	chondrocytes,	up	to	the	second	passage.	
However,	this	was	assessed	using	doublings	per	day,	as	opposed	to	the	method	
adopted	in	our	study	of	using	PDTs	and	absolute	PDs.	One	difference	was	
Candrian	reported	similar	cell	yields	for	the	two	sets	of	chondrocytes	at	
harvesting	which	contrasts	our	findings,	as	we	showed	significantly	higher	cell	
yields	from	knee	cartilage	at	harvest,	compared	to	ankle	cartilage.	We	found	this	
unsurprising,	as	the	chondrocytes	isolated	during	our	study	were	from	
macroscopically	healthy	cartilage	tissue	samples	following	total	joint	
replacement	and	so	less	cartilage	was	available	for	harvest.	Our	finding	of	
different	growth	kinetic	profiles	between	the	chondrocytes	isolated	from	these	
two	joints,	was	further	supported	by	a	study	investigating	chondrocytes	from	
various	joints	and	animal	donors	(Akens	and	Hurtig,	2005).	Representative	
potency	profiles	of	the	ankle	and	knee	chondrocytes	differed	greatly,	with	ankle	
chondrocytes	exhibiting	a	more	potent	profile	as	illustrated	by	higher	
percentages	of	the	key	chondrogenic	cell	surface	markers.	
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	 Our	study	investigated	the	synthesis	of	key	cartilage	matrix	
components	in	primary	isolated	chondrocytes	from	freshly	harvested	human	
cartilage	tissue.	Conflicting	results	have	been	seen	throughout	numerous	studies,	
using	chondrocytes	sourced	from	cadavers.	Some	studies	demonstrate	that	the	
ankle	chondrocytes	exhibit	higher	proteoglycan	synthesis	levels	in	both	cartilage	
slices	and	alginate	chondrocyte	cultures,	compared	to	the	donor	matched	knee	
samples	(Eger	et	al.,	2002;	Huch,	2001).	Further	studies	have	shown	
chondrocytes	isolated	from	the	ankle	joint	to	have	higher	synthesis	rates	of	
cartilage	matrix	proteins	compared	to	chondrocytes	isolated	from	the	knee	joint,	
producing	a	denser	ECM	(Kuettner	and	Cole,	2005;	Treppo	et	al.,	2000).	These	
findings	could	explain	the	reason	why	ankle	cartilage	is	less	susceptible	to	
degenerative	damage	or	has	a	higher	capacity	for	repairing	cartilage	damage,	
preventing	progression	to	more	permanent	degenerative	changes,	including	
osteoarthritis.	However,	other	studies	have	found	that	ankle	and	knee	cartilage	
synthesises	sGAGs	at	similar	rates	(Aurich	et	al.,	2002;	Candrian	et	al.,	2009),	
with	one	particular	study	reporting	that,	in	tissue	explants	ankle	cartilage	had	a	
higher	sGAG	content	than	knee	cartilage,	but	these	levels	became	similar	when	
the	cartilage	was	seeded	into	alginate	cultures	(Kuettner	and	Cole,	2005).	These	
studies	support	the	findings	of	this	study.		
Similar	results	from	our	study	were	seen	with	collagen	synthesis,	in	which	
both	sets	of	chondrocytes	synthesised	similar	levels	of	total	collagen.	This	finding	
was	supported	by	several	studies,	all	of	which	showed	no	difference	in	collagen	
synthesis	between	ankle	and	knee	chondrocytes	(Candrian	et	al.,	2009;	Kuettner	
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and	Cole,	2005).	Collectively,	these	findings	suggest	that	once	chondrocytes	are	
isolated	and	cultured,	they	lose	some	differences	derived	from	the	
microenvironment	of	the	native	cartilage	source.	Therefore,	the	changes	found	
in	freshly	isolated	cartilage	tissue	may	not	be	translated	to	chondrocytes	
following	monolayer	expansion,	or	the	chondrocytes	possibly	need	longer	than	
the	time	frame	investigated	in	this	study	to	fully	recover	their	phenotype	and	
exhibit	the	differences	seen	in	these	native	cartilage	tissues.	
	 We	also	reported	histological	differences	between	human	ankle	and	
human	knee	cartilage	as	both	native	tissue	and	as	chondrogenic	three-
dimensional	pellets.	Representative	core	biopsies	of	native	cartilage	tissue	
demonstrated	both	sets	of	cartilage	tissue	were	hyaline	cartilage	and	had	good	
integration	between	the	bone	and	cartilage	tissue.	The	only	evident	difference	in	
cartilage	structure	was	the	collagen	fibre	arrangement.	When	visualised	under	
polarise	light,	ankle	cartilage	had	an	organised	arrangement	of	collagen	fibres	
aligned	in	a	diagonal	linear	arrangement,	whereas	knee	cartilage	had	a	more	
random	arrangement	of	collagen	fibres.	This	is	unsurprising	as	the	joints	have	
different	loads	and	stress	applied	to	them,	which	is	typically	resisted	by	the	
collagen	fibre	arrangement	and	meshwork.	Representative	core	biopsies	also	
illustrated	the	difference	in	‘healthy’	tissue.	Despite	chondrocytes	being	
extracted	from	macroscopically	healthy	areas	of	harvested	joint	tissue,	
histologically	the	cartilage	biopsies	for	the	knee	tissue	did	not	appear	healthy	but	
had	a	rough	fragmented	surface	edge.	This	was	not	surprising,	as	the	tissue	
obtained	was	following	total	joint	replacement,	so	would	likely	be	osteoarthritic	
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in	nature.	These	findings	also	supports	reports	that	state	histological	analysis	
does	not	always	align	with	other	clinical	findings,	such	as	radiological	analysis	
(McCarthy	et	al.,	2015;	McCarthy	and	Roberts,	2013).		
Our	study	showed	no	expression	for	de-differentiation	or	hypertrophy	of	
ankle	or	knee	chondrocytes	through	assessment	of	ALK1,	COL1A1	and	COL10A1.	
Differing	gene	expression	profiles	between	the	knee	and	ankle	chondrocytes	
were	observed,	with	ankle	chondrocytes	expressing	significantly	higher	levels	of	
COL2A1	(p=0.004)	and	SOX9	(p<0.001)	across	both	time	points,	compared	with	
knee	chondrocytes,	and	these	findings	are	supported	by	several	studies	
(Chubinskaya	et	al.,	1999;	Kang	et	al.,	1998;	Miller	et	al.,	2017).	Ankle	
chondrocytes	were	also	found	to	have	higher	levels	of	ACAN	at	day	0,	indicating	
early	expression	of	the	key	component	of	the	ECM,	aggrecan.	Collectively,	these	
gene	expression	profiles	indicate	that	ankle	chondrocytes	express	not	only	
higher	levels	of	genes	responsible	for	synthesising	aggrecan,	collagen	type	II	and	
SOX9,	but	also	express	these	genes	earlier	compared	with	knee	chondrocytes.	
Our	findings	coincide	with	an	ongoing	study	being	performed	by	Miller,	in	which	
next	generation	sequencing	has	been	used	to	map	the	transcriptome	of	knee	
and	ankle	samples	obtained	following	amputation.	Early	findings	from	that	study	
illustrate	expression	of	809	genes	were	found	to	differ	between	the	two	
chondrocyte	sources,	with	781	genes	being	upregulated	and	27	genes	being	
downregulated	in	ankle	chondrocytes	when	compared	to	knee	chondrocytes	
(Miller	et	al.,	2017).	Another	study	coincides	with	these	findings	and	found	that	
mRNA	expression	of	matrix	metalloproteinase-8,	a	key	enzyme	in	degrading	ECM	
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proteins,	was	not	detected	in	normal	ankle	cartilage	but	was	present	in	normal	
knee	cartilage	(Chubinskaya	et	al.,	1999).	Differing	gene	expression	profiles	could	
be	one	possible	reason	for	ankle	cartilage	being	more	resistant	to	degenerative	
damage	when	compared	with	knee	cartilage.		
Representative	immunoprofiling	of	one	ankle	and	one	knee	sample	
demonstrated	differences	in	the	chondrogenic	potency	illustrated	by	the	
expression	of	cell	surface	markers.	We	are	the	first	study,	to	our	knowledge,	that	
has	directly	compared	ankle	and	knee	chondrocytes	in	this	way.	We	assessed	
four	key	cell	surface	markers:	CD49c,	CD39,	CD44	and	CD166	(Garcia	et	al.,	
2016).	CD44	is	major	cell	surface	receptor	for	HA	and	is	homologous	to	cartilage	
link	proteins	(Ishida	et	al.,	1997).	It	is	a	cell	surface	receptor	that	is	associated	
with	matrix-cell-cytoskeleton	interactions	(Knudson	and	Loeser,	2002).	HA	
adheres	to	CD44	which	regulates	proliferation	and	matrix	synthesis	(Ishida	et	al.,	
1997).	HA-CD44	is	required	for	the	retention	of	proteoglycans	within	the	
cartilage	ECM	(Chow	et	al.,	1998;	Knudson	et	al.,	2000;	Nishida	et	al.,	2004).	
CD44	is	indicative	of	chondrogenic	potency,	as	high	expression	levels	have	been	
associated	with	high	chondrogenic	capacity	and	increased	signalling	of	CD44	has	
been	reported	in	high	levels	of	GAG/DNA	and	type	II	collagen	(Garcia	et	al.,	2016;	
Mennan	et	al.,	2018).	Whereas,	CD49c	is	an	a-3	integrin	subunit,	which	is	
considered	an	important	mediator	for	mesenchymal	condensation,	which	in	turn	
is	necessary	for	the	initiation	of	chondrogenesis	(Delise	et	al.,	2000;	Goldring	et	
al.,	2006).	CD49c	is	associated	with	cell-cell	and	cell-matrix	interactions,	and	
functions	as	a	cell	surface	adhesion	molecule.	It	has	also	been	shown	to	interact	
Chapter	4:	Characterising	the	chondrogenic	capacity	of	chondrocytes	isolated	from	human	
ankle	and	knee	joints.	
 
	
-	137	-	
with	ECM	proteins,	and	high	signalling	of	CD49c	is	associated	with	high	synthesis	
of	GAGs	and	type	II	collagen	(Grogan	et	al.,	2007).	Additionally,	CD39	is	
considered	a	key	MSC	marker	and	is	predictive	of	chondrogenic	potency	
responses.	It	acts	by	hydrolysing	adenosine	triphosphate	and	adenosine	
diphosphate.	It	is	more	recently	being	considered	an	immune	system	mediator	
that	interferes	with	anti-tumour	and	anti-inflammatory	immune	responses	(Tan	
et	al.,	2016).	Finally,	CD166	belongs	to	the	immunoglobulin	superfamily,	and	is	
an	activated	leukocyte	cell	adhesion	molecule	located	on	the	cell-surface.	It	is	
considered	a	key	surface	marker	of	human	MSCs	which	increases	in	expression	
during	monolayer	culture	and	is	therefore	indicative	of	chondrocyte	de-
differentiation.	However,	expression	has	been	shown	to	decrease	following	
culture	in	three-dimensional	culture	system,	as	the	re-differentiation	process	
occurs	(Lee	et	al.,	2009).	It	has	been	reported	to	mediate	cell-cell	interactions	
and	expression	levels	are	suggested	to	reflect	onset	of	cellular	programming	for	
homeostatic	control	of	growth,	as	it	is	involved	with	dynamic	growth	and	
migration	(Lee	et	al.,	2009;	Swart,	2002).	it	binds	to	cell	surfaces	and	is	suggested	
to	be	associated	with	dedifferentiation	and	chondrogenic	potency	(Brady	et	al.,	
2015;	Garcia	et	al.,	2016a).		
A	previous	study	conducted	at	our	centre	concluded	that	CD49c	and	
CD39	immunopositivity	positively	predicts	GAG	production	and	histological	score	
in	cell	pellets	(Garcia	et	al.,	2016).	Positivity	of	CD49c	and	CD39	have	also	been	
shown	to	be	associated	with	increased	in	vitro	chondrogenic	potential	(Grogan	et	
al.,	2007;	Gullo	and	De	Bari,	2013).	High	signals	of	CD44	and	CD49c	have	been	
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reported	as	correlating	with	high	levels	of	GAG/DNA	and	high	levels	of	type	II	
collagen	(Garcia	et	al.,	2016;	Mennan	et	al.,	2018).	It	would	be	useful	to	obtain	a	
higher	number	of	cartilage	samples	for	the	flow	cytometry	analyses	to	allow	for	a	
more	definitive	assessment	of	the	differences	in	chondrogenic	potency	between	
ankle	and	knee	chondrocytes	and	would	allow	for	statistical	calculations	to	be	
performed;	however,	we	were	limited	due	to	the	number	of	cells	required	to	
perform	all	assessments.	As	we	were	only	able	to	obtain	representative	
immunoprofiling	for	one	ankle	and	one	knee	sample,	it	is	difficult	to	draw	
definitive	conclusions	from	these	results,	and	further	samples	would	be	required.	
However,	as	knee	chondrocytes	expressed	little	CD39,	CD166	and	CD49c	
in	this	study,	it	could	be	speculated	that	these	potency	markers	may	not	be	the	
best	representative	markers	of	chondrogenic	potency	in	knee	chondrocytes	and	
could	be	altered.	Further	work	would	be	required	to	determine	more	accurate	or	
representative	potency	markers	from	a	wide	panel	of	available	markers.	
Furthermore,	these	results	could	speculate	that	the	source	of	chondrocytes	(ie:	
from	knee	or	ankle)	could	lead	to	altered	profiles	of	potency	markers,	and	this	
would	be	an	interesting	avenue	to	explore	in	future	research	studies	by	
determining	the	most	representative	panel	of	potency	markers	for	each	different	
sources	of	chondrocytes	that	would	be	the	most	representative	for	that	location.		
We	expected	some	patient	variability	within	our	results	but	found	no	
statistical	evidence	for	a	patient-specific	influence	on	any	of	the	outcomes	
measured	in	these	experiments,	as	assessed	by	multilevel	modelling	analysis	
(Hox,	2010;	Vaughn,	2008).	More	work	could	be	done	to	expand	these	findings	
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further	and	delve	deeper	into	the	differences	between	ankle	and	knee	cartilage	
to	discover	variances	in	osteoarthritis	development	with	ankle	osteoarthritis	
characteristically	being	post-traumatic	osteoarthritis	compared	to	knee	
osteoarthritis	usually	being	primary	in	nature.	An	example	of	further	
investigation	that	could	elucidate	some	findings	further,	would	be	to	utilise	
patient	demographics	further,	for	example	BMI,	smoking	status	and	activity	
levels.	These	were	not	determined	for	this	study,	but	could	be	obtained	from	
patient	electronic	medical	records	and	used	in	future	investigations.		
These	results	should	be	taken	with	caution	when	comparing	to	cell	
therapy	patients,	as	the	samples	were	obtained	following	total	joint	replacement	
surgery.	Due	to	the	nature	of	this	study,	human	primary	cartilage	tissue	was	
obtained	from	total	joint	replacement	surgeries	which	poses	a	limitation	to	our	
study,	as	the	cartilage	obtained	could	potentially	be	osteoarthritic.	Osteoarthritis	
is	classified	as	a	whole	joint	disease	and	although	care	was	taken	to	ensure	
cartilage	was	taken	from	macroscopically	healthy	areas,	chondrocytes	could	still	
have	a	sub-chondrogenic	phenotype	upon	differentiation,	as	indicated	with	our	
core	biopsy	images.	However,	we	did	not	detect	any	ALK1	expression	in	
monolayer-expanded	chondrocytes	harvested	from	either	cartilage	source,	
indicating	that	the	tissue	extracted	was	not	of	an	osteoarthritic	nature.	
Furthermore,	as	these	samples	were	from	patients	undergoing	total	joint	
replacement,	caution	should	be	taken	when	comparing	these	findings	with	those	
from	patients	undergoing	ACI.		
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In	conclusion,	to	our	knowledge	there	is	no	other	study	available	
providing	such	insights	into	characterising	the	chondrogenic	potential	of	
chondrocytes	isolated	from	the	knee	and	ankle.	This	study	clearly	demonstrates	
that	although	there	were	no	evident	significant	differences	in	proliferation	rates	
or	in	the	synthesis	of	total	sGAGs	and	total	collagen,	there	were	significant	
differences	in	the	gene	expression	profiles	between	ankle	and	knee	
chondrocytes.	These	findings	demonstrate	that	the	differences	exhibited	are	
elucidated	from	non-biomechanical	factors	and	are	due	to	the	chondrocytes	
themselves	independent	of	biomechanical	stimuli	or	their	microenvironment.	
However,	differences	reported	between	ankle	and	knee	cartilage	tissue	and	in	
osteoarthritis	development	of	these	two	joints,	are	likely	due	to	synergic	effects	
of	anatomical,	biochemical	and	biomechanical	differences.	Further	research	into	
ankle	and	knee	cartilage	pathophysiology	and	their	regenerative	capacity	is	
required	to	improve	our	knowledge	of	these	joints	and	advance	cartilage	repair	
techniques.	
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Chapter	5:	Clinical	methods	
5.1	Clinical	tests	
The	methodology	to	design	the	PROM	was	adopted	from	the	three-step	
approach	recommended	for	best	practice	by	the	Food	and	Drug	Administration	
(U.S.	Department	of	Health	and	Human	Services	Food	and	Drug	Administration,	
2009).	The	three	steps	are:	item	generation,	scale	generation	and	test	
properties.	Patient	selection	was	also	considered	in	the	design	of	the	PROM.	
	
5.1.1	Item	generation	
Given	the	range	of	foot	and	ankle	scoring	systems,	it	seemed	unwise	to	design	a	
completely	new	PROM.	However,	none	of	the	existing	PROMs	seem	to	address	
all	aspects	that	patients	and	clinicians	find	important	(Devlin,	2010;	Pinsker	et	al.,	
2013).	The	newly	devised	PROM,	named	the	‘Oswestry	Ankle	Score	(OsAS)’	was	
designed	by	selecting	items	through	a	process	of	reviewing	the	existing	foot	and	
ankle	PROMs	and	ensuring	that	all	items	considered	important	for	assessing	
clinic	outcome	from	a	patient	(Pinsker	et	al.,	2013)	or	health	professional	
perspective	were	selected	for	the	newly	devised	scoring	system.	Where	needed,	
the	phrasing	of	items	was	adapted	to	ensure	consistency	of	style	and	formatting	
for	the	score	to	be	solely	patient-reported.	
	 Further	feedback	was	gained	from	appropriate	healthcare	
professionals,	namely	foot	and	ankle	consultant	surgeons	and	physiotherapists,	
to	ensure	that	the	questions	addressed	aspects	that	they	found	important	in	
thoroughly	assessing	the	treatment	outcome	and	rehabilitation	process.	This	
feedback	process	also	allowed	for	the	PROM	to	be	foot	and	ankle	specific.		
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5.1.2	Scale	generation		
The	scale	system	for	use	in	the	questionnaire	was	chosen	to	allow	for	a	wide	
application	and	ease	of	answering	the	score.	A	Likert	scale,	consisting	of	five-
point	Likert-type	items	was	selected	to	capture	and	measure	patient’s	
perception	of	their	ankle	health.	(Kroenkea	et	al.,	2015;	Likert,	1932).	Likert	scale	
was	selected,	due	to	the	ease	of	answering	by	patients.	
	
5.1.3	Patient	selection	
Based	on	statistical	power	analyses	described	in	Table	14	(page	143),	it	was	
determined	that	219	patients	would	be	required	to	perform	all	the	reliability,	
validity	and	responsiveness	assessments.	A	formal	power	calculation	was	not	
performed,	but	a	sample	size	was	selected	based	on	sample	sizes	needed	for	all	
necessary	analysis	outlined	in	Table	14	(page	143).	Based	on	previous	
questionnaire-based	studies	performed	at	our	centre,	a	response	rate	of	
approximately	85%	would	be	expected.	Therefore,	based	on	this	we	aimed	to	
consent	approximately	260	patients,	to	receive	219	completed	questionnaires.	
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Table	14:	Measurement	properties	and	analyses	used	in	this	study,	together	with	
the	sample	sizes,	to	determine	the	measurement	properties	of	the	newly	
developed	score.	The	sample	sizes	were	decided	in	deliberation	with	a	
biostatistician	and	with	consideration	of	published	guidelines	(Frost,	et	al.,	2007;	
Rothman,	et	al.,	2009).		
	
Total	sample	size	=	219	
Property:	 Analysis:	 Sample	
size:	
Criterion	determined	sample	
size:	
Construct	
validity	
Patient	focus	
groups	
20-30	 Allows	for	reliable	and	
valuable	feedback	
Internal	
consistency	
-	Rasch	
analysis	
-	Multilevel	
factor	analysis	
200	
	
300	
Sample	size	determined	from	
Frost,	et	al.,	2007	
Reliability	 Test-retest	 105	 Allows	for	95%	confidence	
interval	(CI)	of	±0.1	or	
smaller,	assuming	the	
coefficient	is	at	least	0.7,	
which	is	reasonable	based	on	
similar	PROM	instruments.	
Sensitivity	to	
change	
Changes	in	
treatment	
scores	prior	
and	post-
surgery	
109	 Allowing	assessments	with	a	
95%	CI	of	±0.2,	assuming	a	
responsiveness	of	0.5	and	a	
correlation	of	0.5	between	
baseline	and	post-treatment	
score.		
Responsiveness	 -	Cohen’s	
effect	size	
measure	
-	Focus	groups	
109	
	
	
20-30	
Allowing	assessments	with	a	
95%	CI	of	±0.2,	assuming	a	
responsiveness	of	0.5	and	a	
correlation	of	0.5	between	
baseline	and	post-treatment	
score.		
Correlation	
with	other	
scores	
Pearson	
moment	
correlation	
coefficient	
219	 Allows	for	assessments	with	a	
correlation	coefficient	with	a	
95%	CI	of	±0.1	or	smaller,	
assuming	the	coefficient	is	at	
least	0.5,	or	a	95%	CI	of	±0.15	
if	the	coefficient	is	smaller.	
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5.1.3.1	Eligibility	criteria	
To	be	eligible,	participants	had	to	be	an	adult,	that	is	over	the	age	of	18,	and	able	
and	willing	to	provide	written	informed	consent	after	reading	and	understanding	
the	patient	information	sheet.	Participants	either	had	to	present	at	a	first	ankle	
clinic	with	symptoms	suggesting	cartilage	defects	or	osteoarthritis,	be	awaiting	
treatment	or	have	already	received	treatment	for	ankle	cartilage	defects	or	
osteoarthritis	using	any	type	of	treatment,	including	cell	therapy,	microfracture,	
fusion	or	total	ankle	replacement.		
Participants	would	be	excluded	if	they	were	unable	or	unwilling	to	read	
and	understand	the	patient	information	sheet,	unable	or	unwilling	to	provide	
written	informed	consent	for	themselves,	be	under	the	age	of	18,	be	unable	or	
unwilling	to	complete	all	questionnaires	for	the	duration	of	the	study	or	had	
symptoms	or	require	treatment	for	any	condition	other	than	cartilage	defects	or	
osteoarthritis	of	the	ankle	joint.	
There	were	high	levels	of	patient	variability	in	the	sample	due	to	the	
nature	of	the	study	and	patient	population.	Variations	occurred	through	age,	
gender	and	activity	levels	(activity	levels	were	not	recorded	for	this	study).	
Further	demographics	could	be	obtained	from	patient	electronic	records	and	
utilised	further	if	required.	
	
5.1.4	Test	properties	
To	confirm	measurement	properties	of	the	OsAS	PROM,	relevant	
recommendations	of	consensus-based	standards	for	the	selection	of	health	
measurement	instruments	(COSMIN)	were	followed	to	examine	each	subscale	in	
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the	whole	sample	and	by	subgroup.		
The	OsAS	PROM	was	designed	to	measure	the	patient-perceived	clinical	
outcome	of	ankle	treatments,	including	cell	therapy	and	total	ankle	replacement	
surgery.	It	aims	to	address	important	aspects	of	the	outcome	following	ankle	
treatments,	including:	symptoms,	ankle	function,	activities,	pain	and	quality	of	
life.	Patients	completed	the	score	both	pre-operatively	and	post-operatively	to	
allow	the	PROM	to	capture	and	determine	the	outcome	of	the	treatment	by	a	
change	in	PROM	score	following	intervention	(Revicki	et	al.,	2008).		
The	score	was	assessed	for	all	recommended	aspects	to	determine	its	
design	quality	and	applicability,	including	validity,	reliability	and	responsiveness	
(Cöster	et	al.,	2014b;	Frost	et	al.,	2007;	Revicki	et	al.,	2008).	Minor	adaptations	of	
existing	validated	scores	do	not	need	an	extensive	“revalidation”	(Snyder,	et	al.,	
2010;	FDA,	2009).	However,	since	our	new	PROM	combined	items	from	many	
existing	PROMs	a	full	validation	seemed	to	be	warranted.	The	psychometric	
validation	of	the	score,	in	particular	the	factor	analysis	and	Rasch	model,	was	
used	to	select	the	most	appropriate	items,	thus	reducing	the	length	of	the	PROM	
and	its	administrative	burden.	Table	14	(page	143)	describes	the	different	
assessments	that	were	used	to	validate	the	OsAS	PROM.	
Internal	consistency	was	assessed	using	factor	analysis	and	a	Rasch	
analysis.	The	Rasch	analysis	required	a	minimum	sample	size	of	200	participants	
(Frost,	et	al.,	2007).	The	factor	analysis	required	around	300	patients	(Frost	et	al.,	
2007),	but	at	least	100	of	the	participants	in	this	study	were	expected	to	provide	
two	scores,	a	score	at	baseline	and	a	score	post-treatment.		
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Test-retest	reliability	required	a	sample	size	of	105	to	estimate	the	
correlation	coefficient	with	a	95%	CI	of	±0.1	or	smaller,	assuming	the	coefficient	
was	at	least	0.7,	a	reasonable	figure	based	on	similar	PROM	instruments.	The	
correlation	with	other	instruments,	a	general	health	score	and	a	specific	
validated	foot	and	ankle	measure,	namely	the	Veteran	Rand-12	questions	(VR-
12;	Appendix	VI,	page	234)	and	the	Manchester	Oxford	Foot	Questionnaire	
(MOxFQ;	Appendix	V;	page	232)	respectively,	was	determined	using	the	Pearson-
moment	correlation	coefficient	(Morley	et	al.,	2013;	Selim	et	al.,	2009).	Assessing	
this	correlation	required	a	sample	size	of	219	people	to	estimate	the	correlation	
coefficient	with	a	95%	CI	of	±0.1	or	smaller,	assuming	the	coefficient	was	at	least	
0.5,	or	a	95%	CI	of	±0.15	if	the	coefficient	was	smaller.	Correlation	with	other	
scores	is	the	chosen	method	for	assessing	validation,	but	there	is	a	plethora	of	
methods	that	could	be	used	(Litwin,	1995).	
A	sample	size	of	109	patients	was	required	to	determine	the	
responsiveness	to	change	as	defined	by	Cohen's	effect	size,	which	is	defined	as	
the	change	in	mean	baseline	to	post-treatment	score,	divided	by	the	standard	
deviation	of	the	baseline	score	(Cohen,	1992a;	Cohen,	1992b).	This	assessment	
required	109	patients	to	achieve	a	95%	CI	of	±0.2,	assuming	a	responsiveness	of	
0.5	and	a	correlation	of	0.5	between	baseline	and	post-treatment	score.	For	all	
analyses,	95%	CI	were	used	to	summarise	results.	The	assessments	are	
summarised	in	Table	9.		
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5.1.5	Ethical	considerations	
The	study	met	all	regulations	and	ethical	considerations	set	by	the	sponsor,	
Keele	University,	and	the	host	study	centre:	The	RJAH	Orthopaedic	hospital	in	
Oswestry.	For	the	OsAS	questionnaire	to	be	approved	by	the	relevant	ethics	
committee,	an	ethics	application	was	submitted	through	the	integrated	research	
application	system	to	the	health	research	authority,	and	ethical	approval	was	
obtained	from	the	Preston	Ethical	Committee	in	May	2017	(REC	reference:	
17/NW/0063;	Appendix	II,	page	226).	During	the	first	12-18	months	of	my	PhD	
study,	all	drafting	of	questionnaires,	letters,	documentation	and	correspondence	
in	relation	to	the	OsAS	score	were	carried	by	myself	with	guidance	from	the	
supervisory	team.		
	
5.1.6	Patient	focus	groups	
The	initial	draft	of	the	questionnaire	was	presented	to	a	patient	focus	group	of	
19	people,	for	their	feedback.	Feedback	was	obtained	on	the	content	of	the	
questionnaire,	the	length	and	duration	of	completing	the	score,	ease	of	
understanding	and	answering	the	questions	and	if	anything	they	considered	
important	was	not	addressed	in	the	questionnaire.	
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Chapter	6:	Design	and	psychometric	testing	of	a	new	
patient-reported	outcome	measure	for	ankle	treatment.		
6.1	Introduction	
Patient-reported	outcome	measures	(PROMs)	are	defined	by	the	US	Food	and	
Drug	Administration	as	‘any	report	of	the	status	of	a	patient’s	health	condition	
that	comes	directly	from	the	patient,	without	interpretation	of	patient	response	
by	a	clinician	or	anyone	else’	(U.S.	Department	of	Health	and	Human	Services	
Food	and	Drug	Administration,	2009).	Health	care	professionals	increasingly	use	
PROMs	to	assess	treatment	outcome	from	the	patient	perspective	(Harris	et	al.,	
2013).	The	patient	usually	fills	these	out	at	set	stages	of	their	treatment,	typically	
pre-operatively	and	post-operatively,	which	allows	surgeons,	doctors	and	
administrators	to	monitor	the	progress	of	the	treatment	on	a	patient-by-patient	
basis.	PROMs	also	allow	for	collective	data	to	be	used	to	assess	feelings	towards	
the	treatment	as	a	whole,	indicating	any	key	areas	that	may	need	to	be	
addressed,	for	example	through	rehabilitation	or	other	areas	of	recovery	(Harris,	
et	al.,	2013;	Devlin,	2010).		
	 The	main	advantages	of	PROMs	in	surgery	is	that	they	allow	capturing	
aspects	of	the	treatment	and	recovery	that	are	important	to	the	patient,	
allowing	patients	to	feel	more	involved	in	their	care	and	treatment	plan,	and	
allow	treatment	strategies	to	be	assessed	on	a	patient-by-patient	basis	(Martin	
and	Irrgang,	2007).	The	limitations	associated	with	the	use	of	PROMs	include	the	
potential	for	a	patient	to	exaggerate	or	understate	their	symptoms,	the	time	
needed	to	collect	and	manage	the	data	and	the	difficulty	for	a	PROM	to	capture	
what	healthcare	professionals	and	patients	find	important	for	assessing	the	
Chapter	6:	Design	and	psychometric	testing	of	a	new	patient-reported	outcome	measure	
for	ankle	treatment.	
 
	
-	149	-	
treatment	outcome	(Pinsker,	et	al.,	2013;	Cook	&	Beckman,	2006).	As	each	
PROM	has	its	own	strengths	and	limitations,	each	healthcare	professional	tends	
to	use	a	PROM	they	find	important	in	capturing	outcome,	which	differs	between	
healthcare	professionals.	
There	are	barriers	associated	with	the	wide	application	of	PROMs,	with	
one	being	that	the	measures	can	prove	difficult	to	administer	to	the	patient.	
These	difficulties	may	be	related	to	the	length	of	time	to	complete	the	PROM;	
the	administrative	burden	on	medical	personnel	to	collect	and	analyse	the	data	
or	difficulties	in	interpreting	the	measure	by	medical	personnel	or	by	patients.	
These	administrative	difficulties	lead	to	a	poor	implementation	of	the	PROM	and	
problems	in	determining	a	final	outcome	from	the	measure.	Consequently,	a	
major	limitation	associated	with	PROMs	is	that	often	too	many	measures	are	
used,	all	assessing	various	aspects	of	the	condition	or	disease,	yet	no	gold	
standard	measure	exists	to	assess	all	aspects	simultaneously.	Therefore,	
selecting	an	appropriate	outcome	measure	proves	to	be	difficult	and	usually	
more	than	one	score	is	required	to	assess	every	important	aspect.	In	turn,	this	
means	that	completing	the	score	sheets	is	time	consuming	for	the	patient	and	
the	analysis	is	time	consuming	for	the	physician.	Furthermore,	not	all	scores	are	
validated	for	a	specific	use	and	this	can	limit	their	applicability	(Nelson	&	
Berwick,	1989;	McHorney	&	Tarlov,	1995;	Martin,	et	al.,	1997;	Binkley,	et	al.,	
1999).		
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Score:	 Type:	 Validation:	
Am rican	academy	of	 rthopa dic	
surgeon’s	lower	limb	outcome	
assessment	instruments	foot	and	ankle	
modules	
RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
Ankle	osteoarthritis	scale		 DisS;	RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
Bristol	foot	score	 RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
Foot	and	ankle	ability	measure	 DimS;	
RS	
Valid	for	assessing	
physical	performance	of	
foot	and	ankle	
musculoskeletal	
disorders.	
Foot	and	ankle	disease	index	(FADI)	 RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
Foot	and	ankle	outcome	score	(FAOS)	 RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	foot	and	
ankle.	
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Foot	function	index	(FFI)	 DimS;	
RS	
Valid	for	assessing	foot	
related	pathological	
disorders.	
Foot	health	status	questionnaire	(FHSQ)	 RS	 Valid	for	assessing	
surgical	treatment	in	
podiatry	for	foot	
problems.	
Juvenile	arthritis	foot	disability	index	
(JAFI)	
PopS;	
DisS;	RS	
Valid	for	assessing	
arthritis	of	the	foot	in	
juveniles.	
Karlsson	ankle	function	score	(KAFS)	 RS	
DimS	
Not	enough	evidence	to	
support	full	validation	
for	use	in	foot	and	
ankle.	
Lower	extremity	function	scale	(LEFS)	 RS;	DisS	 Valid	for	assessing	
musculoskeletal	
disorders	of	the	hip,	
knee,	ankle,	foot	
Maryland	foot	score	(MFS)	 RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
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6.1.1	Current	patient-reported	outcome	measures	for	use	in	the	foot	and	ankle	
There	are	currently	16	scoring	systems	used	for	assessing	foot	and	ankle	
conditions	(Table	15).		
	
Table	15:	The	sixteen	foot	and	ankle	scores	currently	used	to	assess	foot	and	
ankle	conditions.	Table	adapted	from	(Martin	and	Irrgang,	2007).	
Key:	DisS	=	disease	specific;	DimS	=	dimension	specific;	RS	=	region	specific;	PopS	
=	population	specific		
	
All	assess	different	populations,	conditions	and	diseases,	and	
therefore	no	score	is	considered	the	‘gold-standard’	(Pinsker,	et	al.,	2015;	Harris,	
Manchester-Oxford	foot	questionnaire	
(MOxFQ)	
RS	 Valid	for	assessing	
surgical	outcome	of	a	
variety	of	foot	disorders.	
Olerud	scoring	scale	(OSS)	 RS	 Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
Rowan	foot	pain	assessment	
questionnaire	(ROFPAQ)	
DimS	
RS	
Not	enough	evidence	to	
support	full	validation	
for	use	in	ankle.	
Sports	ankle	rating	system	quality	of	life	
(SARQOL)	
DimS	
RS	
Valid	for	assessing	
quality	of	life	after	ankle	
injury.	
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et	al.,	2013).	Different	surgeons	use	different	outcome	measures	depending	on	
what	they	are	trying	to	assess	and	their	own	personal	preference.	Despite	16	
scores	being	in	use,	only	six	of	these	are	validated	for	assessing	the	foot	and	
ankle.	This	is	related	to	some	scores	having	been	devised	through	adapting	other	
scores,	some	scores	having	been	developed	to	assess	areas	other	than	the	foot	
and	ankle	and	some	scores	not	being	sensitive	to	capturing	foot	and	ankle	issues.	
None	of	the	existing	PROMs	were	developed	to	assess	the	clinical	outcome	of	
ankle	cartilage	surgery	and	none	of	these	PROMs	address	all	major	areas	of	
concern	for	ankle	patients,	namely	pain,	swelling	and	recreation	and	leisure,	
specifically	relating	to	sports	(Pinsker	et	al.,	2013).		
	
6.2	Aims	
This	study	aimed	to	develop	and	psychometrically	refine	a	new	PROM	that	can	
be	used	to	assess	the	patient-perceived	outcome	of	treatments	for	ankle	
cartilage	injuries	or	diseases,	such	as	cell	therapy	or	ankle	replacement.		
	
6.3	Methods	and	materials	
6.3.1	Design	of	the	Oswestry	Ankle	Score	(OsAS).	
An	initial	version	of	the	questionnaire	(Appendix	III,	page	227)	was	developed	
based	on	questions	taken	from	nine	existing	questionnaires,	which	focused	on	
four	specific	areas	of	interest	known	to	be	important	to	ankle	patients,	namely	
pain,	swelling,	activities	and	daily	life	(Table	16;	page	155).	These	areas	and	
questions	were	chosen	(section	5.1.1,	page	141)	in	collaboration	with	four	foot	
and	ankle	consultant	surgeons	and	a	specialist	physiotherapist.	Next,	the	draft	
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questionnaire	was	presented	to	a	focus	group	consisting	of	ankle	patients	who	
visited	the	outpatient	clinic	before	or	after	treatment	in	order	to	gain	patient	
feedback	and	refine	the	questionnaire.		This	method	of	questionnaire	design	
followed	relevant	guidelines	(Frost	et	al.,	2007;	Rothman	et	al.,	2007;	Rothman	
et	al.,	2009)	
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Table	16:	Nine	patient-reported	outcome	measures	assessed	and	used	for	
questions	to	draft	our	initial	questionnaire:	the	Oswestry	ankle	score	(OsAS).		
Score:	 Score	name:	 Reference(s):	
FHSQ		 Foot	Health	Status	
Questionnaire	
Palomo-López	et	al.,	2017;	Bennett	
et	al.,	1998.	
FFI	 Foot	Function	Index	 Madeley	et	al.,	2012;	Budiman-Mak	
et	al.,	2013;	Budiman-Mak	et	al.,	
1991.	
SARQOL	 Sports	Ankle	Related	Quality	
of	Life		
Beaudart	et	al.,	2017;	Beaudart	et	al.,	
2017.	
OHS	 Oxford	Hip	Score		 Wylde	et	al.,	2005;	Murray	et	al.,	
2007;	Cöster	et	al.,	2014.	
LKS	 Lysholm	Knee	Score	 Smith	et	al.,	2009;	Tegner	&	Lysholm,	
1985.	
LEFS	 Lower	Extremity	Function	
Scale		
	Binkley	et	al.,	1999;	Dingemans	et	
al.,	2017.	
FAOS	 Foot	and	Ankle	Outcome	
Score	
Cöster	et	al.,	2014;	Roos	et	al.,	2001;	
Dawson	et	al.,	2006.	
FAAM	 Foot	and	Ankle	Ability	
Measure	
Martin	et	al.,	2005;	Martin	&	Irrgang,	
2007.	
SMFA	 Short	Musculoskeletal	
Function	Assessment	
Questionnaire	
Williams,	2016;	Martin	et	al.,	1997.	
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6.3.2	Content	validity	
This	questionnaire	was	trialled	in	a	pre-operative	assessment	clinic	on	
approximately	20	patients	to	gain	patient	feedback	following	Frost’s	guidelines	
(Frost	et	al.,	2007)	for	assessing	content	validity,	and	on	a	physiotherapist	and	
four	foot	and	ankle	consultant	surgeons	to	gain	clinician	input.	This	was	to	
ensure	that	our	newly	developed	outcome	measure	captured	both	what	patients	
and	clinicians	considered	important	when	assessing	clinical	outcome	of	surgical	
intervention.	Patients	were	asked	about	the	length	of	questionnaire,	the	time	
taken	to	complete	the	questionnaire,	wording	of	questions,	ease	of	
understanding,	the	relevance	of	questions	and	if	they	found	anything	important	
to	be	missing	from	the	questionnaire.	Any	valuable	feedback	was	noted	and	the	
score	was	adapted	to	include	any	suggestions,	if	applicable.	
	
6.3.3	Psychometric	refinement	
Eligible	patients	(section	5.1.3.1,	page	144)	were	invited	into	the	study	by	
sending	them	an	invitation	pack	consisting	of	an	invitation	letter,	a	patient	
information	sheet,	a	consent	form	and	a	prepaid	envelope.	The	invitation	letter	
explained	the	reasons	for	doing	the	study	and	what	would	be	required	of	the	
participants.	Participants	were	given	the	opportunity	to	ask	questions	by	
contacting	us	either	by	email,	post	or	telephone.	If	happy	to	partake	in	the	study,	
participants	would	complete	the	consent	form	by	initialling	each	box	on	the	form	
to	confirm	agreement	to	each	statement	and	signing	and	dating	the	bottom	of	
the	form	to	confirm	their	participation.	The	consent	form	was	then	returned	
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using	the	stamped	addressed	envelope	provided.	If	the	returned	consent	forms	
were	completed	incorrectly,	the	forms	were	sent	back	to	the	participants	to	be	
amended	before	enrolment	into	the	study.	We	sent	a	reminder	letter	to	the	
participants	after	approximately	2-3	weeks	if	we	did	not	get	a	response.	Once	
enrolled,	the	consent	form	was	also	signed	and	dated	by	me	and	a	copy	was	sent	
back	to	the	patient	for	their	records.	The	original	was	scanned	into	the	electronic	
patient	records,	with	a	study	enrolment	log,	and	then	filed	into	the	study	notes.	
All	further	correspondence	for	the	duration	of	the	study	(ie:	sending	or	receiving	
questionnaires)	was	documented	in	the	electronic	patient	records.	If	patients	did	
not	wish	to	partake,	they	could	send	the	blank	forms	back	using	the	prepaid	
envelope	provided.		
	
6.3.4	Inclusion	and	exclusion	criteria	
Patients	could	only	be	enrolled	into	the	study,	if	they	met	the	following	inclusion	
criteria:	
• Over	the	age	of	18		
• Either:	(1)	Attending	a	first	ankle	clinic	with	symptoms	suggesting	
cartilage	defects	or	osteoarthritis,	(2)	Scheduled	for	treatment	of	ankle	
cartilage	defects	or	osteoarthritis,	(3)	Having	had	treatment	for	ankle	
cartilage	defects	or	osteoarthritis	
• Prospective	or	actual	treatment	must	be	ankle	surgery	for	cartilage	injury	
or	disease,	including	but	not	limited	to:	cell	therapy,	microfracture,	fusion	
and	total	ankle	replacement.	
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If	a	patient	met	all	inclusion	criteria,	they	were	sent	a	patient	Invitation	letter.	
Patients	were	excluded	if	they	were:		
• Unable	to	read	and	understand	the	patient	information	sheet	
• Unable	or	unwilling	to	provide	written	informed	consent	for	themselves	
• Unlikely	to	complete	the	duration	of	the	study	for	whatever	reasons	
• Unable	to	adequately	understand	verbal	explanations	or	written	
information	given	in	English	or	have	special	communication	needs.		
	
6.3.5	Statistical	analysis	plan	
Content	validity	and	the	response	process	of	our	questionnaire	was	investigated	
using	two	focus	groups,	one	at	the	development	stage	prior	to	the	psychometric	
study	and	a	second	focus	group	after	all	data	was	collected,	in	line	with	current	
guidance	(Rothman,	et	al.,	2009).	The	internal	consistency	of	the	
instrument/questionnaire	was	determined	using	a	principal	component	analysis	
and	a	Rasch	analysis.	The	statistical	analyses	were	performed	using	IBM-SPSS	Vs	
24	(IBM,	New	York,	USA)	for	the	factor	analysis,	and	jMetrik	vs	4.1.1	(jMetrik	
Item	Analysis,	Virginia,	USA)	for	the	Rasch	analysis.		
	
6.3.5.1	Factor	analysis	
Factor	analysis	is	a	statistical	reduction	technique	that	analyses	correlations	
among	multiple	outcomes	in	this	case	the	answers	to	the	separate	questions	
within	the	questionnaire.	It	is	used	to	discover	which	questions	in	the	
questionnaire	form	coherent	subsets	that	are	relatively	independent	from	each	
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other	(Tabachnick	and	Fidell,	2006).	The	purpose	of	this	analysis	within	our	study	
was	to	determine	if	all	questions	addressed	the	same	concept	or	whether	the	
questions	would	address	distinct	aspects,	such	as	pain	and	activity.	In	the	latter	
case,	we	would	consider	eliminating	isolated	questions	that	addressed	distinct	
aspects	or	questions	that	addressed	aspects	deemed	less	important.	In	the	factor	
analysis,	all	factors	with	an	eigenvalue	larger	than	1	were	retained.		
	
6.3.5.2	Rasch	analysis	
The	Rasch	analysis	was	performed	to	determine	the	internal	consistency	of	the	
score	and	followed	published	guidelines	(Linacre	and	Wright,	1998;	Meyer,	2017;	
Smith,	1996).	WMS	(Infit	mean	square)	and	UMS	(outfit	mean	square)	values	
were	used	to	determine	which	questions	were	considered	important	and	which	
were	deemed	unimportant	for	the	OsAS	score.	WMS	is	defined	as	an	inlier	
sensitive	weighted	fit	statistic,	whereas	UMS	is	defined	as	an	outlier	sensitive	
non-weighted	fit	statistic.	Both	are	based	on	the	squared	standardised	residual	
between	what	is	observed	and	what	would	be	expected	on	the	basis	of	the	Rasch	
model	(Linacre,	2002).	The	range	of	UMS	and	WMS	values	is	0	to	infinity,	with	1	
being	the	ideal	value.	Values	significantly	higher	than	1	indicate	noise	within	the	
dataset,	whereas	values	significantly	lower	than	1	indicate	dependency	(Bond	
and	Fox,	2007;	Wright	and	Linacre,	1994).	Importance	was	considered	based	on	
guidelines	from	Smith	(Smith,	1996),	which	state	0.5-1.5	are	deemed	the	most	
suitable	cut	off	values	for	determining	the	fit	of	the	questions	within	the	overall	
score	and	are	deemed	productive	for	measurement	(Smith,	1996;	Wright	and	
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Linacre,	1994).	Questions	whose	answers	did	not	fit	the	Rasch	model	according	
to	these	criteria	were	either	eliminated	or	their	scale	was	collapsed	or	reordered.	
	
6.3.6	Content	validity	of	revised	questionnaire	
Based	on	the	results	of	the	factor	analysis	and	the	Rasch	analysis,	some	
questions	were	eliminated	or	had	their	scales	revised.	Scales	were	collapsed,	
were	necessary,	based	on	theta	plots	(Figure	30;	page	122).	The	analysis	could	
also	identify	overlapping	questions,	which	were	candidates	for	elimination.	The	
revised	questionnaire	was	then	discussed	again	with	the	clinical	team	(consultant	
surgeons	and	physiotherapists)	and	sent	to	a	patient	focus	group	of	13	patients	
to	determine	if	the	revised	questionnaire	still	addressed	all	aspects	deemed	
important	to	patients	and	clinicians.	Both	groups	were	also	asked	which	
questions	(if	any)	could	be	eliminated	from	the	revised	questionnaire.	
	
6.3.7	Sample	size	and	power		
A	sample	size	of	219	was	decided	upon	for	all	psychometric	and	further	
validation	analyses	using	a	combination	of	formal	power	analysis	and	relevant	
guidelines	(Frost,	et	al.,	2007;	Rothman,	et	al.,	2009;	see	also	Chapter	5,	page	
139).	These	guidelines	suggest	a	sample	size	of	200	for	a	Rasch	analysis	and	300	
cases	for	a	factor	analysis,	but	decline	to	advise	on	sample	sizes	for	focus	groups.	
A	formal	power	calculation	was	not	performed,	but	a	sample	size	was	selected	
based	on	sample	sizes	needed	for	all	necessary	analysis	outlined	in	Table	14	
(page	143).	
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6.4	Results	
6.4.1	First	development	and	content	validation	
The	initial	OsAS	score	(Version	2)	was	designed	using	existing	questions	from	
nine	questionnaires:	foot	and	ankle	outcome	score,	sports	ankle	rating	system	
quality	of	life,	foot	health	status	questionnaire,	foot	function	index,	foot	and	
ankle	ability	measure,	lower	extremity	function	scale,	short	musculoskeletal	
function	assessment	questionnaire,	the	Oxford	hip	score	and	the	Lysholm	knee	
score	(section	5.1.1,	page	141).	Once	designed,	the	initial	version	of	the	OsAS	
questionnaire	was	given	to	a	patient	focus	group	of	19	patients	attending	the	
outpatient	clinic	at	RJAH.	All	participating	patients	agreed	that	the	length	of	the	
questionnaire	was	adequate,	the	time	taken	to	complete	the	questionnaire	was	
acceptable	and	the	wording	of	the	questions	was	appropriate.	They	agreed	that	
everything	they	considered	to	be	important	in	assessing	the	outcome	of	their	
surgery	was	addressed	in	the	OsAS	questionnaire.	The	feedback	received	from	
the	healthcare	professional	focus	group	mimicked	that	of	the	patient	focus	
group.	It	was	suggested,	by	both	patients	and	healthcare	professionals,	that	a	
question	should	be	added	to	address	any	other	conditions	which	could	affect	
overall	outcome,	for	example	foot	drop	could	affect	the	surgical	outcome	of	
ankle	surgery	or	depression	could	affect	the	patient	perspective	of	their	
outcome.	Furthermore,	two	questions	about	the	range	of	movement	of	the	joint	
were	suggested	by	the	physiotherapist.	Following	feedback	received	from	
patients	and	healthcare	professionals,	set	time	frames	were	given	for	the	
questions	(i.e.:	“in	the	last	two	weeks”).	The	initial	questionnaire	was	amended	
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to	version	3	(Appendix	III,	page	227),	to	include	the	suggested	added	questions,	
and	the	time	frames,	and	is	shown	below.		
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6.4.2	Psychometric	validation	and	refinement	
We	screened	more	than	5,400	patients	across	four	surgeon	clinic-lists	between	
the	months	of	September	2017-June	2018.	This	is	based	on	150	mean	patients	
per	clinic	list,	for	each	of	the	four	surgeons.	A	total	of	360	patients	were	eligible	
for	the	OsAS	study,	all	of	which	were	sent	study	information.	We	had	a	
recruitment	rate	of	57.2%,	having	successfully	recruited	206	patients	over	a	9-
month	period,	between	September	2017	and	June	2018.	Recruited	patients	
consisted	of	a	wide	age	range	(18-91	years,	mean	age:	62	years),	relatively	equal	
split	of	gender	(49.51%	female:	50.49%	male	split,	consisting	of	102	females	and	
104	males).	A	relatively	equal	split	of	treatment	status	was	observed	in	the	
participants,	(60.68%	post-operative:	39.32%	pre-operative,	consisting	of	125	
post-operative	patients	and	81	pre-operative	patients).	All	demographics	for	all	
patients	are	recorded	in	Table	17	(page	164).	Four	patients	withdrew	from	the	
study	after	consenting,	giving	a	low	withdrawal	rate	of	1.94%,	but	data	collected	
during	their	time	in	the	study	remained	within	the	data	analysis,	as	per	study	
protocol.		
The	factor	analysis	indicated	that	the	29	questions	loaded	onto	four	factors	
(Figure	37,	page	172,	Table	18,	page	166),	which	corresponds	to	(1)	daily	life,	(2)	
activities,	(3)	pain/sleep	and	(4)	movement.	Whereas	the	questions	that	
comprised	factors	2	and	3	also	loaded	onto	factor	1,	the	questions	that	
comprised	factor	4	(symptoms	questions	5	and	6	and	activity	question	5)	loaded	
entirely	onto	their	own	category.		
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Table	17:	Demographics	collected	from	consented	patients	in	the	OsAS	study.	
TAR	=	total	ankle	replacement;	CCR	=	complete	cartilage	regeneration	
	
	
	
	
	
	
	
Patient	demographics:	
Gender:	 Age:	 Status	of	treatment:	
Female	 Male	 Age	range	 Mean	age	 Pre-
operative	
Post-operative	
102	 104	 18-91	years	 62	years	 81	 125	
Symptoms:	
Pain	 Osteochon
dral	
lesions	/	
defects	
Arthritis	/	
Degenerative	
changes	
	
Instability	
or	
discomfort	
Previous	
trauma	
Other	 Unknown	
32	 24	 136	
	
6	 4	 5	 10	
Treatments:	
TAR	 Fusion/	
arthrodesis	
CCR	 Microfracture	 Arthroscopy	
/	
debridement	
Osteotomy	 Unknown	
34	 64	 6	 7	 12	
	
3	 1	
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Figure	34:	Scree	plot	of	the	factor	analysis	performed	on	the	OsAS	questionnaire,	
demonstrating	that	all	questions	fell	under	one	main	category,	while	four	
questions	had	an	eigenvalue	above	1.0	(indicated	by	the	blue	horizontal	line).	
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Table	18:	Factor	analysis	performed	on	the	Oswestry	Ankle	Score	questionnaire,	
demonstrating	that	all	questions	fell	under	four	categories.		
Note:	The	largest	factor	loading	of	each	question	has	been	formatted	in	bold	to	
illustrate	which	factor	it	mainly	loaded	onto.		
	
We	felt	factor	4	corresponded	with	movement	as	these	three	questions	
focused	on	range	of	motion,	for	example:	‘what	difficulty	have	you	experienced	
from	your	ankle	when	raising	your	heel	to	stand	on	tip	toes.’	When	these	three	
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questions	were	excluded	and	the	factor	analysis	was	run	again,	all	questions	
loaded	one	factor	(Table	19).	
	
Table	19:	Factor	analysis	performed	on	the	OsAS	questionnaire	following	the	
elimination	of	questions	highlighted	in	the	initial	factor	analysis	in	Table	18	(page	
166).	
Note:	The	largest	factor	loading	of	each	question	has	been	formatted	in	bold	to	
illustrate	which	factor	it	mainly	loaded	onto.		
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This	factor	analysis	demonstrated	that	all	remaining	27	questions	fell	under	one	
main	category,	which	could	be	termed	“patient-perceived	ankle	impairment	and	
activity”.		
An	initial	Rasch	analysis	was	performed	on	all	remaining	questions	
following	the	factor	analysis.	The	results	of	the	Rasch	analysis	suggested	that	all	
questions	apart	from	one	symptom	question	(question	7)	and	one	activity	
question	(question	18)	fitted	the	Rasch	model.	The	two	questions	that	did	not	fit	
the	model	had	WMS	or	UMS	values	outside	the	0.5-1.5	fit	guidelines	and	
therefore	did	not	fit	well	with	the	total	score	(Table	20;	page	169).	These	
questions	were:	‘how	often	did	you	experience	swelling	in	your	ankle,	during	the	
last	week?’	and	‘how	often	did	you	feel	the	need	to	use	a	walking	aid	(for	
example:	crutches,	walker)?’	and	were	removed	and	the	Rasch	analysis	was	
performed	again	to	ensure	that	the	remaining	25	questions	showed	a	‘good	fit.’	
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Table	20:	Values	of	fit	of	the	Rasch	model	with	the	27	OsAS	PROM	questions.		
Question	 WMS	value	 UMS	value	
Pain	1	 0.81182852	 0.81201876	
Pain	2	 0.78184903	 0.72738411	
Pain	3	 0.89179109	 0.88843466	
Symptoms	1	 0.60296132	 0.60239852	
Symptoms	2	 0.54902974	 0.55101998	
Symptoms	3	 0.70112567	 0.70445605	
Symptoms	4	 0.6768304	 0.68898128	
Symptoms	7	 1.55262554	 1.65873145	
Symptoms	8	 1.0880462	 1.10843352	
Activities	1	 0.69064299	 0.67700314	
Activities	2	 0.88987609	 0.83323497	
Activities	3	 0.52647104	 0.52333665	
Activities	4	 0.61764944	 0.59363475	
Activities	6	 0.60779212	 0.60413362	
Activities	7	 0.78222338	 0.75304616	
Activities	8	 0.77736046	 0.7640934	
Activities	9	 0.60129212	 0.5876738	
Activities	10	 0.74453717	 0.74254932	
Activities	11	 0.69061886	 0.64266852	
Activities	12	 0.86571299	 0.87680084	
Activities	13	 0.70046456	 0.67095696	
Activities	14	 0.60794945	 0.58626078	
Activities	15	 0.72988718	 0.74599126	
Activities	16	 0.79257873	 0.7657765	
Activities	17	 1.42503286	 1.48904447	
Activities	18	 1.34985453	 1.68511376	
Activities	19	 0.98234759	 1.09978342	
Note:	Bold	font	indicates	values	outside	the	guideline	values	of	0.5-1.5.	
Theta	plots	of	all	30	questions	of	the	initial	OsAS	PROM	(Figure	35;	page	
170)	illustrated	which	questions	did	not	fit	the	Rasch	model	and	how	the	
question	scales	could	be	collapsed	for	many	questions	to	provide	answer	options	
that	were	arranged	better.	Broadly,	the	theta	plots	tend	to	follow	the	same	
trend	for	each	of	the	three	subsections:	pain,	symptoms	and	activities.		
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Figure	35:	Theta	plots	for	each	of	the	30	questions	of	the	OsAS	questionnaire	
generated	from	a	Rasch	analysis.	These	plots	demonstrate	the	relevance	of	each	
answer	option,	and	the	data	was	used	to	collapse	the	scales.	
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Most	questions	demonstrated	a	good	fit	to	the	Rasch	model,	indicated	by	
distinctive	peaks	for	each	answer	option	with	minimal	overlap	and	a	consistent	
trend.	An	example	is	pain	question	1	(Figure	36).	
	
	
	
	
	
	
	
	
	
Figure	36:	A	theta	plot	demonstrating	good	fit	to	the	Rasch	model,	illustrated	by	
distinct	peaks	with	minimal	overlap.	
	
These	questions	required	no	manipulation	with	the	question	or	scale.	
Other	questions	demonstrated	borderline	fit	to	the	Rasch	model	(Figure	37;	page	
172),	indicated	by	some	overlap	between	the	peaks.	These	questions	required	
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scale	collapse	to	provide	more	distinct	answer	options	and	thus	better	fit	to	the	
Rasch	model.		
	
	
	
	
	
	
	
	
	
Figure	37:	A	theta	plot	demonstrating	borderline	fit	to	the	Rasch	model,	
illustrated	by	distinct	peaks	with	some	significant	overlap,	as	indicated	by	the	
green	peak	which	is	completely	overlapped	by	the	blue	and	purple	peak.		
	
Five	questions	demonstrated	poor	fit	to	the	Rasch	model.	These	
questions	identified	in	the	factor	analysis	(Table	18;	page	166)	and	the	two	in	the	
initial	Rasch	analysis	(Table	20;	page	169):	symptom	questions	5,	6	and	7,	and	
activity	questions	5	and	18.	These	questions	were	therefore	eliminated	from	the	
OsAS	questionnaire	due	to	the	poor	fit.	An	example	is	shown	in	Figure	38	(page	
173).		
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Figure	38:	A	theta	plot	demonstrating	poor	fit	to	the	Rasch	model,	illustrated	by	
small	peaks	that	completely	overlap	one	another	with	no	consistent	pattern,	as	
indicated	by	the	red,	blue	and	green	peaks	all	completely	overlapped	by	the	
black	and	purple	lines.	
	
6.4.3	Development	and	content	validity	of	the	final	version	
All	25	remaining	questions	had	similar	UMS	and	WMS	values	and	showed	a	
similar	weight	of	importance.	Close	examination	of	the	remaining	questions	
suggested	that	the	questionnaire	could	be	condensed	further	as	many	questions	
were	similar	in	nature,	such	as	symptom	questions	1	and	2	both	ask	about	the	
effect	on	daily	life,	and	symptom	questions	3	and	4	both	ask	about	being	limited	
with	certain	activities.	We	therefore	decided	to	perform	a	second	focus	group	
round,	asking	specifically	which	questions	were	considered	relevant.	This	group	
comprised	the	five	clinicians	who	helped	design	the	original	questionnaire,	plus	
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13	patients.	The	13	patients	completed	content	validity	feedback	on	the	
condensed	OsAS	(Version	3.3;	Appendix	IV;	page	230),	which	contains	18	
questions.	All	feedback	received	was	in	response	to	importance,	which	ranged	
between	76.9-100%	(Table	21).		
	
Table	21:	Content	validity	for	the	condensed	OsAS	measure	(Version	3.3),	
determined	by	asking	a	focus	group	of	13	patients	to	rate	if	a	question	addressed	
an	important	aspect.		
Question:	 Number	of	patients	considering	
this	question	important:	
Importance	(%):	
Pain	question	1	 13	 100	
Pain	question	2	 12	 92.3	
Symptoms	question	1	 12	 92.3	
Symptoms	question	2	 12	 92.3	
Symptoms	question	3	 11	 84.6	
Symptoms	question	4	 11	 84.6	
Symptoms	question	5	 12	 92.3	
Activities	question	1	 11	 84.6	
Activities	question	2	 10	 76.9	
Activities	question	3	 13	 100	
Activities	question	4	 12	 92.3	
Activities	question	5	 10	 76.9	
Activities	question	6	 11	 84.6	
Activities	question	7	 11	 84.6	
Activities	question	8	 12	 92.3	
Activities	question	9	 12	 92.3	
Activities	question	10	 11	 84.6	
Activities	question	11	 13	 100	
	
The	condensed	and	final	version	of	the	OsAS	questionnaire,	with	the	collapsed	
scales,	was	the	version	used	for	all	subsequent	data	analysis	and	validation	
purposes	(Version	3.3,	Appendix	IV,	page	230).	
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Based	on	their	suggestions,	the	OsAS	questionnaire	was	condensed	
from	25	questions	across	3	pages,	to	19	questions	across	2	pages.	This	
condensed	and	final	version	of	the	OsAS	questionnaire,	with	the	collapsed	scales,	
was	the	version	used	for	all	subsequent	data	analysis	and	validation	purposes	
(Version	3.3,	Appendix	V,	page	232).	
	
6.5	Discussion	
We	have	successfully	developed	and	psychometrically	refined	a	new	PROM	
entitled	the	‘Oswestry	Ankle	Score	(OsAS)’.	The	questionnaire	is	aimed	
specifically	at	patients	with	ankle	problems,	before	or	after	treatment.	The	
questionnaire	has	a	good	internal	consistency,	as	demonstrated	by	its	fit	to	the	
Rasch	model,	and	good	content	validity,	as	indicated	by	patient	focus	groups	and	
clinicians.	The	questionnaire	was	designed	with	assistance	from	two	patient	
focus	groups,	the	first	consisting	of	19	patients,	and	the	second	consisting	of	13	
patients,	our	foot	and	ankle	clinical	care	team	consisting	of	four	foot	and	ankle	
surgical	consultants	and	one	specialist	physiotherapist,	and	a	biostatistician.	The	
patient	focus	groups	and	the	foot	and	ankle	clinical	care	team	found	that	the	
questionnaire	addressed	all	aspects	considered	important,	from	both	a	clinical	
and	patient	perspective.	The	first	patient	focus	group	also	stated	that	they	felt	
the	questionnaire	was	of	adequate	length,	easy	to	understand,	easy	to	complete	
and	of	adequate	time	for	completion.	
As	with	every	study	design,	there	were	a	few	limitations.	One	potential	
limitation	to	our	study	was	that	the	study	only	occurred	at	one	site	(a	large	
tertiary	referral	centre	at	a	rural	location),	which	could	have	skewed	the	patient	
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population.	However,	this	hospital	admits	a	mixture	of	patients,	consisting	of	
referrals	from	the	local	area	that	are	consistent	with	referrals	to	other	secondary	
centres,	and	referrals	from	a	wider	area	that	require	specialised	care.	A	second	
concern	associated	with	this	study	might	be	the	response	rate.	As	with	all	paper-
based	studies,	there	are	some	participants	who	do	not	return	the	questionnaires	
or	lose	them.	
	 Now	developed,	we	aim	to	further	validate	the	OsAS	measure,	using	
test-retest	reliability,	responsiveness	and	construct	validity	in	the	form	of	
hypothesis	testing	regarding	correlation	with	two	existing	scores:	the	MOxFQ	for	
assessing	foot	health	(Appendix	V,	page	232)	and	the	VR-12	for	assessing	general	
health	(Appendix	VI,	page	234).	These	are	reported	in	the	next	chapter.			
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Chapter	7:	Validation	of	the	Oswestry	Ankle	Score	(OsAS).		
7.1	Introduction	
Many	surgical	treatments	for	cartilage	disorders	in	the	ankle	are	in	use,	including	
ankle	fusion,	debridement,	microfracture,	autologous	chondrocyte	implantation	
(ACI),	matrix-assisted	chondrocyte	implantation	(MACI),	implantation	of	a	stem-
cell	concentrate	and	total	ankle	replacement.	However,	assessing	and	comparing	
the	outcomes	of	these	treatments	is	problematic	because	there	are	very	few	
ankle-focused	PROMs.	More	specifically,	there	are	sixteen	PROMs	for	assessing	
the	foot	and	ankle	(Table	16;	page	155),	of	which	only	six	have	been	successfully	
validated.	Furthermore,	these	six	validated	scores	have	all	been	developed	for	
assessing	different	conditions,	age-ranges	and	populations.	This	limits	the	use	of	
the	scores	and	thus	has	resulted	in	there	being	no	‘gold-standard’	for	assessing	
clinical	outcome	of	the	foot	and	ankle.		
With	between	a	quarter	and	a	third	of	all	patients	stating	they	are	
dissatisfied	with	their	surgery	(Dawson	et	al.,	2006),	this	highlights	the	demand	
for	a	new	validated	PROM	to	be	developed	for	assessing	clinical	outcome	of	
ankle	surgery	for	treating	cartilage	disorders,	which	includes	cell	therapy	surgery.	
The	new	outcome	score	would	also	aim	to	address	areas	to	improve	that	could	
increase	patient	satisfaction	of	their	surgery.	We	developed	a	new	PROM,	the	
Oswestry	Ankle	Score	(OsAS),	to	assess	clinical	outcome	of	ankle	surgery.	In	the	
previous	chapter	(Chapter	6)	we	described	the	development	stages	and	item	
selection	for	the	score	in	detail	and	demonstrated	its	good	internal	consistency	
and	content	validity.	
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	 For	the	OsAS	to	be	used	clinically,	it	needs	to	be	valid,	reliable	and	
responsive	(Mokkink	et	al.,	2010).	Validity	is	defined	as	the	extent	to	which	a	
measure	measures	the	construct	it	purports	to	measure.	The	content	must	
capture	what	the	score	aims	to	capture	and	must	be	considered	important	from	
the	patient	perspective.	The	OsAS	must	also	be	responsive,	that	is	sensitive	to	
changes	in	clinical	outcome.	Therefore,	it	must	be	able	to	accurately	detect	when	
a	patient’s	clinical	outcome	is	improving	or	declining.	Finally,	the	score	must	be	
reliable.	More	specifically,	if	no	change	has	occurred	in	clinical	outcome	then	the	
OsAS	score	should	remain	relatively	constant.	The	quality	of	the	OsAS	in	these	
three	domains	can	be	assessed	using	the	parameters	listed	in	Chapter	6	(Table	
14;	page	143).		
This	study	aimed	to	validate	the	final	18-item	version	of	the	OsAS	
questionnaire	described	in	the	previous	chapter.	Specifically,	it	aimed	to	
determine	if	the	OsAS	is	valid,	responsive	and	reliable	using	the	statistical	
analyses	recommended	in	the	checklist	from	COSMIN	(consensus-based	
standards	for	the	selection	of	health	status	measurement	instruments;	Mokkink	
et	al.,	2010).		
	
7.2	Methods	and	materials	
The	18-question	OsAS	was	sent	to	patients	either	pre-operatively	or	post-
operatively,	together	with	two	other	relevant	PROMs,	the	Manchester	Oxford	
Foot	Questionnaire	(MOxFQ;	Appendix	V;	Dawson	et	al.	2006,	and	the	Veterans	
Rand	12	(VR-12;	Appendix	VI;	Selim	et	al.,	2009).	The	MOxFQ	is	a	16-question	
instrument	developed	to	assess	the	outcomes	of	foot	surgery,	which	determines	
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the	outcome	in	three	separate	dimensions:	walking/standing,	pain	and	social	
interactions,	each	scored	0	(best)	to	100	(worst)	(Dawson	et	al.,	2006).	More	
recently,	a	method	to	derive	a	single	summarising	MOxFQ	score	was	described,	
scored	from	0	(worst)	to	100	(best)	(Morley	et	al.,	2013),	which	we	also	
determined.	The	VR-12	is	a	12-question	general	health-related	quality	of	life	
instrument,	which	summarises	the	general	health	along	two	dimensions:	a	
physical	component	score	(PCS)	and	a	mental	component	score	(MCS),	each	
scored	0	(worst)	to	1	(best)	(Selim	et	al.,	2009).	If	sent	pre-operatively,	where	
appropriate	and	relevant	we	sent	a	further	OsAS	score	to	the	patient	at	least	
three	months	after	their	operation.		
	
7.2.1	Responsiveness	to	change		
We	hypothesised	that	a	minimum	two-month	time	frame	was	sufficient	to	allow	
recovery	and	that	the	patients’	outcome	would	have	changed.	Patients	who	had	
completed	both	a	pre-operative	and	post-operative	OsAS	score	were	used	to	
analyse	the	responsiveness	of	the	score	(sensitivity	to	change).	It	was	
hypothesised	that	if	the	condition	of	the	patient	had	changed,	for	example	
through	surgical	intervention,	the	OsAS	results	would	also	change.	The	
responsiveness	was	analysed	by	performing	a	paired	t-test	and	determine	
Cohen’s	effect	size,	which	is	the	ratio	of	the	difference	in	score	and	the	baseline	
standard	deviation	(Cohen,	1992).	We	aimed	to	obtain	a	sample	size	of	109	
patients	to	assess	the	Cohen’s	effect	size	with	a	95%	CI	of	±0.2,	assuming	a	
responsiveness	of	0.5	and	a	correlation	of	0.5	between	baseline	and	post-
treatment	score.	
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7.2.2	Test-retest	reliability	
Two	OsAS	scores	were	sent	to	patients	within	a	short	time-period,	less	than	six	
weeks	apart.	We	hypothesised	that	in	this	small	time-frame	the	patients’	
condition	would	not	change,	provided	there	had	not	been	an	intervention	in	the	
meantime.	The	scores	from	patients	who	had	completed	two	scores	within	an	8-
week	timeframe	and	who	had	no	intervention	in	that	time	were	used	to	
determine	the	test-retest	reliability	using	the	intra-class	correlation	coefficient	
(ICC)	based	on	a	1-way	mixed	ANOVA	model	with	“patient”	as	the	random	factor.	
We	aimed	to	obtain	a	sample	size	of	105	patients	to	estimate	the	test-retest	
correlation	coefficient	with	a	95%	CI	of	±0.1	or	smaller,	assuming	that	the	
coefficient	was	at	least	0.7,	a	reasonable	number	based	on	similar	PROM	
instruments	such	as	the	MOXFQ.	
	
7.2.3	Construct	and	criterion	validity		
The	correlation	of	the	OsAS	score	with	scores	on	two	other	relevant	PROMs	was	
determined,	namely	the	MoXFQ	and	the	VR-12.	Higher	scores	on	both	the	OsAS	
and	the	MOxFQ	instrument	denote	poorer	outcomes,	whereas	they	denote	
better	outcomes	on	the	VR-12.	We	therefore	hypothesised	that	the	OsAS	would	
have	a	positive	correlation	with	the	three	domains	of	the	MOxFQ	but	a	negative	
correlation	with	the	two	components	of	the	VR-12.	We	also	hypothesised	that	
the	correlation	with	the	MOxFQ	(a	region-specific	PROM)	would	be	stronger	than	
that	with	the	VR-12-PCS	(a	general	health-related	PROM),	and	that	the	
correlation	with	the	VR-12	PCS	would	be	stronger	than	that	with	the	VR-12	MCS.	
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We	aimed	to	obtain	a	sample	size	of	219	people	to	complete	the	three	
questionnaires,	based	on	estimating	the	Pearson	product-moment	correlation	
coefficient	with	a	95%	CI	of	±0.1	or	smaller,	assuming	that	the	coefficient	was	at	
least	0.5,	or	a	95%	CI	of	±0.15	if	the	coefficient	was	smaller.	Due	to	the	study	
design,	several	patients	would	submit	more	than	one	set	of	questionnaires.	
However,	to	avoid	bias	we	used	one	set	of	questionnaires	per	patients	for	the	
correlation	analysis.	All	statistical	analyses	were	carried	out	using	SPSS	vs	24	
(IBM,	New	York,	USA).		
	
7.3	Results	
We	used	the	same	cohort	of	patients	from	Chapter	6.	
	
7.3.1	Test-retest	reliability	
We	obtained	responses	from	106	patients	for	the	reliability	(test-retest)	analysis	
(section	7.2.2,	page	180).	The	two	sets	of	questionnaires	were	received	within	
approximately	8	weeks	of	each	other.	The	mean	age	of	the	sample	population	
for	the	test-retest	reliability	analysis	was	64	years	±	SD	1.13;	age	range:	18-88	
years).	
	 The	OsAS	had	a	test-retest	ICC	of	0.93	(95%	CI	0.89	to	0.95;	Table	22;	
page	182).	In	comparison,	the	test-retest	ICC	for	the	MOxFQ	sub-scales	for	pain,	
symptoms	and	activity	were	0.75	(95%	CI	0.65-0.83),	0.80	(0.70-0.86)	and	0.78	
(95%CI	0.67-0.85)	respectively	(Table	22;	page	182).		
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Table	22:	The	test-retest	intraclass	correlation	coefficient	(ICC)	calculated	using	a	
1-way	mixed	ANOVA	model	with	“patient”	as	random	factor.	
	 ICC:	 95%	CI:	
Lower	bound:	 Upper	bound:	
OsAS	 0.928	 0.891	 0.952	
MOxFQ	Pain	 0.757	 0.652	 0.834	
MOxFQ	Symptoms	 0.795	 0.704	 0.861	
MOxFQ	Activities	 0.782	 0.686	 0.852	
	
	
7.3.2	Responsiveness	
We	obtained	112	sets	of	questionnaires	from	61	patients	suitable	for	the	analysis	
of	responsiveness	(sensitivity	to	change).	The	two	sets	received	for	each	patient	
were	obtained	pre-operatively	and	a	minimum	of	two-months	post-operatively	
(mean	time	after	surgery	3.36	months	±	0.23	SD,	range	2-9	months).	The	mean	
age	of	the	sample	population	for	the	responsiveness	analysis	was	60.46	years	±	
SD	1.68;	age	range:	19-92	years).	The	mean	outcomes	on	all	three	instruments	
(OsAS,	MOxFQ	and	VR-12)	changed	following	surgery,	except	the	VR-12	MCS	
(Table	23;	page	183).	When	expressed	as	Cohen’s	effect	size,	the	OsAS	was	found	
the	most	responsive	(effect	size	1.59;	95%	CI	1.21	to	1.97),	which	was	2-4	times	
higher	than	the	standardised	effect	size	obtained	from	the	three	components	of	
the	MOxFQ,	and	more	than	10	times	higher	than	that	obtained	for	the	VR-12	
(Table	23;	page	183).	The	higher	effect	size	of	OsAS,	compared	to	the	MOxFQ	
and	VR-12,	could	be	due	to	the	OsAS	being	sensitive	than	the	other	two	scores	or	
could	be	because	the	effect	size	was	inflated.	
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Table	23:	Responsiveness	of	the	OsAS,	MOxFQ	and	VR-12	PROMs,	including	each	
sub-scale	for	the	MOxFQ	and	VR-12.		
Score:	 Mean	
score	at	
baseline	
(±SD)	
Mean	score	
at	post-
operative	
(±SD)	
Mean	
differenc
e	(±SD)	
p	value	 Effect	
size	
	
95%	CI	
Lower	
bound	
Upper	
bound	
OsAS	 56.83	±	
20.30	
40.05	±	
20.96	
16.78	±	
20.63	
<	0.001	 1.59	 1.21	 1.97	
MOxFQ	
Pain	
68.56	±	
28.64	
55.74	±	
30.61	
12.82	±	
3.76	
<	0.001	 0.62	 0.35	 0.89	
MOxFQ	
Symptoms	
52.62	±	
26.72	
45.66	±	
28.53	
9.67	±	
3.63	
0.001	 0.37	 0.11	 0.63	
MOxFQ	
Activities	
45.33	±	
27.51	
35.66	±	
29.32	
6.97	±	
3.53	
0.006	 0.45	 0.19	 0.72	
VR-12	PCS	 44.60	±	
8.66	
43.32	±	
9.37	
1.28	±	
1.16	
<	0.001	 0.148	 -0.11	 0.40	
VR-12	MCS	 37.86	±	
5.38	
38.02	±	
4.28	
-0.16	±	
0.62	
0.821	 0.030	 0.00	 0.19	
	
7.3.3	Construct	and	criterion	validity	(correlation	with	other	instruments)	
In	all,	159	patients	returned	a	full	set	of	three	instruments	(OsAS,	MOxFQ	and	
VR-12).	Our	analyses	of	the	correlation	of	the	OsAS	with	the	other	instruments	
were	therefore	based	on	a	sample	size	of	159	patients.	The	mean	age	of	the	
sample	population	for	construct	and	criterion	analysis	was	62	years	±	SD	1.62;	
age	range:	19-88	years).	
The	correlation	of	the	OsAS,	the	total	MOxFQ	score	and	each	domain	of	
the	MOxFQ	(pain,	walking/standing	and	social	interaction)	varied	from	0.78	(95%	
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CI	0.72-0.83)	for	the	social	interactions	domain	to	0.85	(95%	CI	0.80-0.89)	for	the	
pain	domain	(Table	24).	The	positive	directions	of	these	correlations	were	in	line	
with	our	hypothesised	direction.	
	
Table	24:	Correlation	between	the	OsAS	and	the	MOxFQ	scores,	based	on	159	
responses,	using	one	scores	per	patient.		
Correlations:	 MOxFQ	
total	
MOxFQ	
pain	
MOxFQ	walking/	
standing	
MOxFQ	social	
interactions	
	
	
	
OsAS	
Pearson	
correlation	
0.810	 0.850	 0.828	 0.780	
95%		
Lower	CI	
0.729	 0.802	 0.770	 0.723	
95%	Upper	
CI	
0.868	 0.889	 0.879	 0.829	
	
The	correlation	coefficient	of	the	OsAS	with	the	two	domains	of	the	VR-12	
were	-0.68	(95%	CI	-0.76	to	-0.60)	for	the	PCS	and	-0.08	(95%	CI	-0.26-0.09)	for	
the	MCS	(Table	25).	The	non-overlapping	95%	CIs	demonstrated	a	stronger	
correlation	between	the	OsAS	and	the	PCS	than	between	the	OsAS	and	the	MCS.	
The	negative	directions	of	the	correlations	and	the	stronger	correlation	of	the	
PCS	were	in	line	with	the	hypothesised	direction	and	size.		
	
Table	25:	Correlation	between	the	OsAS	and	the	VR-12	
Correlations:	 VR-12	MCS	 VR-12	PCS	
	
OsAS	
Pearson	correlation	 -0.079	 -0.684	
95%	Lower	CI	 -0.257	 -0.758	
95%	Upper	CI	 0.092	 -0.599	
	
Chapter	7:	Validation	of	the	Oswestry	Ankle	Score	(OsAS).	
 
	
-	185	-	
The	non-overlapping	95%	CIs	demonstrated	that	the	correlations	between	the	
OsAS	and	two	domain	scores	of	the	MOxFQ	(pain	and	walking/standing)	were	
stronger	than	those	between	the	OsAS	and	the	VR-12	PCS	score.	This	was	in	line	
with	the	hypothesised	order.	
	
7.4	Discussion	
The	Oswestry	Ankle	Score	(OsAS)	is	a	new	18-item	PROM	to	assess	outcome	of	
patients	following	treatment	of	cartilage	disorders	in	the	ankle.	The	OsAS	has	
good	content	validity	and	internal	consistency	(Chapter	6,	page	number	146).	
This	study	aimed	to	determine	its	construct	and	criterion	validity,	test-retest	
reliability	and	responsiveness	to	change.	The	OsAS	was	found	to	have	a	good	
construct	and	criterion	validity,	demonstrated	by	a	very	strong	correlation	with	a	
validated	questionnaire	for	outcomes	of	foot	surgery	(MOxFQ),	which	can	be	
regarded	a	“gold	standard”,	and	a	general	health-related	quality	of	life	
instrument	(VR-12).	The	OsAS	also	had	an	excellent	test-retest	reliability	
(ICC=0.93)	and	a	high	responsiveness.	Furthermore,	our	study	assessed	the	OsAS	
across	both	genders,	a	wide	age	range	(18-91	years)	and	a	variety	of	presenting	
symptoms	and	ankle	treatments.	Based	on	our	analyses,	the	18-item	OsAS	score	
is	suitable	for	clinical	use	to	assess	the	patient-perceived	outcome	for	a	wide	
range	of	treatments	of	ankle	cartilage	disorders.		
The	OsAS	was	found	to	have	an	excellent	test-retest	reliability.	Its	
value	of	0.93	was	above	the	value	of	0.75	commonly	used	to	indicate	excellent	
agreement	(Fleiss,	1999).	An	excellent	test-retest	reliability	above	0.75	was	also	
found	for	the	MOxFQ	instrument.	The	values	for	the	test-retest	ICC	of	the	
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MOxFQ	found	in	this	study	(0.76	to	0.78)	were	slightly	smaller	than	those	found	
by	the	originators	of	the	MOxFQ,	who	found	values	in	the	range	of	0.93	to	0.95	
in	a	group	of	ankle	patients	(Dawson	et	al.,	2011).	Their	sample	had	a	lower	
mean	age	than	our	sample	(50	years	versus	62	years)	and	a	slightly	lower	
proportion	of	women	(46%	vs	50%),	which	may	explain	some	of	the	differences.	
On	the	other	hand,	to	our	knowledge	our	study	is	the	first	external	study	to	
confirm	the	excellent	test-retest	reliability	of	the	MOxFQ	score.		
The	OsAS	instrument	was	found	to	have	a	high	sensitivity	to	change	
following	interventions	to	help	patients	with	cartilage	disorders	in	the	ankle,	
such	as	total	ankle	replacement	or	an	ankle	arthrodesis.	In	our	study,	the	OsAS	
had	a	standardised	effect	size	that	was	two	to	four	times	higher	than	the	current	
PROM	used	at	our	centre	to	assess	the	outcome	of	foot	and	ankle	surgery,	
namely	the	MOxFQ,	and	more	than	ten	times	higher	than	a	general	health-
related	quality	of	life	instrument,	the	VR-12.	In	line	with	our	hypothesised	
responsiveness,	we	found	that	the	effect	size	found	using	the	OsAS,	an	ankle-
specific	outcome	measure,	was	larger	than	that	found	by	the	MOxFQ,	which	is	
aimed	at	measuring	outcome	of	foot	and	ankle	surgery	and	is	therefore	less	
specific.	Both	the	OsAS	and	the	MOxFQ	showed	a	larger	standardised	effect	size	
than	the	PCS	and	particularly	the	MCS	of	the	VR-12.	The	VR-12	is	a	general	
health-related	questionnaire	and	thus	less	specific	to	outcomes	of	ankle	or	foot	
and	ankle	surgery,	which	would	explain	its	smaller	responsiveness.	An	earlier	
study	also	found	that	the	MOxFQ	was	more	responsive	to	change	after	ankle	
surgery	than	a	general	health-related	quality	of	life	instrument,	in	that	case	the	
SF-36	(Dawson	et	al.,	2012).	In	that	study,	a	larger	standardised	effect	size	was	
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reported	for	the	MOxFQ,	namely	0.86	to	1.10	for	the	three	domains	versus	0.26-
0.45	in	our	study.	The	lower	responsiveness	of	the	MOxFQ	in	our	study	may	be	
related	to	the	shorter	mean	time	after	surgery,	which	was	3.36	months	in	our	
study	and	9	months	in	the	study	by	Dawson	et	al.	(Dawson	et	al.,	2012).	One	
would	expect	more	improvement	and	thus	a	larger	standardised	effect	size	after	
a	larger	period.	Nevertheless,	our	results	do	suggest	that	the	OsAS	is	more	
sensitive	to	ankle-specific	changes	than	more	generic	foot-ankle	scale.	
The	OsAS	instrument	was	also	found	to	have	a	good	construct	and	
criterion	validity.	The	OsAS	correlated	well	with	the	three	domains	of	the	MOxFQ	
and	its	summary	total	score,	with	correlation	coefficients	ranging	from	0.78-0.85.	
Such	a	strong	positive	correlation	would	be	expected	for	instruments	that	are	
specific	to	similar	parts	of	the	body,	in	this	case	the	ankle	and	the	foot/ankle.	The	
items	in	the	OsAS	measure	cover	the	content	of	the	three	domains	of	the	
MOxFQ,	namely	pain,	walking/standing	and	social	interactions,	but	on	a	single	
uni-dimensional	scale,	and	we	therefore	had	hypothesised	this	strong	
correlation.	Since	the	MOxFQ	can	be	regarded	a	standard	instrument,	this	strong	
correlation	is	a	good	indicator	of	the	criterion	validity	of	the	OsAS.	The	OsAS	
score	also	correlated	with	the	VR-12	PCS,	which	quantifies	general	physical	
health-related	quality	of	life,	but	less	well	than	with	the	MOxFQ.	However,	the	
OsAS	correlated	poorly	with	the	VR-12	MCS,	which	quantifies	general	mental	
health-related	quality	of	life.	These	finding	supported	our	prior	hypotheses	
regarding	these	correlations.	Taken	together,	they	provide	strong	support	for	the	
construct	validity	of	the	OsAs	because	they	indicate	that	the	OsAS	measures	a	
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physical	health-related	construct	that	is	more	region-specific	than	that	obtained	
by	a	general	health-related	instrument.		
Our	study	does	have	some	limitations.	Firstly,	we	did	not	manage	to	
recruit	the	number	of	patients	that	were	needed	for	each	analysis,	most	notably	
the	correlation	with	other	scores	(56%	of	the	aimed	recruitment	rate)	and	the	
correlation	with	other	scores	(73%	of	the	aimed	recruitment	rate).	However,	as	
we	had	CI’s	narrower	than	planned,	the	lower	recruitment	rate	would	not	impact	
on	the	conclusions	obtained	from	our	study.	Secondly,	the	time	since	surgery	for	
the	sensitivity	to	change	analysis	was	relatively	short	(mean	time	3.26	months;	
range:	2-9	months)	and	patients	could	still	have	been	undergoing	recovery	
following	their	surgery.	Thus,	the	sensitivity	to	change	analysis	performed	may	
be	higher	than	calculated.	However,	the	sensitivity	to	change	calculations	
demonstrated	that	the	changes	in	score	within	this	short	time	frame	was	still	
large	enough	to	measure	an	effect.	Future	studies	using	the	OsAS	PROM	would	
be	able	to	calculate	the	responsiveness	after	a	longer	time-period	between	pre-
operative	and	post-operative	intervention.	Our	score	could	potentially	be	used	
to	individualise	treatment,	by	assessing	the	treatment	outcome	on	a	patient-by-
patient	basis	and	from	the	patient	perspective.	However,	a	PROM	approach	is	
not	always	the	purest	analysis	methods	for	predicting	patient	outcome.	The	
OsAS	would	not	be	able	to	determine	the	most	appropriate	treatment	for	a	
personalised	approach,	but	assess	the	outcome	of	the	treatment	given.	
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The	OsAS	was	designed	by	clinicians	and	researchers,	with	patient	input	from	the	
beginning	and	throughout.	Doing	so	ensures	that	the	OsAS	captures	what	
clinicians	and	patient	find	important	when	assessing	their	clinical	outcome	and	
surgical	success	(Pinsker	et	al.,	2013).	Moreover,	this	continuous	input	of	
patients	and	clinicians	resulted	in	a	unidimensional	scale	with	a	high	internal	
consistency	between	the	18	questions	(chapter	6,	page	number	146).	The	
unidimensional	nature	means	that	the	OsAS	gives	a	single	outcome	reflection	the	
patient-perceived	“ankle	quality”,	which	will	facilitate	its	use	in	clinical	practice	
and	research.	The	results	from	Chapters	5	(page	number	140)	and	this	chapter	
indicate	that	the	OsAS	measure	can	be	used	as	a	PROM	for	assessing	the	
outcome	of	a	wide	range	of	treatments	for	ankle	cartilage	disorders,	probably	
with	a	higher	sensitivity	to	change	than	the	MOxFQ	score	(Dawson	et	al.,	2011;	
Morley	et	al.,	2013)	
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Chapter	8:	General	Discussion	
Damaged	articular	cartilage	has	a	limited	potential	for	healing	and	untreated	
cartilage	defects	often	progress	to	osteoarthritis.	In	the	UK,	osteoarthritis	affects	
8.75	million	people	costing	the	NHS	£850	million	annually.	High	hopes	have	been	
pinned	on	regenerative	medicine	strategies	to	meet	the	challenge	of	preventing	
progress	to	osteoarthritis.	The	ACI	procedure	has	evolved	over	the	last	twenty	
years	but	it	still	requires	additional	refinement	to	further	improve	upon	the	
technique.	Optimising	the	expansion	and	chondrogenic	capacity	of	cultured	
human	articular	chondrocytes	is	one	of	these	refinements.		
	 We	investigated	an	alternative	serum	supplement	to	the	current	gold-
standard	 used	 in	 research;	 FBS.	 Stemulate™,	 a	 commercially	 available	 human	
platelet	 lysate,	 has	 been	 previously	 utilised	 to	 improve	 MSC	 expansion.	 With	
freshly	isolated	human	chondrocytes,	we	reported	an	increase	in	proliferation	in	
monolayer	culture,	however,	despite	a	28-day	three-dimensional	culture	period	
the	 chondrocytes	 did	 not	 recover	 their	 chondrogenic	 capacity	 to	 the	 extent	 of	
those	cells	cultured	in	the	presence	of	FBS.	Although	this	research,	which	has	been	
published	 (Sykes	 et	 al	 2018;	 page	 238),	 determined	 that	 Stemulate™	was	 less	
effective	than	FBS,	it	might	still	have	some	place	in	the	ACI	protocol.	We	would	
need	 to	 find	 methods	 to	 enhance	 chondrogenic	 capacity	 after	 monolayer	
expansion.	This	could	involve	loading	three-dimensional	pellets	to	enhance	ECM	
production	or	using	the	addition	of	ECM	components	such	as	HA	to	encapsulate	
the	three-dimensional	pellet.		
The	 long-term	 strategy	 for	 ACI	 is	 to	 translate	 the	 technique	 to	 treat	
other	joints,	including	the	ankle	and	the	hip.	With	this	in	mind,	it	is	important	to	
explore	both	cell	type	and	cell	source.	Herein,	we	chose	to	investigate	whether	
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chondrocytes	 sourced	 from	 ankle	 cartilage	 could	 be	 of	 ‘better	 quality’	 than	
chondrocytes	sourced	from	knee	cartilage.	Our	research	showed	that	ankle	and	
knee	 chondrocytes	 differed	 metabolically	 and	 histologically,	 with	 ankle	
chondrocytes	 demonstrating	 a	 slower	 growth	 in	monolayer	 culture	 but	 higher	
chondrogenic	 capacity	 compared	 to	 knee	 chondrocytes,	 irrespective	 of	 the	
microenvironment	 or	 biomechanical	 stimuli.	 This	 indicates	 that	 ankle	 cartilage	
could	be	harvested	to	treat	other	injured	joints.		
	 As	well	as	refining	the	current	ACI	protocol,	we	also	set	out	to	design	a	
novel	PROM	to	assess	clinical	outcome	of	ankle	treatments,	including	ACI.	This	was	
a	challenge	since	there	are	very	few	published	validated	PROMs	and	those	that	do	
exist	 are	 not	 designed	 for	 ankle.	 Our	 novel	 approach	 consisted	 of	 designing	 a	
simple,	short	questionnaire,	with	both	 initial	patients	and	clinician	 input,	which	
could	be	used	in	the	clinic	prior	to	surgery	and	then	followed	up	at	home	after	
surgery.	The	success	of	this	approach	was	confirmed	by	the	rapid	recruitment	of	
206	patients	within	a	short	time	frame	of	a	few	months.	With	this	response	rate,	
we	were	able	to	show	that	our	PROM	had	proven	reliability	and	responsiveness	to	
change,	 much	 higher	 than	 the	 currently	 used	 PROMs	 used	 at	 our	 centre:	 the	
MOxFQ	and	the	VR-12.	The	OsAS	also	demonstrated	high	internal	consistency	and	
good	correlation	with	the	MOxFQ	and	the	VR-12.	The	exciting	outcome	is	that	our	
foot	and	ankle	clinicians	are	implementing	the	OsAS	to	monitor	clinical	outcomes.	
With	the	publication	of	two	back	to	back	papers	(currently	in	preparation)	we	will	
be	able	to	engage	with	other	clinicians	both	nationally	and	internationally.	
In	conclusion,	the	results	presented	here	provides	new	insights	into	the	
biology	of	chondrocytes	including	the	characterisation	of	ankle	and	knee	
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chondrocytes	and	provides	further	insight	into	the	optimisations	of	the	ACI	
technique.	The	development	of	OsAS	has	provided	a	new	method	of	assessing	
clinical	outcome	of	ankle	treatments,	including	ACI,	which	can	be	utilised	by	
clinicians	and	patients	alike	from	herein.	Therefore,	this	work	has	increased	the	
knowledge	in	this	field	and	provided	information	into	the	potential	implications	
in	the	development	and	assessment	of	cell	therapies	for	cartilage	regeneration,	
and	in	particularly	ACI.		
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Miss Jessica Sykes 
Institute for Science & Technology in Medicine, 
University of Keele, 
Arthritis Research Centre, Robert Jones & Agnes Hunt 
Orthopaedic NHS Hospital Trust 
Oswestry, Shropshire 
SY10 7AG 
 
Email: hra.approval@nhs.net 
 
10 May 2017 
 
Dear Miss Sykes,     
 
 
Study title: A study to develop a new and validated questionnaire to 
assess the outcomes for foot and ankle surgical treatments 
at The Robert Jones & Agnes Hunt (RJAH) Orthopaedic NHS 
Hospital. 
IRAS project ID: 216460  
Protocol number: RG-0048-16-ISTM 
REC reference: 17/NW/0063   
Sponsor Keele University 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter.  
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England.  
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections: 
x Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities 
x Confirmation of capacity and capability - this confirms whether or not each type of participating 
NHS organisation in England is expected to give formal confirmation of capacity and capability. 
Where formal confirmation is not expected, the section also provides details on the time limit 
given to participating organisations to opt out of the study, or request additional time, before 
their participation is assumed. 
x Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable. 
Letter of HRA Approval 
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Appendix	III	
	
Version	3	
19th	May	2016	
Oswestry	Ankle	Score	(OsAS)	
	
The	Oswestry	Ankle	Score	(OsAS)	has	been	devised	to	provide	information	on	the	
patient’s	opinion	of	their	ankle	condition.	The	information	will	help	clinicians	keep	track	
of	how	the	patient	feels	about	their	condition,	can	be	used	to	evaluate	functional	
impairment,	and	monitor	the	effectiveness	of	interventions.	Please	answer	every	
question	regarding	your	ankle	problem	specifically,	by	selecting	the	most	appropriate	
answer.	
	
Pain:	
The	following	questions	refer	to	the	pain	you	currently	experience	from	your	ankle.		
	
1. During	the	last	week,	what	level	of	pain	have	you	experienced	from	your	ankle?	
Severe	 	 moderate	 	 mild	 	 	 none	
	
2. During	the	last	week,	what	level	of	pain	have	you	experienced	from	yourankle	at	night?	
Severe	 	 moderate	 	 mild	 	 	 none	
	
3. During	the	last	week,	how	often	did	you	experience	pain	from	your	ankle?	
Constantly		hourly	 	 daily	 		 weekly	 	 monthly
	 never	 	
	
Symptoms:	
The	following	questions	refer	to	the	symptoms	you	currently	experience	from	your	
foot/ankle,	during	the	last	week.		
	
1. To	what	extent	have	you	had	to	alter	your	daily	lifestyle	due	to	the	pain	and/or	difficulty	
you	experience	from	your	ankle?	
Always	 	 Often	 	 Sometimes	 Rarely	
	 Never	
	
2. To	what	extent	did	your	ankle	problem	affect	your	daily	life?	
Always	 	 Often		 	 Sometimes	 Rarely	
	 Never	
	
	
3. To	what	extent	did	you	avoid	performing	certain	activities	that	you	felt	could	damage	or	
cause	pain	in	your	ankle?	
Always	 	 Often	 	 Sometimes	 Rarely	
	 Never	
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4. To	what	extent	did	you	feel	limited	in	certain	activities	due	to	the	difficulty	or	pain	you	
experience	in	your	ankle?	
Always	 	 Often	 	 Sometimes	 Rarely	
	 Never	
	
5. How	often	were	you	able	to	point	your	foot	away	from	you?	
Always	 	 Often	 	 Sometimes	 Rarely	
	 Never	
	
6. How	often	were	you	able	to	pull	your	foot	up	towards	you?	
Always	 	 Often	 	 Sometimes	 Rarely	
	 Never	
	
7. How	often	did	you	experience	swelling	in	your	ankle,	during	the	last	week?	
Always	 	 often	 	 sometimes		 rarely	
	 never	
	
8. How	often	did	you	experience	stiffness	in	your	ankle,	during	the	last	week?	
Always	 	 often	 	 sometimes		 rarely	
	 never	
	
Activities:	
The	following	questions	refer	to	the	difficulty	you	have	experienced	from	your	ankle	during	
the	listed	activities,	in	the	last	week.	
	
1. Standing	for	a	long	period	of	time	(for	example:	1	hour)	
Unable		 	 extreme	 moderate	 	 mild	 	 none		
	
2. Sitting	for	a	long	period	of	time	(for	example:	1	hour)	
	Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
3. Walking	for	a	short	period	of	time	(for	example:	1-15	minutes)	
		Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
4. Walking	a	long	distance	(for	example:	greater	than	1	kilometre)	
		Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
5. Raising	your	heel	to	stand	on	your	tip	toes	
		Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
6. Climbing	up	and	down	stairs	
	Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
7. Getting	in	and	out	of	the	car	or	public	transportation	
	Unable		 	 extreme	 moderate	 	 mild	 	 none		
	
8. Getting	in	and	out	of	the	shower	or	bath		
	Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
9. Performing	light	daily	household	activities	(for	example:	cooking)	
Unable		 	 extreme	 moderate	 	 mild	 	 none		
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10. Performing	heavy	daily	household	activities	(for	example:	scrubbing	floors)	
Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
11. Sleeping	
Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
12. How	difficult	is	it	for	you	to	continue	with	your	usual	physical	recreational	activities,	
such	as	bicycling,	jogging,	swimming,	due	to	your	ankle?	
		Unable		 	 extreme	 moderate	 	 mild	 	 none		
			
13. How	difficult	is	it	for	you	to	continue	with	your	usual	leisure	recreational	activities,	such	
as	hobbies	and	seeing	friends,	due	to	your	ankle?	
		Unable		 	 extreme	 moderate	 	 mild	 	 none		
	
14. To	what	extent	did	your	ankle	problem	affect	your	daily	life?	
			Never	 	 rarely	 	 sometimes		 often	
	 always	
	
15. To	what	extent	did	your	ankle	affect	your	usual	work	activities?	
			Never	 	 rarely	 	 sometimes		 often	
	 always	
	
16. To	what	extent	did	your	ankle	affect	your	emotional	wellbeing	or	social	activities?	
			Never	 	 rarely	 	 sometimes		 often	
	 always	
	
17. To	what	extent	did	you	struggle	to	find	shoes	that	fit	and/or	don’t	hurt	your	feet?	
	 Never	 	 rarely	 	 sometimes		 often	
	 always	
	
18. How	often	did	you	feel	the	need	to	use	a	walking	aid	(for	example:	crutches,	walker)?	
	 Never				 					 rarely	 				 	sometimes	 						often							
	 always							don’t	have	any	
	
19. How	often	did	you	walk	with	a	limp	due	to	your	ankle	problem?	
	 Never	 	 rarely	 	 sometimes		 often	
	 always		
	
General:	
The	final	question	referS	to	your	general	health,	outside	of	your	ankle	problem.	
	
19. Do	you	have	any	other	issues	with	your	general	health	that	may	have	an	affect	your	
ankle	problem,	for	example:	a	spinal	condition,	chronic	fatigue	etc…?	
Yes	–	please	give	details	below	 	 	 	 No	
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Appendix	IV	
Oswestry	Questionnaire	
Version	3.3	
19th	May	2016	
	
Oswestry	Ankle	Score	(OsAS)	
	
The	Oswestry	Ankle	Score	(OsAS)	has	been	devised	to	provide	information	on	the	
patient’s	opinion	of	their	ankle	condition.	The	information	will	help	clinicians	keep	track	
of	how	the	patient	feels	about	their	condition,	can	be	used	to	evaluate	functional	
impairment,	and	monitor	the	effectiveness	of	interventions.	Please	answer	every	
question	regarding	your	ankle	problem	specifically,	by	selecting	the	most	appropriate	
answer.	
	
Pain:	
The	following	questions	refer	to	the	pain	you	currently	experience	from	your	ankle.		
1. During	the	last	week,	what	level	of	pain	have	you	experienced	from	your	ankle?	
Severe	 	 Moderate	 	 Mild	 	 None	
	
2. During	the	last	week,	how	often	did	you	experience	pain	from	your	ankle?	
Constantly		 Sometimes		 Rarely	 	 Never	 	
	
Symptoms:	
The	following	questions	refer	to	the	symptoms	you	currently	experience	from	your	ankle,	
during	the	last	week.		
	
3. To	what	extent	have	you	had	to	alter	your	daily	lifestyle	due	to	the	pain	and/or	
difficulty	you	experience	from	your	ankle?	
Always	 	 Often	 	 Rarely	 	 Never	
	
4. To	what	extent	did	your	ankle	problem	affect	your	daily	life?	
Always	 	 Often		 	 Rarely	 	 Never	
	
5. To	what	extent	did	you	avoid	performing	certain	activities	that	you	felt	could	damage	
or	cause	pain	in	your	ankle?	
Always	 	 Often	 	 Rarely	 	 Never	
	
6. To	what	extent	did	you	feel	limited	in	certain	activities	due	to	the	difficulty	or	pain	
you	experience	in	your	ankle?	
Always	 	 Often	 	 Rarely	 	 Never	
	
	
7. How	often	did	you	experience	stiffness	in	your	ankle,	during	the	last	week?	
Always	 	 Often	 	 Rarely	 	 Never	
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Activities:	
The	following	questions	refer	to	the	difficulty	you	have	experienced	from	your	ankle	during	
the	listed	activities,	in	the	last	week.	
	
8. Standing	for	a	long	period	of	time	(for	example:	1	hour)	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
9. Sitting	for	a	long	period	of	time	(for	example:	1	hour)	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
10. Walking	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
11. Climbing	up	and	down	stairs	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
12. Getting	in	and	out	of	the	car	or	public	transportation	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
	
13. Getting	in	and	out	of	the	shower	or	bath		
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
14. Performing	daily	household	activities	(for	example:	cooking,	scrubbing	floors)	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
		
	
15. Sleeping	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
16. How	difficult	is	it	for	you	to	continue	with	your	usual	activities,	such	as	cycling,	
jogging,	swimming,	seeing	friends,	doing	usual	hobbies,	due	to	your	ankle?	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
			
17. To	what	extent	did	your	ankle	affect	your	emotional	wellbeing?	
			Never	 	 Rarely	 				Sometimes	 Often	 	 Always	
	
18. How	often	did	you	walk	with	a	limp	due	to	your	ankle	problem?	
	 Never	 	 Rarely	 				Sometimes	 Often	 	 Always	
	
General:	
The	final	question	referS	to	your	general	health,	outside	of	your	foot	and	ankle	problem.	
19. Do	you	have	any	other	issues	with	your	general	health	that	may	have	an	affect	your	
ankle	problem,	for	example:	a	spinal	condition,	chronic	fatigue	etc…?	
Yes	–	please	give	details	below	 	 	 	 No	
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